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 ABSTRACT 
 
 
 
 
Breast cancer is a heterogeneous disease displaying different histopathological 
characteristics, biomarker expression profiles and clinical behaviour. Senescence-associated 
biomarkers exhibit distinctive molecular changes at different stages of cancer development 
which can be used for molecular characterisation of breast cancer. The research programme 
described in this thesis aims to characterize the expression patterns of the senescence markers 
P14, P16, P21, P53, DCR2 and DEC1 during cancer progression in a large cohort of breast 
cancer patients. A retrospective study of 1080 patients with invasive ductal carcinoma, of no 
special type, spanning over an 11 year period, was investigated. Immunohistochemical 
staining was performed on tissue microarrays that include normal, benign hyperplasia, ductal 
carcinoma in situ and invasive ductal carcinoma from each patient. Pearson chi-square was 
undertaken to determine the associations, Kaplan-Meier log rank test to study the survival 
analyses and Cox proportional hazard regression test to identify independent predictors of 
patient prognosis. Invasive ductal carcinomas demonstrated greater expression of P14, P16, 
p53 and DCR2, but lower expression of P21 and DEC1 when compared to non-malignant 
tissues.  There was a significant correlation between normal, benign, premalignant and 
malignant tissues with P14, P21, P16, P53, DCR2 and DEC1 expression (p<0.05). A pattern 
of increasing expression of these biomarkers was observed at different stages of disease 
progression from normal to benign to premalignant stage, and a plateauing level from 
premalignant to malignant lesions. Of the six markers studied, five (P14, P21, P16, P53, 
DCR2) showed significant association with at least one clinicopathological covariate, 
whereas one marker (DEC1) did not establish any significant association. P14 expression 
was associated with tumour grade and estrogen receptor (p<0.05. P21 was only related to 
tumour grade (p<0.05). P16
INK4a
 expression correlated significantly with tumour grade, 
estrogen receptor (ER) and progesterone receptor (PR) status (p<0.0001 respectively). P53 
protein expression significantly associated with age, grade, staging, lymphovascular invasion 
(LVI), ER, PR and human epidermal growth factor receptor 2 (HER2) (p<0.05).Lastly, 
DCR2 was related to tumour grade, ER, PR and HER2. Univariate comparison showed 
correlation between strong P16 expression and poor survival (p=0.000) and increased risk of 
relapse (p=0.000), whereas high P14 and high P53 expression correlated only with increased 
risk of relapse (p=0.038 and p=0.002 respectively). Multivariate analysis of all tumour 
markers showed that P16 and P14
 
were important prognostic factors for disease-free survival 
(p=0.024 and p=0.034 respectively), but none was important prognostic factor for overall 
survival. Moreover, patients displaying both strong P16 and P14 expressions had an adjusted 
3-fold increased risk of disease recurrence (p<0.05) and 2-fold increased risk of all-cause 
related death (p<0.05). Besides, patients whose breast cancer tissues exhibited both high P53 
and P16 expression had an adjusted 4-fold increased risk of having disease recurrence 
(p=0.000) and 3-fold increased risk of all-cause related death (p=0.000). High expression of 
P14 and P53 had an adjusted 3-fold increased risk of having disease recurrence (p=0.002). In 
conclusion, these findings suggest P16, P14
 
and P53 expression may play a major role in the 
progression of proliferative breast tissue to invasive cancer, and may be useful as prognostic 
factors. 
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1.1 OVERVIEW 
This chapter will review the current literature on the normal anatomy of the breast, 
and the epidemiology, clinical, pathological and molecular features of breast cancer. 
It is now evident that some breast cancers have a hereditary basis and both hereditary 
and sporadic cancers appear to involve molecular mechanisms that are linked to the 
cell cycle. Frequently, changes in the molecular pathways such as gene deletions, 
point mutations or overexpression of growth factors can be seen in these cancers. 
Recently the senescence pathway appears to be implicated in breast carcinogenesis. 
This chapter will also review the current evidence on the known molecular pathways 
in breast cancer and its progression. 
 
1.2 DEVELOPMENT, ANATOMY & HISTOLOGY OF THE 
BREAST 
The human breast starts to develop at the age of sixth week during prenatal life when 
the emergence structure called ‘milk streaks’ of ectodermal thickenings in the skin 
become visible.
[1]  
The breast is composed of mammary glands with overlying skin 
and connective tissues. During the 20
th
 weeks of gestation, solid epithelial cords cells 
invaginate to form a network of about 15-25 branching primary mammary ducts 
occurred in response to maternal and placental hormones.
[2, 3]
 Mammary glands are 
sweat gland modifications which are attached to the superficial fascia anterior to the 
pectoral muscles and anterior thoracic wall.
[4]
 The breast structures of a male are 
similar to those of a female but with the only discrepancy being in size and 
composition. Development of the breast accelerates at puberty when ducts begin to 
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elongate and branch. Estrogen and progesterone cause the terminal end buds and 
connective stroma to proliferate, differentiate and remodel to form the terminal duct 
lobular unit (TDLU) of the adult breast.
[5]
 In boys, development of the breast tissue is 
stunted due to the testicular secretion of androgenic hormones resulting in the 
predominant composition being ducts and only very few if any lobules.
[6]
  
 
Figure 1.1 shows collecting ducts of the breast opening at the nipple through the 
areolar opening. Just beneath the nipple, collecting ducts dilate to form lactiferous 
sinuses which subdivide into 15-25 lobes with segmental and subsegmental ducts and 
terminate in the terminal duct lobular unit (TDLU). The TDLU is composed of the 
terminal ductules or acini, whose epithelium differentiates into secretory acini in 
pregnant or lactating glands, the intralobular collecting duct and the specialized 
intralobular stroma.
[5] 
It is well known from breast development studies that the key 
structure to the emergence of the most common site of breast malignancy is origin 
from the terminal duct lobular unit.
[7]
 Breast normal anatomy and its relation to 
specific pathological abnormalities are depicted in Figure 1.
[8] 
 
Microscopically, the breast can be categorized into epithelial and stromal component. 
From 28 weeks of intrauterine life, there are two types of cells in the growing breast 
epithelium. The epithelial component consist of a system of lobules and ductules 
while the stromal component is made up of a variable amount of loose connective 
tissue and adipose tissue.
[9] 
Myoepithelial cells line the outer aspect and are separated 
from the inner luminal cell population by a basement membrane.
[10]
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                                  Figure 1.1: Gross Anatomy of breast 
(Source: Hayes D: Breast cancer. In Skarin AT (ed): Atlas of Diagnostic 
Oncology. Philadelphia, JB Lippincott, 1991, p 64)  
 
 
 
 
The myoepithelial cells have contractile function and assist in milk ejection during 
lactation. The cells that overlay the myoepithelial cells are luminal epithelial cells 
which produce milk.
[11] 
Breast stroma can be categorized into intralobular and 
interlobular regions. Intralobular stroma surrounds the acini, the functional lobular 
units of human mammary consists of loose connective tissue, fibroblasts and 
scattered lymphocytes.
[12] 
In contrast, interlobular stroma is composed of dense 
fibrous connective tissue admixed with adipose tissue.
[13] 
The main histological 
difference between inactive and active mammary glands is active or secretory 
mammary gland dominated by active glandular cells on the contrary resting 
mammary gland is predominated by the duct system, shown by Figure 1.2.
[14]
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  Resting mammary gland                           Active mammary gland 
Figure 1.2: The difference of histology of resting and active mammary gland 
(Adapted from Martini FH, Timmons MJ, Tallitsch RB: Human Anatomy. 
7th edition. United States of America: Pearson Education 2009)  
 
1.3 BIOLOGY OF CANCER 
Cancer is the overgrowth of cells in an uncontrollable manner. According to Collins 
et. al 1997, cancer can be described as a disease of cell cycle.
[15]
 Early written 
descriptions of cancer originate from classical Greek and Roman physicians such as 
Hippocrates (460-370 BC).
[16] 
Demographic factors such as age, gender, 
race/ethnicity, socioeconomic status and geographical location are the key factors to 
the occurrence of cancer
 [17]
 There are three rival models of cancer origin. The first 
model suggests that cancer is the disease of spontaneous abnormal differentiation 
whilst the second model is postulated by virologists who suggest that cancer arises 
from induction through viruses. The last model, which eventually dominate the other 
two models, documents that cancer is caused by carcinogens and mutagens.
[18]  
Tumour development or tumorigenesis requires novel physiological changes in the 
manifestation of a normal cell to a cancerous phenotype. A neoplastic cell in contrast 
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to its normal counterpart has several unique features such as rate of  proliferation, 
morphology, cell-to-cell contact, membrane structure, cytoskeletal organization, 
protein expression and gene translation.
[19]
 Progression from a normal to a  cancerous 
cell occurs after manifestation of eight essential alterations that includes the capacity 
to proliferate irrespective of exogenous mutagens, resistance to growth-inhibitory 
signals, resistance to apoptosis, limitless replicative potential, sustained 
angiogenesis, ability to invade and metastasise, reprogramming of energy 
metabolism and evading immune system.
[20] 
Although all of these features can 
determine the formation of a cancer, it is not necessary to possess all of them to 
become a malignant phenotype. Hence, by evading apoptosis as well as overriding 
limited replication, cancer cells can gain growth advantages.
[21]
 Scientific data has 
supported the concept of a multistep disease progression via protracted accumulation 
of multiple genetic changes in cancer development.
 [18] 
 
Cancer is the accumulation of genetic mutations that have been successfully escaped 
repair mechanisms. Therefore cancer may be classified as a genetic disorder although 
most cancers are sporadic.
[22] 
Interestingly, it has been estimated only 1 mutation 
occurs in 2x10
7
 per cell cycle, and it takes three lifetimes to generate a cancer cell.
[16]
 
Nevertheless, mutations in key regulatory genes; oncogenes, tumour suppressor 
genes and caretaker genes appear to be play a significant role in carcinogenesis.
[23] 
Oncogenes are cancer-causing genes which are derived from the activation of proto-
oncogenes.
[24]
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1.4  BREAST CANCER 
1.4.1 Epidemiology  
1.4.1.1 Incidence  
Breast cancer (BCa) is the commonest cancer in women worldwide, although it can 
also infrequently affect men. The incidence of breast cancer is amongst the highest of 
all cancer types.
[25]
 It accounts for about 28.2% of all cancers diagnosed in Australia 
(http://www.aihw.gov.au/cancer/index.cfm).  In 2007, breast cancer ranked third 
amongst the most commonly reported cancers in Australia. Cancer of the breast 
accounted for 27% of all cancer diagnoses in 2007 among Australian women. From 
1982 to 2007, the number of breast cancer cases increased by a total of 7276. Breast 
cancer is the commonest cancer experienced by Aboriginal and Torres Strait Islander 
Women. Statistical data from 2003-2007 shows that non-indigenous women in 
Australia are more likely to be diagnosed with breast cancer than indigenous 
women.
[26]
 International comparisons show differences in breast cancer incidence. 
The Asian population has lower risk group when compared to people in Western 
countries. The worldwide discrepancy in breast cancer incidence rates is broadly 
affected by differences in socioeconomic status which tends to correlate with 
reproductive, hormonal and nutritional status.
[27]
 In 2010, the disease mainly 
concentrated on younger age groups (40-79 years) which peak at the age of 55 to 59 
years. 
[26] 
BCa is rare before 25 years of age. Its incidence rises steadily after the 3
rd
 
decade, peaks at the 6
th
 decade and decreases slightly and plateaus in the 8
th
 decade.    
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1.4.1.2 Mortality 
Breast cancer mortality in Australia fluctuates in the number of cases from 1970 to 
1994. The highest mortality rate is in between year 1940-1944 with steady increment 
from 1970 to 1980.
[28] 
More recent data in 2006, shows the mortality rate the highest 
in the older age group between 1990 to 2004.
[29]
 According to New South Wales 
cancer incidence and mortality report, in 2008, breast cancer was responsible for 
12% of all new cases of diagnosed cancer and 7% of  cancer deaths in NSW.
[30] 
An 
updated breast cancer statistic in 2009 shows a decreasing trend from 2001 to 
2006.
[31]
 Reduction in mortality rates from 66 deaths to 47 deaths per 100,000 
women in 1995 to 2007 appears to coincide with better education and access to 
health care along with advances in the management and treatment of invasive breast 
cancer.
[26]  
 
1.4.1.3 Screening 
At present, the most pragmatic approach to lessen the burden of breast cancer is by 
increasing survival rate through early detection screening programme. 
Mammographic screening programme that has been well recognized includes 
mammography, breast self-examination (BSE) and clinical breast examination 
(CBE).
[32]
 In Australia, the Australian Government with the joint of state and 
territory governments have established a program called BreastScreen Australia in 
1991. The program aims are to increase availability of mammography in screening 
programme in order to abate mortality in breast cancer patient by providing free 
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mammographic screening and assessment for females aged 40 years and over with 
the primary target group women aged 50 to 69 years.
 [26]
  
 
1.4.1.4 Risk factors 
Breast cancer is a heterogeneous disease.
[33]
 Multiple risk factors have been 
identified either as modifiable or non-modifiable factors. The incidence, mortality 
and survival of breast cancer shows disparities around the world. These may be due 
to several underlying complex factors including age, ethnicity, diet and lifestyles.
[34]
 
Women age 50 and over have higher risk than women younger than 50 years. 
Although women younger than 50 represent 73% of female population, only 23% of 
them are diagnosed with the disease.
 [34]
 Large differences in breast cancer 
epidemiology are seen by race and ethnicity. However, the differences are influenced 
by socioeconomic and cultural factors rather than inherited genetic susceptibility. 
This was supported by migrant studies which have shown Japanese and Chinese 
migrants offspring generations in the United States have an increased risk in 
acquiring the disease.
[27]
   
 
The duration of active reproductive status which is early age at menarche and late 
age at menopause has shown greater risk in developing breast cancer. Pre-
menopausal and post-menopausal women possess the same risk in developing breast 
cancer. A delay of 2 years at age of menarche is associated with a 10% reduction in 
breast cancer risk. The difference at each 5 years delay of having menopause impose 
as much as 17% higher risk of developing breast cancer.
[35]
  Genetic factors account 
for at least 5% of the breast cancer cases as evident from the study of familial breast 
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cancer with mutation of Breast cancer gene 1 (BRCA1).
[36]
 A woman with a family 
history of breast cancer is at risk of developing the cancer if she inherits the harmful 
mutation of the gene. A meta-analysis study estimates 57% of women with BRCA1 
mutation and 49% of women with Breast cancer gene 2 (BRCA2) mutation will 
develop the disease by the age of 70 years.
[37] 
 
 
1.4.2 Clinicopathological features 
1.4.2.1 Pathological types 
Cancer progression of the breast is a multistep process which manifests itself as a 
sequence of defined pathological stages. It has been proposed that the low grade 
invasive lesions arise from a clustered group of lesions called ‘low grade breast 
neoplasia family’ and high grade carcinoma develops from high grade precursor. 
Contrary to the low grade tumours, the high grade group is found to be a more 
heterogeneous disease.
[38]
 Through this hallmark progression of breast cancer, there 
is the need to detect the cancer as it still in the early clinical disease stage for better 
prognostication.
[39]
 Invasive breast carcinoma is a malignant epithelial lesion that has 
been initiated from the benign stage over a long period of time. Benign conditions 
can be further subcategorized into nonproliferative breast changes and proliferative 
disease with or without atypia based on their risk in developing the invasive state.
[5]
 
 
The nonproliferative lesion, fibrocystic changes  which is characterised by the 
presence of apocrine metaplasia is not correlated with an increased risk of carcinoma 
formation.
[40]
 Proliferation without atypia includes usual epithelial hyperplasia, 
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sclerosing adenosis, radial scar and intraductal papilloma are diseases associated with 
1.5-2 fold relative risk of eventually developing carcinoma. Nonetheless, 
proliferative lesions with atypia entail an even greater relative risk of up to 4-5 fold 
risk of developing premalignant and malignant lesions including atypical ductal 
hyperplasia, atypical lobular hyperplasia and flat atypia.
[5]
 There is no discrete 
boundary between breast cancer type, and benign lesions may acquire premalignant 
features. Breast tissue lesion is classified according to the main feature, for example 
a tissue is categorized as a premalignant lesion although it possess malignant feature 
such as relative loss of growth control but lacking the ability to invade and 
metastasize.  
 
Traditionally, invasive breast carcinoma has been classified into subgroups based on 
morphological features and the different histological type. However, breast cancer is 
a heterogeneous disease in relation to its clinical, genetic and phenotypic features. 
[33, 
39, 41] 
Recently, breast cancer is classified based on its molecular profile. The subtypes 
are defined as Luminal-like A (ER
+
/PR
+/-
/HER
-
) and B (ER
+
/ PR
+/-
/HER2
+
), Basal-
like (triple negative, ER
-
/PR
-
/HER
-
), HER2-positive (ER
-
/PR
-
/HER
+
) and Normal-
like. These subtypes are found to correlate with different tumour features and clinical 
outcomes. 
[41]  
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1.4.2.1.1 Morphological Features of Breast Cancer Precursors 
The morphological features of precursor lesions of breast cancer are well-
characterised. Morphologically, these lesions are generally categorised according to 
histogenesis from the terminal-duct lobular unit (TDLU) of the breast.  
 
a) Intraductal precursors of breast cancer 
The intraductal precursors of BCa are a heterogeneous group of lesions that include 
columnar cell lesion (CCL) with or without atypia, usual ductal hyperplasia (UDH) 
and atypical ductal hyperplasia (ADH). These lesions have an increased risk 1.2 to 5 
times of developing breast cancer.
 [42, 43]
 
 
UDH is defined by the presence of proliferating epithelium of more than 2-cell thick 
and can range from mild to florid. Ductal architectural abnormalities, often resulting 
in distension of the duct lumen, may take the form of elongated or tufted papillary 
projections and cribriform masses with slit-like spaces at the periphery. The 
epithelial cell population has a polymorphic appearance with irregular arrangement 
of cells, and where they form bridges, the cells show a streaming pattern with cell 
nuclei arranged parallel to one another and with the cell bridges. The main diagnostic 
challenge for UDH is to distinguish it from ADH and low grade ductal carcinoma in 
situ (DCIS). 
 
ADH on the other hand has epithelial proliferation characterised by architectural and 
cytological features that are atypical but fall short of the diagnosis of DCIS. Hence, 
the distinction between ADH and low grade DCIS can be very difficult. According to 
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a recent review,
[44]
 ADH can be considered to have 3 diagnostic features: (i) uniform 
architecture that may be cribriform, micropapillary or solid, (ii) cytological features 
characterised by small to medium cells that may be round, cuboidal or polygonal 
with evenly distributed nuclei, and (iii) disease extent, in which the lesion is focal 
and small, occupying less than two separate duct spaces or up to 2mm.
 [45]
 
 
Ductal carcinoma in situ (DCIS), as the name implies, is premalignant with in situ 
proliferation of neoplastic epithelial cells usually within a duct, although the cells 
may spread into a lobule (“lobular cancerisation”), with no invasion into the stroma 
surrounding the involved TDLU. However, the diagnostic difficulty in distinguishing 
ADH from low grade DCIS, particularly the cribriform type, is highlighted. As noted 
in the aforementioned features of ADH, the architectural and cytological features of 
these 2 entities can be very similar, if not identical, and it is a matter of disease extent 
that separates the 2 entities.
 [44]
 On the other hand, high grade DCIS is readily 
recognised and its diagnosis is straight forward, with high reproducibility amongst 
practising diagnostic pathologists. 
 
The current internationally accepted grading system for DCIS is now based on a 
combination of nuclear grade and the presence or absence of luminal necrosis, which 
is more reproducible and more importantly, appears to correlate with clinical 
outcomes.
[46-48]
 DCIS is classified as low, intermediate or high grade: 
[44, 48]
 
i) Low grade DCIS is often characterised by micropapillary and cribriform growth 
patterns. The lesions show a population of uniform appearing, evenly distributed 
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cells with round, central nuclei, finely dispersed chromatin pattern, small nucleoli, 
and few mitoses.  
ii) Intermediate grade DCIS shows the features between those of low and high grade 
DCIS with micropapillary, cribriform, and often solid growth patterns. The cells 
show moderate nuclear pleomorphism, 
iii) High grade DCIS often has a solid growth pattern with comedo necrosis, 
although other growth patterns can also be seen. It is composed of large cells with 
pleomorphic nuclei with coarse chromatin patterns and prominent variably sized 
nucleoli. Many mitoses with abnormal forms are seen. 
 
From a diagnostic viewpoint, the growth patterns of DCIS and even nuclear grade 
can sometimes be heterogeneous but the grading should be based on the highest 
nuclear grade observed. Distinguishing between low grade DCIS and lobular 
carcinoma in situ (LCIS) can sometimes be difficult but this can usually be resolved 
by assessment for cellular cohesion with the presence of cell borders, absence of 
intracytoplasmic lumens and presence of E-cadherin immunostaining in DCIS.
[48]
 
Another diagnostic issue is microinvasive carcinoma that can occasionally be seen in 
high grade DCIS, and its diagnosis can often be made by breach of the myoepithelial 
layer that can be highlighted by immunostaining for smooth muscle actin and p63.
 [48]
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b) Lobular precursors of breast cancer 
 
The lobular precursors of BCa or lobular neoplasms are well-described in the 
literature and are consisted of atypical lobular hyperplasia (ALH) and lobular 
carcinoma insitu (LCIS).
[49]
 They are characterised by proliferation of small regular 
monomorphous, round to cubidal or polygonal and dyscohesive epithelial cells that 
lack cell borders, with high nuclear:cytoplasmic (N:C) ratio. ALH is distinguished 
from LCIS by having a lesser proportion of the lobule involved (some authors refer 
to less than 50%)
[49, 50]
 by these cells, less distension of the involved acini, 
incomplete obliteration of acinar lumens,  less uniformity of cell types, more 
irregular spacing of tumour cells and more cellular cohesiveness. Pagetoid extension 
of the tumour cells along ducts can occur in both ALH and LCIS.
[49]
 Distinction of 
LCIS from low grade DCIS can be problematic and the diagnostic features for this 
distinction have already been mentioned earlier. However, combined LCIS/DCIS can 
sometimes occur in the same TDLU, in which the diagnosis of both should be 
described in the pathology report. 
 
1.4.2.2 Clinical behaviour  
While the cancer is a silent progression of uncontrollable cell growth, a combination 
of breast examination and mammography may identify the asymptomatic individuals 
in early stages before they have had time to give rise to clinical symptoms and to 
metastasise. Biological aggressiveness of the breast cancer is dependent on the 
histological criteria and molecular lesions that underlie the cancer.
[51]  
Despite the 
fact that invasive carcinoma is a lethal malignant lesion, the premalignant types may 
Ch 1. Introduction 
 
 
16 
 
shows variable outcome. A small proportion of women with ductal carcinoma in situ 
present symptomatically with a mass lesion or with Paget’s disease of the nipple. On 
the other hand, Paget’s disease is clinically characterised by the present of erythema 
or an eczematous change to the nipple and areola. Nevertheless, lobular carcinoma in 
situ is generally asymptomatic.
[5]
  
 
The clinical outcome of the breast cancer has been well recognized by the expression 
of molecular markers that underlie the lesion. Approximately 70% of breast cancers 
that express estrogen receptor (ER) tend to grow slowly and have good response to 
anti-hormonal therapy. Progesterone receptor (PR) is variably expressed in ER-
positive tumours and show variable prognosis. ER-positive/PR-negative tumours 
tend to present as larger lesion with more frequent nodal involvement compared to 
ER/PR-positive tumours. The over expression of proto-oncogene HER2 is found to 
be associated with poorer clinical outcome and reduced survival time compared to 
tumours with normal level of HER2.
[34]
 The triple-negative (ER, PR, HER2-
negative) subtypes tend to have a more aggressive clinical course than other forms of 
breast tumour with an increment of recurrence and mortality within 5 years of 
diagnosis but not thereafter.
[52] 
In
 
addition, breast cancer with BRCA1 mutation share 
several pathological features with sporadic triple-negative cancers, including low or 
absent expression of hormone receptors and HER2, high histological and nuclear 
grade, and high mitotic index.
[53]  
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1.4.2.3 Staging and prognostication 
Uniform staging system allows categorising tumour with similar disease burden 
based on their size, invasiveness and metastases state, which guides clinical 
management, prognostication, and the evaluation of novel markers and therapies. 
Traditionally, breast cancer is staged under the TNM staging system (T-Tumour size, 
N-presence of Nodal metastasis and M-presence of distant Metastasis). Recently, 
several studies have also assessed the histological, biochemical and molecular 
biological characteristics to predict the outcome of the disease.
[54]
  
 
Invasiveness and total number of axillary lymph nodes involved in the disease is a 
paramount prognostic characteristic for overall survival rates. It has been known that 
larger breast cancers and high involvement of lymph nodes have poorer prognostic 
outcome. However, recently the existence of molecular markers such as ER, PR, 
HER2 and BRCA1 have provided newer information in predicting the outcome of 
the disease which also serve as a determinant for therapy selection.
[34]
 
Prognostication of the expression of each molecular marker is the same as mentioned 
in clinical behaviour in this chapter. 
 
1.4.3 Management 
Management of early breast cancer includes surgery with or without radiotherapy, 
axillary sentinel lymph node biopsy and systemic adjuvant therapies. The goal 
management of the early breast cancer is to control the disease in total by eliminating 
the primary tumour and to improve survival.
[55] 
Surgery is the mainstay of breast 
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cancer treatment. A study shows surgery was significantly associated with higher 
survival rate and lower incidence of recurrence compared to less aggressive 
treatment in the elderly.
[56]
 Another randomised trial of mastectomy only versus 
tamoxifen only involving women over 70 has been conducted to study the best 
treatment intervention in the elderly. After 20 years of follow-up, the study found 
that patients receiving tamoxifen without surgery develop local recurrence in shorter 
time compared to patients who mastectomy only. On the other hand the study did not 
show any difference in regional recurrence, distant metastases or overall survival 
between the mastectomy only and mastectomy plus tamoxifen arms.
[57]
  
 
Though surgery is the most important intervention in the management of breast 
cancer patients, the recurrence rate may be reduced with adjuvant radiotherapy.
[58] 
In 
addition to local therapy for early breast cancer, systemic adjuvant therapy which 
includes hormonal manipulation and/or cytotoxic chemotherapy may be administered 
a the treatment of choice.
[55]
 It is undisputed that adjuvant endocrine therapy plays a 
significant role in treating breast cancer patients where it has been found to have a 
major contribution to lower the mortality rate of breast cancer in the United 
Kingdom.
[59]
 As 80% of breast cancer patients are hormone receptor positive, 
tamoxifen and aromatase inhibitors are used as first and second line therapies for 
breast cancer treatment.
[60]
 Chemotherapy may be administered as pre-operative or 
post-operative intervention. Whilst the pre-operative (neoadjuvant) chemotherapy is 
used to shrink large tumours to allow breast conserving surgery, post-operative 
chemotherapy can also be effective.
[61]
 The post-operative chemotherapy treatment 
guidelines for primary breast cancer in premenopausal women with luminal B and 
TNBC subtypes should contain anthracyclines and taxanes whereas luminal A 
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phenotype was reported as less responsive to chemotherapy. Postmenopausal patients 
with endocrine responsive disease can be treated with adjuvant endocrine therapy 
and bisphosphonates without cytotoxic therapy.
[62]
  
 
Recently, several studies have suggested the induction of cancer cell into the 
senescence state can be exploited in managing cancer progression.
[63-66]
. It is reported 
that senescence-inducing chemotherapeutic agents have the advantage over 
apoptosis-inducing agents due it has the ability to induce senescence at low dose, 
resulting in less toxicity.
[63]
 However, a recent study has also indicated that 
senescence can promote tumour progression in some circumstances. Thus, there is a 
need to critically evaluate the side effects of therapy that primarily involves 
senescence as its mechanism of action. Senescence-induced therapy may well stop 
any further tumorigenicity, however it may induce neoplastic change in adjacent 
normal cells.
[67] 
 
1.4.4 Molecular pathogenesis of breast cancer 
In recent years, many studies have been focused on the molecular characteristics of 
benign breast diseases, precursor lesions, as well as invasive carcinomas of the 
breast. Not only new molecular phenotypes of breast cancers are identified, a new 
multistep pathway of progression from precursor lesions to invasive carcinoma has 
been postulated.
[68] 
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In clinical practice, breast cancers are categorised into either hormone receptor -
positive or -negative, which appear to respond specifically to different types of 
adjuvant therapy. Recent molecular techniques such as gene profiling of breast 
cancers have identified specific molecular subtypes in addition to the traditionally 
recognised ER and PR status categories. The luminal A and luminal B groups form 
the major molecular subtype of hormone receptor-positive cancers. On the other 
hand, the cancers that are HER2 positive and basal-like are the major subtypes 
among hormone receptor-negative breast cancers. The luminal C and normal breast-
like tumours that are described in some studies are, however not well characterised.
 
[69-73]
   
 
A significant molecular discovery in breast cancers is the identification of basal-like 
breast cancers, which are recognised by the WHO and being variably applied into 
clinical practice. These tumours have similar molecular signatures but display 
heterogeneous histopathological characteristics, biomarker expression profiles, and 
clinical behaviour. The clinical outcome of patients with these tumours is variable 
and may not necessarily be as uniformly poor as first thought.
[74, 75]
  Approximately 
80% of BRCA1-associated breast cancers have similar gene expression profiles as 
the basal-like cancer, and many sporadic basal-like breast cancers also show BRCA1 
dysfunction.
[76, 77]
 
 
Based on the molecular characteristics, it is clear that breast cancer can no longer be 
considered as a single disease.  Since the first set of data of molecular portraits and 
gene expression patterns of breast cancer published in 2000 by the Stanford group
[70, 
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78]
, it is apparent that breast cancers may have the same phenotypic histogenetic 
origin from the terminal ductal lobular unit (TDLU) but are fundamentally a 
collection of multiple diseases that affect the same anatomical site.
 [79, 80]
  Hence, ER-
positive and ER-negative breast cancers are essentially distinct diseases that have 
different molecular signatures.
[79-83]
  ER-positive breast cancers have histological 
grade and proliferation that are strongly associated with the extent, complexity and 
type of genetic changes.
[68]
  These cancers usually share similar genetic alterations 
such as 16q deletion.  The ER-negative breast cancers, on the other hand, are usually 
high grade and composed a group of diseases with more heterogeneous molecular 
alterations.
[84-92]
  Currently, available evidence on the evolution of breast cancer 
suggests that it can be categorised into two groups based on histological grade: (i) A 
low grade group that encompasses low grade  neoplasms, and (ii) a high grade group 
that is consisted of high grade DCIS and high grade infiltrating carcinomas.
[68]
  
 
Although there are many studies on the molecular characteristics of invasive breast 
cancer, the molecular events that occur during the development and progression of 
breast cancer precursors are less well established. Molecular mechanisms mediating 
the progression of in situ carcinoma to infiltrating breast cancer remain largely 
unknown. Traditionally, the multistep progression pathway of breast cancer is 
assumed to be similar in concept to the Vogelstein model for colorectal cancer.  In 
brief, initial alterations of epithelial cells in the TDLU transform to UDH with 
recognisable morphological features, and then progress to ADH with involvement of 
a part of TDLU, followed by low grade DCIS in which the entire duct is involved.  
At this stage, further progression is ensured by further acquisition of genetic and 
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epigenetic alterations resulting in the progression to high grade DCIS, and 
subsequent invasive carcinoma. A similar multistep process is also believed to occur 
in invasive lobular carcinoma (ILC). However, this traditional theory has been 
superseded by the latest evidence shown that UDH does not increase the risk for 
breast cancer and thus, not considered as breast cancer precursor.
[93]
 Carcinoma of 
the breast has been evolved in a linear pathway from their associate non-obligate 
precursor. It has been proposed that the low grade invasive lesions arise from a 
clustered group of lesions called ‘low grade breast neoplasia family’ and high grade 
carcinoma develops from high grade precursor. Contrary to the low grade lesions, the 
high grade group is found to be a more heterogeneous disease.
[38]
 
. 
Although progression from hyperplasia to ADH to DCIS to invasive carcinoma 
pathway is still accepted by some 
[94, 95]
, there is emerging evidence from genomic 
and transcriptomic studies to suggest that histologically low and high grade in situ 
lesions and their respective invasive counterparts are essentially different.
[91, 96-98]
 It 
is now recognised that low grade and high grade invasive breast carcinomas show 
very different molecular alterations. There is emerging data showing that the low 
grade DCIS and high grade DCIS are also different diseases based on genetic 
profiling.
[85, 99]
  Low grade DCIS is more likely to show deletion of chromosomal 
16q and gain of 1q. Similar genetic alterations are however less common in high 
grade DCIS, in which heterogeneous genetic profiles including alterations at 13q, 
17q, and 20q are more frequent.
[68]
  The molecular hallmark of low grade neoplasia 
group is concurrent presence of deletion of 16q (>80%) and gains of 1q (>75%) and 
16p (15%).
[81, 85, 86, 88, 91, 98, 100, 101]
  On the other hand, high grade DCIS and its 
invasive counterpart have more complexity in genomic alterations, with deletions of 
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16q found in less than 30% of cases. The absence of 16q deletions in the majority of 
high-grade breast cancers appears to indicate that most high grade DCIS arise either 
de novo or from a precursor lesion other than ADH and or low grade DCIS.
 [68]
  
 
The breast cancer precursor ADH shares many similar molecular features with  low 
grade DCIS 
[102]
 and low grade IDC.  Flat epithelial atypia (FEA), another precursor 
lesion, shares similar molecular features with tubular carcinoma, a variant of low 
grade breast carcinoma.
[85]
 The different molecular signatures of low grade neoplasia 
and high grade neoplasia families also closely correlate with clinical and histological 
findings, in which high grade DCIS is usually associated with high grade breast 
carcinoma, and low grade DCIS associated with low grade invasive carcinoma. In 
tubular carcinomas, the precursor component is most likely to be FEA or low grade 
DCIS with cribriform pattern. The similarity in growth patterns, hormone receptor 
status and gene expression profiles strongly suggests that low grade DCIS is a 
precursor of low grade IDC, whilst high grade DCIS is a precursor of high grade 
IDC.
 [85, 99] 
 
ADH is one of the precursor lesions of low grade DCIS and invasive carcinoma, as 
classified in the traditional progression pathways.  The molecular similarity of ADH 
and low grade DCIS has been confirmed by genetic analyses showing allelic 
imbalances at similar frequencies in both lesions.
[68]
  Furthermore, allelic imbalances 
were concordant in matched sample study of ADH, low grade DCIS and low grade 
breast cancer, indicating ADH is in fact a neoplastic lesion with very similar 
molecular characteristics as low grade DCIS. With these molecular characteristics, it 
Ch 1. Introduction 
 
 
24 
 
is not difficult to accept that ADH plays an unequivocal role in the progression of 
breast cancer 
[103, 104]
 along similar molecular pathways.  Similar to other low grade 
lesions, ADH demonstrates the low grade family’s molecular signature with 
recurrent deletion of 16q and 17p and gains of 1q.
[103-105]
 CGH studies have 
confirmed both ADH and low grade DCIS to be clonal.
[105-107]
  Hence, ADH and low 
grade DCIS may be considered a continuum of the same disease, distinguished 
arbitrarily by the extent of ductal involvement or lesional size, an approach adopted 
to avoid overtreatment and classification of small low grade lesions as DCIS.
[45]
  
 
With increased number of gene profiling studies, it has now become clear that a 
group of low grade lesions show striking similarity in terms of genetic alterations.   
This group of lesions include CCLs, ADH, low grade DCIS, as well as FEA and 
LCIS, which are also frequently found in association with low grade invasive breast 
cancer.  It is postulated that they may constitute a family of first morphologically 
identifiable precursors of low grade breast cancers 
[68, 98, 108, 109]
, the so-called low 
grade breast neoplasia family. 
 
It is understandable that there may be genetic alterations occurring even in normal 
breast tissues during life, as in any other type of tissues.  These alterations are not 
significant and do not shows overlap with specific genetic alterations seen in DCIS 
and IDC.  However, the presence of molecular alterations is not necessarily sufficient 
to suggest that these cells are non-obligate precursors.  It is worth noting that LOH in 
normal TDLUs does not seem increased in prevalence in breast tissues adjacent to 
breast carcinoma 
[110]
. By gene profiling, synchronous DCIS and invasive breast 
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cancer are found to have similar molecular profiles 
[111]
, particularly those of similar 
histological grade 
[112]
.  However, in the group with pure DCIS and IDC harvested 
from separate patients, gene profiling shows very different profiles, indicating that 
there are also unique patterns of gene expression in these two stages of breast cancer.   
 
When comparing gene expression profiles of DCIS and invasive breast cancer, Lee 
and colleagues identified 470 differentially expressed genes, of which 74 genes were 
found to be particularly significant with overlapping findings in 9 other similar 
studies in the literature 
[111]
.  The progression of DCIS to invasive breast cancer was 
studied in vivo using DCIS.com cell line engineered to express specific genes into a 
mammary DCIS xenograft model. Using lentiviral mediated RNA interference 
technique, progression of xenografts to invasive cancer is dramatically increased by 
suppressing four genes that are usually elevated in clinical samples of DCIS, which 
included a protease inhibitor (CSTA) and genes involved in cell adhesion and 
signalling (FAT1, DST, and TMEM45A), and strongly suggested that they normally 
function to suppress progression.  
 
When matched by histological grade and hormone receptor status, in situ and 
invasive breast cancer of either low or high  grade shows similar genetic profiles 
[85, 
104, 113]
,  i.e. low grade DCIS shares similar molecular signatures with low grade IDC, 
and high grade DCIS is similar to high grade invasive carcinoma.  Molecular 
analysis has failed to reveal any specific difference between in situ and invasive 
carcinoma in both categories.  No specific molecular events have so far been 
identified to illustrate the progression from in situ to invasive carcinoma, and this 
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process of progression may not necessarily be determined by specific genetic 
alterations or gene expression patterns. There may be multiple genetic or epigenetic 
aberrations occurring simultaneously in progression in each individual case, possibly 
with distinct genetic aberrations.  
  
The recent use of revolutionary technologies such as next generation sequencing 
(NGS) has seen a marked increase in the discovery rate of clinically relevant 
biomarkers. This has allowed the stratification of breast cancer into further detailed 
subtypes at the structural gene alteration level.
[114]
  The high throughput NGS is 
capable of screening multiple gene mutation and characterized the tumour 
heterogeneity at molecular level in a shorter period of time compared to conventional 
techniques.
[115] 
Recent NGS studies have revealed tumour in the same 
histopathological or immunohistochemical subtype display different classes of 
mutation. For instance, the tumours in luminal B subtype have unique gene mutation 
pattern involving  PIK3CA, TP53, BRAF, PTEN, GNAS, IDH1 and KRAS, 
[116]
 
whereas luminal A breast cancers show enrichment of specific mutations in PIK3CA, 
MAP3K1, GATA3,TP53, CDH1 and MAP2K4 
[117]
. Luminal subtypes acquired more 
diverse and recurrent significantly mutated gene compared to basal-like and HER2-
enriched subtypes.  Basal-like tumour often referred as the triple-negative breast 
cancer (TNBC) because they are typically negative for ER, PR and  HER2. However, 
a recent study has reported approximately 75% of TNBC are basal-like whereas the 
other 25% comprised all other mRNA subtype.
[118]
 The advent of molecular 
stratification of the breast cancer may shift our conventional “one size fits all” 
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approach to personalized treatment tailored to the specific characteristics of the 
tumour.
[119]
 
1.5 CELL CYCLE IN NEOPLASIA 
1.5.1 Overview of cell cycle 
The cell cycle is an important process in ensuring human wellbeing through its well 
organised and ‘high tech’ machinery system. It is of utmost importance to have a 
comprehensive knowledge of the regulation of cell cycle in order to reach better 
understanding of cancer. Generally, the cell cycle is composed of four concisely 
monitored phases, which begin from an active gap phase for growth and preparation 
of chromosomes replication (G1), followed by deoxyribonucleic acid (DNA) 
synthesis phase (S phase), after which the cell enters the premitotic gap where the 
cell prepares for mitosis (G2) and finally permits cell mitosis, nuclear and cytoplasm 
division (M phase), depicted as in Figure 1.3. In a condition whereby either in the 
absence of mitogenic signalling or in the presence of antimitogenic signalling, the 
cell may be brought forward to enter the non-dividing, quiescent state (G0).
[120]
 
Adhering to its tightly regulated process, the cell cycle built up two main 
checkpoints, which are at the G1/S and G2/M transitions where the cell can stop cell 
cycle progression in the effort to ensure DNA integrity. 
[121]
 There are also other 
minors checkpoints such as S-phase checkpoint which is activated by genotoxic
 
and 
spindle (mitotic) checkpoint activated by failure of kinetochore occupancy by 
microtubules or through lack of tension.
[122] 
Typically, a complete round of the cell 
cycle lasts about 24 hours though it may vary widely, mostly at the G1 phase.
[123] 
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The progression of a cell in a cell cycle is positively regulated by cyclin dependent 
kinase (CDK) whereas CDK inhibitors (CDKI) provide negative feedback to the cell 
cycle. Nevertheless, in order to become catalytically active, CDK needs to bind to its 
regulatory subunit namely cyclin after which it will undergo phosphorylation at  the 
threonine residue.
[124]
 On the other hand, CDK inhibitors which effectively act as 
tumour suppressors are classified into two classes that include the INK4 family such 
as P16, P15, P18 and P19 (inhibit CDK4 and CDK6) and the CIP/KIP family such as 
P21, P27 and P57 (inhibit cyclin A and E of CDK2 and of cyclin B-CDK1).
[122] 
The 
key factors that trigger activation of signal transduction of the negative regulators 
pathways either at G1 or G2 checkpoint are activation of phosphatidyl-inositol-3-OH 
kinase-like kinases (PIKKs), ataxia telangiectasia mutated (ATM) and AMT- and 
Rad3-related (ATR).
[121] 
Not least important, DNA damage leads to activation of P53 
gene the guardian of the cell genome which in turn acts as a cell break and arrest cell 
from further division.
[125] 
 
Inactivation of RB protein through phosphorylation catalysed by complex of cyclin 
D-CDK4/6 leads to activation of E2F, which in turn activates genes whose products 
are important in ensuring entry into S phase. The complex of cyclin E-CDK2 assists 
the Rb phosphorylation and E2F release.
[126]
 The cyclin A-CDK2 complex regulates 
the S phase whilst CDK1 (Cdc2) binds to cyclin B and monitors the G2/M 
checkpoint .
[127]
 At the end of G2, CDK1 is activated via dephosphorylation 
mediated by CDC25.
[128]
 Oncogenic stress or DNA damage activate cyclin-
dependent kinase inhibitors such as p53, INK4 family and CIP/KIP family.
[129] 
It is 
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postulated that RB maintains its hyperphosphorylated state until the completion of 
mitosis due the effect of high expression of cyclin A- and cyclin B in the G2-M 
phase.
[126]  
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         Figure 1.3 Schematic diagram showing an overview of cell cycle (adapted from  Pelengaris & Khan 
[130] 
) 
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1.5.2 Aberrant cell cycle in neoplasia 
The hallmark of cancer progression as observed by Hanahan and Weinberg (2000) is 
the direct general rules that cancer arises from compromised control of cell 
proliferation. Alteration in genetic control of the cell cycle results in uncontrolled 
cell growth. This unrestrained cell proliferation can be attributed to the aberrant 
function of key regulatory proteins that incorporate the cell cycle machinery 
itself.
[129]
 Generally, mutation can occur in two classes of genes which can promote 
cancer vis-a-vis proto-oncogenes and tumour suppressor genes. Proto-oncogenes are 
found in normal cell that regulate cell replication, growth, survival, differentiation or 
mortality. Mutation of the genes brings up the mutated form called oncogenes. 
Subsequently, this confers a growth advantage or increased survival of cells carrying 
mutations.
[15]
 This activation can be either  point mutation, gene amplification, 
chromosomal rearrangement or promoter insertion.
[131]
 Oncogenes are classified into 
four common, functional classes based on its function in regulating cancer which 
includes signal transducers, growth factor, transcription factors or receptors.
[23] 
Activation of oncogenes contributes to hematopoietic tumours and soft-tissue 
sarcomas, confirming their roles in aberrant cell cycle of tumour cells.
[132]
 Being the 
only proto-oncogenes involved in apoptotic pathway, altered regulation of its 
antiapoptotic or proapoptotic function of oncogene BCL-2 family proteins is 
common in many human cancers.
[133]
 Uncontrolled cell cycle may be plays an 
important role in the activation of oncogenes. 
 
In contrast to alterations in oncogenes, most carcinomas are initiated by the loss of 
function of a tumour suppressor gene
[132] 
Mutation in tumour suppressor gene may 
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cause a cell to lose its inhibitory function during cell proliferation. Fail-safe 
mechanisms of cell cycle checkpoint are interrupted, hence any genetic instability 
may progress the cycle and the abnormal the DNA information is passed on to the 
daughter cell.
[134]
 Deregulation of cell cycle checkpoints is common in human 
tumours. Abnormalities in expression of Rb pathway component including p16 
protein, G1 cyclins - cyclin D, CDK 4/6 and retinoblastoma protein (Rb) contribute 
to development of a number of human cancers.
[135]
 According to the NGS data, out 
of 572 genes listed in the cancer census, P53 is the most frequently mutated overall 
and is among the top three mutated genes in a majority of cancers.
[136]
 The mutated 
p53 gene loses its ability to control cell fate especially cell cycle arrest and apoptosis 
which eventually lead to the neoplastic development in the affected cell.
[137]   
 
The human genome is continuously being subjected to assault by exogenous and 
endogenous factors. Any damage or alteration in genetic sequence will be subjected 
to cell’s built-in repair system during cell cycle halt. Subsequently, the negative 
effects of toxic agents or mutagens are minimized through repair pathways with at 
least 130 known human DNA repair genes described.
[138]
 Mutation to the repair 
genes itself results in alteration in genetic information that leads to cancer formation. 
Rather than causing cancer directly, its mutation allows accumulation of mutated 
genes.
[139] 
This theory has been proven in the development of colorectal cancers as 
demonstrated by defective in the mismatch repair genes.
[140]
 In addition, it has been 
found that epigenetic silencing of the human nucleotide excision repair gene, hHR23, 
has attributed to myeloma progression.
[141] 
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1.5.3 Deregulation of the tumour suppressor pathway  
1.5.3.1 The role of p53 in neoplasia 
The p53 gene is the first tumour suppressor gene identified by Lane and Crawford in 
1979.
[142]
 The p53 gene is located on the short arm of human chromosome 17 
(17p13.1).
[143]
 Stress signals such as DNA damage, hypoxia, rNTP depletion, spindle 
damage, nitric oxide and oncogene activation can activate p53 via several mediators 
that act upstream of the pathway. The activation of p53 thus leads p53 protein to 
behave as a transcription factor and exhibit anti-cancer function through several 
mechanisms. It can arrest cell cycle at the G1/S checkpoint, activate repair genes that 
control the rate of mutation of all genes, indu ce programmed cell death or inhibit 
angiogenesis and any further metastasis.
[144]
 Through its important roles in regulating 
the integrity of the DNA, researchers has recognised it as the ‘guardian of the 
genome’ as shown by many studies that the most commonly mutated gene in cancer 
is the p53 gene.
[145, 146]
 In contrast to high expression of p53 protein in cancer cells, 
p53 has been found to have short half-life in normal cells due to MDM2-mediated 
degradation activity.
[147]
 Genetic alterations in p53 are seen in oesophageal 
tumorigenesis 
[148]
 and lung cancer 
[149]
. p53 mutations are present in 79% in 
squamous cell carcinoma (SCC) and 36% in dysplasia.
[150]  
 
The most commonly mutated tumour suppressor gene in breast cancer, p53, is 
affected in the form of specific hotspot point mutations.
[151]
 The mutation can be 
either somatically altered gene or inherited germline variant. The p53 mutations are 
distributed in all coding exons with a strong predominance in exons 4-9, which 
encode the DNA binding domain of the protein.
[152]
 It can be observed in 30% of 
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breast carcinomas wherein their distribution is highly linked to molecular subtypes of 
the breast lesion. It was reported p53 mutations can be found in 26% of luminal 
tumours, 50% of HER2 amplified tumours, 69% of molecular apocrine breast 
carcinomas and 88% of basal-like carcinomas.
[151]
 Germline mutations most 
frequently affected by missense variants and may derived from single base 
substitution.
[153]
 In addition to Li-Fraumeni syndrome, germline p53 mutations can 
be found significantly higher frequency in breast carcinomas arising in carriers of 
germline BRCA1 and BRCA2 mutations.
[154]
 
 
1.5.3.2 The role of P16 in neoplasia 
P16 belongs to the INK4 family which is one of the cyclin-dependent kinase 
inhibitors family. It inhibits cyclin dependent kinase 4 (CDK4) the mediators protein 
at G1 phase of cell cycle.
[155]
 Similar to other CDKI, deletion, mutation or 
transcriptional repression of P16 lead to unconstrained cell proliferation and cancer 
formation.
[156]
 Located at INK4A/ARF (CDKN2A gene) locus on the short arm of 
human chromosome 9 (9p21), P16 shared the same exons with P14 which only differ 
in the alternative reading frame.
[157] 
This chromosomal region has been found to be 
inactivated in almost half of all human cancers with inactivation frequency ranging 
from 25% to 70%.
[158]
 A study conducted using human cell lines shows the gene 
undergoes frequent deletion and rearrangement in human cancers such as melanoma, 
glioma, lung cancer and leukaemia.
[159] 
In addition, several mechanisms that lead to 
P16 inactivation including loss of heterozygosity, homozygotic deletions, point 
mutations and promoter methylation.
[158]
 INK4a protein mutations inhibit its binding 
to CDK4 or CDK6, and allow Rb protein phosphorylate ion and thus permit the cell 
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to exit at the S phase even in the presence of aberrant genetic information. This 
breakable checkpoint leads to inheritance of unstable genetic information thus brings 
the cell to neoplasia changes.
[160] 
Taken together, these finding suggest the role of 
P16 in suppressing tumour progression as its normal function, and disruption in 
genetic organisation of P16 will predispose a cell to undergo unrestrained cell 
proliferation. According to TCGA databases, high expression of CDKN2A is a 
signature characteristic of basal-like subtype 
[117]
 and a subgroup of TNBC subtype 
(basal A TNBC).
[161]
  Breast cancers reported with elevated P16 expression are 
associated with a high proliferative index which is believed to be indicative of Rb 
functional loss.  
 
1.5.3.3 The role of P21 in neoplasia 
P21 protein is a product of WAF1/CIP1/SDI1 (wild-type p53-activated fragment 1/ 
cyclin dependent kinase-interacting protein1/ senescent cell-derived growth inhibitor 
1) gene on the short arm of chromosome 6 in 6p21 region.
[162]
 It is may also be 
known as melanoma-derived antigen 6 (MDA6) or cyclin-dependent kinase inhibitor 
1A (CDKN1A). P21 may be activated via p53 dependent or independent pathways.  
Activation of p53 upon DNA damage leads to transcriptional activation of P21 and 
blockage of cyclin A, thus arresting the cell cycle at G1 phase and concomitantly 
prevent apoptosis.
[163] 
Though P21 activation is a critical downstream effector of the 
p53 pathway, it may be activated independently by the presence of mitogens such as 
transforming growth factor-β1 (TGF β1).[164, 165] P21 carries the load for p53-
mediated proliferation arrest following DNA damage and is known to maintain cell 
cycle arrest to ensure continuation of terminally differentiated cells such as skeletal 
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muscle cells.
[166] 
It has been observed that P21 expression is interrupted in various 
human neoplasms. P21 is over expressed in 32 % breast cancer patients and is 
associated with large tumour size, positive nodal status, high histological grade and 
high mitotic count.
[167] 
Loss of P21 in human colon carcinoma results in cancer cells 
entering cell cycle arrest in G2-like state and form polyploidy nuclei which then 
undergo apoptosis following genomic stress.
[168] 
Manipulating the expression of P21 
can be used to support chemoprevention and other therapies.
[169]
 Based on the current 
knowledge of P21 as an anti-apoptotic protein, it is clear that attenuation of P21 level 
in cancer cells may improve the efficacy and decrease the toxicity of standard DNA-
damaging chemotherapeutic agents.
[163]
 
 
 
1.5.3.4 The role of P14 in neoplasia 
P14 is encoded within CDKN2A locus on the 9p21 region of human chromosome 9. 
It shares the same exons with P16, only differ on the alternative reading frame - it is 
also known as ARF. Its tumour suppressor activities are projected in both G1 and G2 
phases.
[170] 
Instead of acting directly as a tumour suppressor, P14 mediates activation 
of p53 via ARF binding to the P53 inhibitor, MDM2 and enhanced degradation of 
MDM2.
[171]
 It has been postulated that stabilisation of p53 from induction of 
abnormal proliferative signals or loss of Rb is mediated by P14 via activation of 
E2F1 protein. It is suggested the P14 plays and important role in activation the P53 
pathway without direct induction from DNA damage.
[172]
 Hence, alteration in P14 
expression is shown to contribute to the progression of cutaneous squamous cell 
carcinoma.
[173]
 Lower expression of P14 has been observed in oesophageal squamous 
cell carcinoma.
[174] 
Though specific ARF mutations are less frequent than P16 
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mutations, mutations on INK4a/ARF locus affect expression of P16 and P14. 
INK4a/ARF gene mutations impaired p14 function and have been found to contribute 
to melanoma formation.
[175]
 
 
1.6 SENESCENCE 
1.6.1 Molecular and cell biology of senescence 
In 1961, Hayflick and Moorhead convincing showed that human cells in vitro do not 
divide indefinitely as previously thought, originating the theory of cellular 
senescence
[176]
. The latter is defined as  the state of irreversible loss of cell replicative 
ability and appears to be influenced  intrinsically and extrinsically via the signal 
transduction cascade in cancer involving the p53 and P16 pathways
[177]
. One of the 
critical responses for sustaining cellular integrity is when a cell irreversibly desists to 
replicate after exposure to influences promoting  perpetuated cell replication and to 
environmental stress
[178]
. 
 
Cellular senescence is the state of irreversible loss of cell proliferation in response 
towards two factors: i) Intrinsic factor involving telomere shortening and ii) extrinsic 
factors involving oncogenic/mitogenic stimuli, DNA damage and tumour suppressor 
mutation mechanisms.
[179]
 In conjunction with molecular changes, senescent cells 
also acquire characteristic morphological features. At the ultrastructural level, 
senescent cells show protein misfolding in the endoplasmic reticulum
[180]
. 
Microscopically, the cells are enlarged, flat and irregular
[181]
 with vacuolated, 
granular cytoplasm
[178]
. In addition, a study using human diploid fibroblast cell lines 
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showed phenotypic changes involving the activation of Rb family proteins, with 
enhancement of actin stress fibres and the redistribution of focal adhesion 
proteins
[182]
.  It has been proposed that the key to regulation of focal adhesion kinase 
activity and the formation of altered actin stress fibre in the senescent cells is 
caveolin-1 (Cav-1)
[181]
.  Cav-1 has been found to play a role in regulating 
tumourigenesis in a number of human cancers, including breast cancer. Cav-1 is 
shown to suppress the growth of breast tumours.
[183] 
 
The growth cessation of a senescent cell is attributed to cell cycle arrest at the G1/S 
interface.
[184]
 Though senescent cells are incapable of dividing in the presence of 
mitogenic stimuli, they are still metabolically active. Senescent cells are capable of 
expressing senescence-associated β-galactosidase (SA-B-gal) and P16, and show 
robust secretion of numerous growth factors, cytokines, proteases and other proteins 
(SASP) as well as nuclear foci containing DDR proteins (DNA-SCARS/TIF)  or 
heterochromatin (SAHF).
[185]
 Production of SA-B-gal at pH 6.0 either in vivo or in 
vitro by senescent cells is now used as the standard biomarker of senescence 
activity
[186]
. In addition, expression of matrix metalloproteinases, cathepsin B and β4 
integrin are elevated in senescent prostatic epithelial cells 
[187]
. 
 
Senescence can be categorised as replicative or oncogene-induced. Replicative 
senescence is the state that accompanies the exhaustion of replicative potential of 
cells, and is triggered by telomere shortening during cell division.
[188] 
On the other 
hand, oncogene-induced senescence (OIS) is promoted by the activated RAS 
oncogenes,
[189]
 DNA damage or other cellular stresses
[190]
. 
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1.6.2 Replicative Senescence vs Premature Senescence 
Proliferation of human cell does not progress in an indefinite manner but instead they 
are actually mortal after undergoing a few rounds of cell cycling. The irreversibly 
arrested ability to divide has affected not only the human somatic cells, but also adult 
stem cells in a similar manner.
[191] This phenomenon which known as Hayflick’s 
limit was discovered after Hayflick and colleagues found that  embryonic tissues 
could only divide a finite number of times in culture.
[176]
 The limitation which is now 
well recognised as replicative senescence is believed to be related to shortening of 
telomeres that occur with each replication cycle.
[192]
 Telomere, the tandem repeats of 
six nucleotide sequence TTAGGG functions to maintain chromosomal integrity from 
being recognised as damaged DNA. Its length are being preserved by means of an 
enzyme activity called telomerase.
[193]
 Telomerase prevent exposure of the uncapped 
ends of telomeres, and thus ensures the continuity of cellular proliferation. 
Surprisingly, even in the presence of telomerase activity, telomere can undergo 
progressive shortening which eventually limits the replication capacity.
[194]
 Telomere 
becomes progressively shorter with every round of cell cycle as part of the ageing 
process whereby double-stranded DNA breaks occur. The consequence of telomere 
shortening is the activation the p53 and Rb tumour suppressor pathways which result 
in either senescence or apoptosis pathway.
 [195] 
 
Premature senescence is a telomere-independent pathway induced under various 
conditions.
[196]
 It was first classified as oncogene-induced senescence due to the 
finding of RAS activation that has led to permanent replication cessation which is 
similar to those seen in replicative senescence. Activation of premature pathway is 
Ch 1. Introduction 
 
 
40 
 
the consequence of response towards environmental factors such as DNA damage, 
oxidative stress as well as oncogenic activation.
[190]
 In vitro experimental work has 
shown that premature senescence can result from unconducive culturing conditions 
which provoke culture shock.
[197]
 The loss of tumour suppressor has similar 
induction as in oncogenic mutation. Loss of the tumour suppressor B-cell 
translocation gene 3 (BTG3) in normal cells divert its proliferation into cellular 
senescence through the activation of P16. 
[198]
 
 
1.6.3 Senescence pathway in tumorigenesis 
Tumourigenesis in human cells arise by the stepwise accumulation of mutations and 
epigenetic factors that alter gene expression. The process may require a cell to 
undergo three lifetimes to evade the various neoplastic limiting processes at different 
check-points of the cell cycle to generate a cancer cell with estimated mutation rate 
at one in 2 x 10
7
 per gene cell division
[16]
. Whilst there are repair mechanisms to 
correct minor genetic events to preserve genome integrity, more deleterious gene 
alterations will direct cancer cells to undergo either programmed cell death or 
senescence.
[21] 
 
Senescence opposes cellular transformation in vitro, and OIS is emerging as a potent 
protective response to oncogenic events in vivo, by removing early neoplastic cells 
from the proliferative pool.
 [199-201]
 OIS prevents tumour growth via two main 
pathways: P16 INK4a-RB and ARF-p53. The senescent state of neoplastic cells can 
be induced or maintained by a number of factors via these two pathways. Many 
human cancers are associated with mutations in these pathways that are linked to 
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senescence or polymorphisms to P21, and the inactivation of p53 or Rb appears to 
extend the replicative lifespan of cells.
 [202]
 However, both P16 and p53 proteins are 
at the beginning of the senescence cascade and tumour cells can acquire downstream 
mutations that can block senescence despite high levels of these proteins.  Activation 
of p53 may lead to either quiescence (reversible cell arrest) or senescence 
(irreversible growth arrest) but the divergence between p53-induced quiescence and 
senescence is determined by the mTOR pathway in which p53 can suppress cellular 
senescence and convert to quiescence through the inhibition of mTOR
[203]
. 
 
Senescence markers have been identified in a number of human and animal tumours 
such as melanocytic naevi 
[204, 205]
, murine lung adenomas 
[206]
, human dermal 
neurofibromas 
[206]
, human and murine prostatic adenocarcinomas 
[200]
, murine 
pancreatic intraductal neoplasias 
[207]
 and murine lymphomas 
[201]
. Reinforcing the 
concept that senescence acts as a tumour suppressor, senescent cells in murine 
tumours induced by oncogenic RAS or inactivation of PTEN are enriched in the 
premalignant but not the malignant tumours 
[200, 201]
.  
 
As well as arresting proliferation of pre-neoplastic cells, senescence may also 
suppress tumour growth by initiating an immune response against the senescent cells. 
Reactivation of p53 in a murine liver carcinoma model not only induces senescence 
of the tumour cells, but provokes tumour clearance by the innate immune system.
 [208]
 
This is due, at least in part, to the production of inflammatory cytokines released by 
the senescent cells. 
[208]
 Indeed, it has recently been shown that senescent cells 
derived from different cell types have a similar ‘senescent-associated secretory 
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phenotype’ [209] that may contribute to the immune response against senescent cells 
in vivo. 
 
A significant aspect of OIS markers is their role in tumour chemosensitivity. An 
example is the decoy death receptor DcR2, which suppresses the tumour necrosis 
factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. DcR2 is 
involved in the regulation of chemosensitivity and its expression has been shown to 
be important in the progression of a number of human malignancies 
[210, 211]
. The 
efficacy of some chemotherapeutic drugs is dependent on their ability to trigger 
senescence at low doses, in contrast to those drugs requiring higher doses by acting 
via the apoptosis pathway.
[212]
 An inhibitor of NEDD8-activating enzyme drugs 
(MLN4924) has been shown to induce cellular senescence at low dose via 
inactivation of the Skp2-SCF complex, a protein which normally mediates 
degradation of a number of proteins including P21 and P27.
[213]
 Hence, senescence-
inducing chemotherapeutic agents have the advantage of less toxicity due to lower 
dosage and may be a useful alternative to treat tumours that are resistant to 
apoptosis-induced drugs.  
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Figure 1.4 Illustration of induction and molecular mediators involved in cellular 
senescence. Initiation signalling of cellular stresses or telomere shortening activate 
DNA damage response (DDR) pathway which in turn would activate senescence 
pathway.  
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1.6.4 Senescence dilemma in human cancers. 
The antiproliferative effect of senescence should raise the possibility that it may be a 
tumour suppressor mechanism. It is a critical regulator of tumour initiation and 
progression that may rival apoptosis in its roles in tumour biology.
[214]  
While there is 
protection from cancer at an early stage, it can ironically promote carcinogenesis in 
the later stages of progression.
 [215-217] 
  
 
It has been clear that cellular senescence encompass the two crucial tumour 
suppressor pathways: the p53 and P16 pathways which converge at the Rb 
pathway.
[178, 218-220]
 By entering either one of the pathways, the cancer cell may be 
directed into the senescence state and blocking cancer progression. Many studies 
have demonstrated that senescence blocks the proliferation of neoplastic cells 
through in vivo and in vitro studies. 
[189, 215, 221] 
In an in vivo study, H3K9me-
mediated senescence acts as a cellular brake in lymphomagenesis at an initial 
step.
[215]
 This theory was also supported by an in vitro study using rodent and human 
cells line. Induction of either p53 or P16 in response to abnormal mitogenic 
signalling promotes premature senescence, suggested it is a mechanism of tumour 
suppression.
[189]
  In addition, a study found inactivation of  tumour suppressor P16 
plays a role in cancer progression of a subset of sporadic endometrial carcinomas, 
especially in cases exhibiting aggressive clinical behaviour.
[222]
 Moreover, activation 
of BRAF
V600E
- induced senescence promotes cessation growth of benign naevi for 
decades and they only rarely become malignant.
[223] 
Further support of the role of 
senescence in preventing neoplastic transformation demonstrated by the finding of 
loss of tumour suppressor PTEN in the prostate, mediated through the induction of 
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P53 which in turn blocked further tumour progression.
[200]
 Taken all together, 
regardless of the initiation pathway, senescence plays an important role in 
terminating the growth of tumour cells.  
 
However, senescence acts as a double-edged sword, by acting as a cancer protector 
on the one hand and cancer promoter on the other. It is believed that senescent cells 
may change the tissue environment which in turn can promote tumour formation in 
the adjacent cells. Though senescent cell are inactive mitotically, it is still 
metabolically active. Production of growth stimulatory factor by senescent fibroblast 
cell results in the growth of mouse mammary epithelial cells.
[224] 
Importantly, the 
incidence of cancer increase exponentially with age.
[225] 
It is thought that the 
underlying mechanism of cancer formation is related to the cellular aging process. 
There is growing evidence that increase accumulation of senescent cells in aging 
tissues contributes to age-related pathology.
[186, 226, 227]  
It is not only the growth 
inhibitor pathways that are being activated, senescent cells also show increased 
expression of genes for secreted mitogenic, anti-apoptotic and angiogenic factors 
such as extracellular matrix (ECM) proteins Cyr61 and prosaposin and transforming 
growth factor (TGF)-α which are associated with paracrine tumour-promoting 
effects.
[228] 
 
 
1.6.5 Senescence and breast cancer 
Senescent cells accumulate in aging tissues and contribute to age-related pathology 
such as cancer 
[186, 226, 227]
.
 
 Since the incidence of breast cancer increases with age, it 
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is likely that the senescence pathway is involved in its development. Induction of 
cancer formation is associated with the accumulation of replicative senescence in 
normal human cells
[229]
 and with p21-induced senescence in tumour cells
[230]
. In 
addition to the activation of growth inhibitor pathways, senescent cells also show 
increased expression of genes for secreted mitogenic, anti-apoptotic and angiogenic 
factors such as extracellular matrix (ECM) proteins Cyr61 and prosaposin and 
transforming growth factor (TGF)-α associated with paracrine tumour-promoting 
effects
[228]
.This theory has been supported by a study which shows senescence may 
predispose  hepatocellular carcinoma development from chronic hepatitis C viral 
infecton
[231]
. 
 
The senescence response can be negated by inactivation of p53 and/or Rb function 
by any mutation of these genes, which can lead to continuous cellular proliferation. 
Mutation of the p53 gene, the guardian of the genome, is among the commonest 
genetic event in primary breast cancer
[136]
 and it appears to be more likely to be 
altered in high grade ductal carcinoma insitu (DCIS) that low-grade DCIS 
[232]
. p53 
gene mutations are found to occur before the development of invasive breast cancer, 
specifically in high grade DCIS
[233]
. p53 mutation is associated with more aggressive 
stage of breast cancer with worse survival rates 
[234]
. Patients with Li-Fraumeni 
syndrome possess high risk of developing breast cancer because they carry the germ-
line p53 mutation.
[235]
 Whilst mutation in p53 is common in primary breast cancer, 
mutation of CDKN2 gene which encodes P16 is a rare event, implying that the latter 
is not a critical genetic change in primary breast cancer formation 
[236, 237]
. However, 
a study has shown P16 overexpression in the cytoplasm and nuclei is associated with 
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a highly malignant phenotype of breast cancer 
[238]
. P16 gene activity reversely 
modulates the function of p53 in human mammary epithelial cells via the Rb 
pathway 
[239]
. Additionally, loss of p16 does not abrogate senescence in mouse 
embryonic fibrobalsts (MEFs)
[240, 241]
. 
 
The tumour suppressor gene P14, which acts as upstream regulator of p53, induces 
premature senescence through the activation of P21-dependent pathway. Induction of 
p21 has led to the formation of enlarged and flattened senescent cells 
[242]
. P14
 
is 
shown to contribute to the tumourigenic process within the breast in a p53-
independent pathway via association with HMdm2 (human Mdm2). It has been 
shown that there is over expression of P14 in 47% of invasive and non-invasive 
breast cancers 
[243]
. In addition, P21 is over expressed in 32 % breast cancer patients 
and is associated with large tumour size, positive nodal status, high histological 
grade and high mitotic count
[167]
. Despite its function as a tumour suppressor, P21 
found to be paradoxically induced cell cycle progression. In a recent finding, 
progestin, the synthetic progesterone showed induction of breast tumour progression 
by inducing expression of P21 via formation of a transcriptional complex with stat3, 
progesterone receptor and ErbB-2
[244]
. Recently, a novel senescence-associated 
miRNAs, miR-22 has been found to play important roles on the progression cancer 
of the breast. miR-22 activates senescence in breast carcinoma and restrains tumour 
enlargement as well as metastasis of the cancer 
[245]
. 
Tumourigenesis of the breast is believed arise from the overexpression of cyclin D1 
through its involvement with PRb inactivation
[246]
. The oncogenic properties of 
cyclin D1 make it a target for breast cancer therapy. Surprisingly, kinase-deficient 
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cyclin D1
KE/KE 
in mammary epithelial cells is still able to proliferate in response to 
ErbB2. This is due to upregulation of autophagy which account for reduced 
premature ErbB2-induced senescence
[247]
. Nevertheless, high activity of autophagy 
in breast cancer cells have been associated with retarded tumour growth by virtue of 
the contribution of overexpression of CDK-inhibitors (P16 and P21) inducing 
senescence
[248]
. Breast carcinoma is frequently under persistent oxidative stress 
caused by the overproduction of reactive oxygen species (ROS)
[249]
. ROS are major 
players downstream of RAS protein in the senescence pathway
[250]
. Oxidative stress 
can induce DNA damage and impel telomere shortening rates. Elevated ROS levels 
have shown to induce senescence through i) ARF/p53 pathway via activation 
ATM/ATR or ii) P16/Rb pathway via activation p38-MAPK
[251]
. 
 
Interestingly, the senescence pathway appears to play two contradictory roles in 
carcinogenesis. At the stage early carcinogenesis, cellular senescence acts as a 
protective mechanism against neoplastic transformation. However, later in the 
evolution of malignancy, senescence appears to stimulate neoplastic growth.
[201]
 This 
is because senescent cells may change the tissue environment that promotes tumour 
formation in the adjacent cells. Though senescent cells are inactive mitotically, they 
are still active metabolically in protein expression and secretion, thus acquiring a so-
called senescence-associated secretory phenotype (SASP) 
[252]
. Hence, senescent 
fibroblasts are found to have the ability to produce growth stimulatory factor that 
favours the growth of mouse mammary epithelial cells.
[224]
 Irradiated fibroblasts 
which are presumed to be senescent are shown to decompose the mammary epithelial 
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microenvironment and to stimulate relevant epithelial cell growth in the mammary 
gland, thus contributing to breast carcinogenesis 
[253]
. 
 
Hyperplasia of the breast is induced by activation of low levels the RAS oncogene
 
[254]
. On the other hand, further upregulation of the oncogene promotes permanent 
cell cycle arrest. However, breast cancer will eventually develop when the cells 
evade the senescence checkpoints
[254]
. Senescent cells secrete high levels of some of 
the matrix metalloproteinases (MMPs)
[255]
. High expression of RAS in senescent 
murine mammary gland is found to be associated with the production of matrix 
metalloproteinase-3 (MMP-3) and plaminogen activator inhibitor-1 (PAI-1)
[254]
. 
These metabolites are major contributors to breast cancer progression 
[256, 257]
. It has 
been shown high expression of MMP-3 and PAI-1 are correlated with malignancy in 
the mammary gland 
[258]
. Moreover, attenuation of TGF-ß signalling suppresses 
premature senescence in a P21-dependent manner and promotes oncogenic RAS-
mediated metastatic transformation in human mammary epithelial cells 
[259]
. 
 
1.6.6 Senescence de novo markers DcR2 and DEC1 in breast cancer 
Senescence de novo markers such as differentiated embryonic chondrocyte-1 (DEC1) 
and decoy receptor 2 (DcR2) were previously identified in cultured cells during 
tumour progression. DEC1 is also known as Stra13 or Sharp2 located at 3p26.1 
locus. It is a basic helix-loop-helix (bHLH) transcription factor that plays an 
important role in regulating circadian rhythm, cell division, cell death and 
malignancy in various cancers 
[260, 261]
. DEC1 is found to be a p53 target in the 
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induction of premature senescence. Over-expression of DEC1 initiates G1 arrest and 
senescence, and knockdown of DEC1 attenuates DNA damage induced premature 
senescence
[262]
. DEC1 mediates premature senescence through the Rb pathway by 
regulating phosphorylation of p130 (Rb2) protein.  In addition, it has been shown 
that expression of DEC1 and DcR2 is more likely in premalignant lung adenomas 
rather than in malignant adenocarcinomas 
[263]
. It has been observed that there is an 
increase in the expression of DEC1 during progression from normal to in situ and 
invasive breast carcinoma 
[264]
. These findings suggest that DEC1 may contribute to 
breast cancer progression to the invasive phenotype. This is in common with the 
finding of high expression of DEC1 in tumour tissues when compared to normal 
tissues in human kidney and lung 
[265]
.  
 
DcR2 or TRAIL-R4 is one of the genes targeted by p53, which acts as an anti-
apoptotic receptor for the tumour necrosis factor (TNF)-related apoptosis ligand 
(TRAIL). It acts as competitor to DR4 and DR5 for binding to Apo2L/TRAIL in 
order to inhibit apoptosis induction 
[266]
. Studies of DcR2 protein function have 
shown conflicting roles, with down regulation of its expression in various types of 
cancers, but high expression in more aggressive types.
[267]
 Cancers with over 
expression of DcR2 either within or over the cell surface are more aggressive 
compared to similar cancers with lower expression. This is due to association with 
TRAIL resistance.
[268]
 Loss of expression of DcR2 in carcinogenesis is directly 
related to aberrant methylation of its genetic make-up.
[269]
 Interestingly, reduced 
overall survival and disease-free survival have been shown in breast cancer patients 
with high expression of TRAIL-R4.
[270]
 Allelic polymorphism of 2699A/G of DcR2 
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gene with reduced DcR2 expression appears to be associated with reduced breast 
cancer risk 
[271]
. 
 
1.6.7 Important tools in senescence marker detection 
Senescence-associated marker is a network of tumour suppressor that can be assessed 
at different molecular levels. The senescence pathway profile can be measured in 
human breast tumour samples through their constituent DNA, RNA or protein. The 
majority of the techniques can be integrated for the benefit of diagnosis and therapy. 
Formalin-fixed paraffin-embedded (FFPE) tissues were long known for its poor 
molecular biological materials due to its protein cross-linking characteristics.
[272]
 
Over the past two decades, the techniques have been developing and have 
successfully extracted DNA, RNA and proteins from FFPE tissues, albeit 
fragmented.
[273]
 The use of FFPE blocks for protein expression analysis through 
immunohistochemistry techniques has been found since 1991 after a new approach 
on antigen retrieval was discovered.
[274]
 It is the most cost effective techniques and 
world widely accepted in diagnostic pathology. With the current growing availability 
of wide range of antibodies, it allows broader contribution to the diagnostic, 
prognostication and prediction of response to the therapy within practical time.
[275]
 
Protein expression in FFPE tissue samples also can be assessed by western blot and 
reverse phase protein arrays techniques. Both techniques can quantitatively analyse 
the protein abundance. Nevertheless, both techniques only recently became possible 
to successfully analyse protein from FFPE tissues.
[276]
 Thus, it is less matured 
techniques compared to IHC when it comes to FFPE samples.   
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Studies on genetic aberration may further extensively develop senescence marker 
profiles. Fluorescence in situ hybridization (FISH) is the companion diagnostic test 
of an equivocal IHC results. It allows de novo discovery and routine detection of 
chromosomal rearrangement, amplifications and deletions that may associated with 
tumorigenesis.
[277] 
It was reported FISH results of HER-2 gene amplification is more 
precise predictor to Herceptin therapy than IHC overexpression.
[278]
 Although IHC is 
a semiquantitavive analysis of clinical proteomics, it is the gold standard for 
histopathology diagnosis because of its simplicity, easier, widely accessible, quicker, 
informative result (differential diagnostic, localisation and functional) and cost-
effective procedure.
[275, 279, 280]
  Other translational analysis may be relatively 
sophisticated and less ambiguous, however due to budget limitation and large sample 
size, IHC is the most suitable techniques to address the hypothesis of this study.    
 1.7 HYPOTHESIS 
It is hypothesised that: 
- Molecular markers involved in the pathogenesis of breast cancer are aberrantly 
expressed in breast cancer tissue. 
- Senescence markers are expressed in benign hyperplasia and low grade invasive 
ductal carcinoma (IDC) but expression is lost in high grade tumours.   
- Loss of expression of senescence markers is associated with good prognostic 
indicators. 
- Variations in expression levels of molecular markers reflect differences in 
biological behaviour of primary breast cancer and can be used in predicting the 
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survival rate thus giving prognostic information beyond that provided by 
conventional pathological tumour assessment and staging. 
1.8 AIMS  
Thus the specific aims of this thesis are: 
 Set up a large clinical pathological data base of breast cancer patients in 
Sydney South West 
 Data mining of clinical, pathological and senescence biomarkers in breast 
cancer 
 Construct a large tissue microarray cohort for breast cancer to examine 
immunohistochemical expression of senescence markers (P53, P16, P14, P21, 
DEC1 and DcR2) 
 Assess expression of epithelial senescence markers in breast cancer tissues 
during its tumour progression 
 Determine the correlation between clinicopathological parameters with early 
validated senescence biomarkers  
 Clarify the prognostic value of the senescence markers in early stage of breast 
cancer to help define if these proteins could be of clinical value. 
 
1.9 THESIS OUTLINE 
This thesis is consisted of 10 chapters. Chapter 2 describes the materials and 
methods used in the study. Chapter 3 provides details of the clinicopathological 
aspects of the patient cohort and their tumours studied. Chapter 4-9 present 
results of immunohistochemical assessment of molecular markers and their 
relationship to clinicopathological parameters and patient survival. Chapter 10 is 
the conclusion describes how the aims have been fulfilled.  
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2.1 OVERVIEW OF RESEARCH DESIGN 
The study involved the retrospective cohort analysis of breast cancer progression 
from normal to malignant conditions based on patient tissue block for the period year 
2000 to 2011. Patient demographic data, histopathological data and 
clinicopathological parameters were retrieved and expressions of senescence 
molecular markers involved were evaluated by immunohistochemistry (IHC) 
staining techniques. The available data will be correlated to assess the role of 
senescence in breast cancer progression. A total of 6 validated senescence 
biomarkers in previous studies namely p53, P16, P21, P14, DEC1 and DcR2 will be 
examined. The molecular markers are involved in telomerase-independent 
senescence pathway; the former are either in the p53 or PRb pathway.  
 
Briefly, the steps involved in the project are consisted of: 
1. Retrospective cohort of patients with breast cancer information obtained from 
Liverpool Hospital database. 
2. Slides are retrieved from tissue archives to review pathological features of 
resected tumours.  
3. Paraffin-embedded blocks of resected tumours are used to construct tissue 
microarrays (TMAs) according to cancer stage. 
4. IHC staining of TMAs with antibodies against molecular markers of interest 
5. Assessment of IHC expression of molecular markers in different groups of 
breast cancers  
6. Correlation of molecular marker expression with clinicopathological 
parameters 
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7. Interpretation of results 
2.2 ETHICS APPROVAL 
This study has been granted ethical approval by the committee of South Western 
Sydney Local Health District Ethics and Research Governance Office 
(HREC/12/LPOOL/158). This study is conducted in accordance with the National 
Health and Medical Research Council’s National Statement on Ethical Conduct in 
Research involving Humans and the CPMPACH Note for Guidance on Good 
Clinical Practice. 
 
2.3 PATIENT COHORT  
The study cohort is consisted of up to 1080 women who underwent surgical resection 
at Liverpool Hospital in Sydney between 2000 and 2011. Cases which did not fit the 
subject criteria are excluded. Women with primary tumour are included in this study 
whereas patients who received preoperative neo-adjuvant chemotherapy or had 
previous excision or in review case were excluded from the study. Patient 
demographic data and clinicopathological data is obtained and correlated with the 
expression of senescence markers (Table 2.1).  The majority of tumours were 
estrogen receptor (ER)-positive, progesterone receptor (PR)-positive and HER2-
negative, accounting for 73.6%, 64.2% and 51.9% of the cases, respectively. Of the 
cases, 37.7% had missing HER2 status, as these cases were from earlier years in the 
cohort (2000-2005), when this marker was not routinely assessed in breast 
carcinomas.  
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Characteristics No of patients (%) 
Age 
≤60 years 
>60 years 
572     (53.0) 
508     (47.0) 
Tumour size 
≤20mm 
>20mm 
641     (59.4) 
439     (40.6) 
Grade 
Well 
Moderate 
Poor 
261     (24.2) 
441     (40.8) 
378     (35.0) 
Stage 
I 
II 
III 
IV 
451     (41.8) 
503     (46.6) 
115     (10.6) 
11       (1.0) 
LVI 
Negative 
Positive 
711     (65.8) 
369     (34.2) 
LNI 
Negative 
Positive 
679     (62.9) 
401     (37.1) 
ER 
Negative 
Positive 
Missing 
227     (21.0) 
795     (73.6) 
58       (5.4) 
PR 
Negative 
Positive 
Missing 
330     (30.6) 
693     (64.2) 
57       (5.3) 
HER2 
Negative 
Positive 
Missing 
561     (51.9) 
112     (10.4) 
407     (37.7) 
Normal tissue 
Available 
NA 
1053   (97.5) 
27       (2.5) 
ADH  
Available 
NA 
553     (51.2) 
527     (48.8) 
DCIS  
Available 
NA 
778     (72.0) 
302     (28.0) 
IDC  
Available 
NA 
1080   (100) 
0         (0) 
Table 2.1 Clinicopathological parameters included in the study. LVI, 
lymphovascular invasion; LNI, lymph node invasion; ER, estrogen receptor; 
PR, progresteron receptor; ADH, atypical ductal hyperplasia; DCIS, ductal 
carcinoma in situ; IDC, invasive ductal carcinoma; NA, not available 
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2.4 PATHOLOGICAL EXAMINATION OF TUMOUR SAMPLES 
2.4.1 Handling and Fixation of Specimens 
Tissue handling and fixation was done by the medical laboratory technologist. 
Resected breast specimens formalin fixed, processed and paraffin embedded before 
they are sectioned for microscopical examination. Macroscopic pathological 
examination of each specimen is undertaken and representative samples of tumour 
are cut and the tissue excision margins and lymph nodes are obtained by the registrar. 
These samples are sectioned approximately 3-5mm in thickness and are placed in 
labelled cassettes for processing into paraffin-embedded blocks using the Excelsior 
AS tissue processor. Prior to the processing of breast tissue, all breast specimens 
must be fixed overnight in 10% buffered formalin in room temperature. The tissues 
then processed through 14 solutions for 1 hour in each solution (Table 2.2). Formalin 
fixation is used to chemically preserve cells by crosslinking the proteins in tissue.
[281]
 
In addition, fixation stops tissue decaying by preventing autolysis by proteolytic 
enzymes as well as to inhibit microbial growth in tissue.
[282]
 However, prolonged 
fixation can chemically mask protein target and antibody binding. For optimum 
antigen retrieval immunohistochemistry the specimens should be fixed for no longer 
than 12 hours.
[283]
 Nevertheless, underfixed has more deleterious effect rather than 
overfixed.
[284]
 The American Society of Clinical Oncology/College of American 
Pathologist (ASCO/CAP) recommends fixation in 10% buffered formalin cannot be 
less than 6 hours and should be no longer than 72 hours.
[285] 
The issue of longer 
fixation times and protein cross-linking has been overcome through the modern heat-
retrieval methods.
[284] 
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Station Solution/Reagent Time Temperature 
1 10% Formalin 1 hour 45
0
C 
2 10% Formalin 1 hour 45
0
C 
3 75% Alcohol 1 hour 37
0
C 
4 90% Alcohol 1 hour 37
0
C 
5 95% Alcohol 1 hour 37
0
C 
6 100% Alcohol 1 hour 37
0
C 
7 100% Alcohol 1 hour 37
0
C 
8 100% Alcohol 1 hour 37
0
C 
9 Xylene 1 hour 37
0
C 
10 Xylene 1 hour 37
0
C 
11 Xylene 1 hour 37
0
C 
12 Paraffin wax 1 hour 60
0
C 
13 Paraffin wax 1 hour 60
0
C 
14 Paraffin wax 1 hour 60
0
C 
 
 
 
 
 
Table 2.2 Steps of tissue processing in the Excelsior AS tissue 
processor.  
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2.4.2 Specimen processing for histopathological examination 
Tissues are more commonly taken through a series of reagents and finally infiltrated 
and embedded in a stable medium which, when hard, provides the necessary support 
for microtomy. This treatment is termed tissue processing (Table 2.2). The sampled 
tissue blocks are processed overnight according to routine protocols. After fixation, 
tissue is dehydrated through a series of graded ethanol baths to displace the water, 
and then infiltrated with wax. The tissue is introduced to the 75% alcohol which is 
then gradually introduced into absolute alcohol. After that, the tissue will be 
immersed into the xylene, the solvent that is miscible with wax. Alcohol and xylene 
process are run at 37
0
C. Finally tissues are infiltrated with paraffin wax at 60
0
C. The 
blocks are cut at 4µm thin sections using the microtome which are then mounted on 
superfrost ultra plus glass slides. The slides improves tissue adherence to assist 
special staining.    
 
2.4.3 Haematoxylin and Eosin Staining 
The hematoxylin and eosin stain or also known as H&E stain is the primary 
diagnostic technique to analyze tissue section for diagnosis. Oxidisation of 
haematoxylin results in haematin, a colored compound when it binds to metallic 
salt.
[286]
 This complex has the characteristic of a strong cationic dye. The negative 
charge of nuclear chromatin creates a strong bond with the dye which then gives rise 
to the appearance of blue colour.  Eosin is an anionic dye that will stain pink the 
cationic protein groups such as collagen, red blood cells and the cytoplasm of most 
cells.
[287] 
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2.4.4 Light Microscopic Examination of Tumours 
The original H&E slide of every case is retrieved from the archives and reviewed 
along with the original histopathology reports to look for the tumour blocks. The 
pathological parameters (Table 2.2) of interest are obtained and recorded in a spread 
sheet. Tumour size is obtained from the macroscopically recorded largest dimension 
in the original pathological reports. The parameters are divided into categories that 
are dichotomous where possible to assist in statistical analyses.  
 
Table 2.3 Pathological parameters are dichotomized for statistical analyses. 
 
2.4.4.1 Tumour Typing  
The histological subtype of tumours is determined according to the world Health 
Organization (WHO) classification of tumour. The great majority of breast 
neoplasms arise from epithelial cells with non-epithelial cancer accounting for less 
than 1%.
[288]
 Typing of pre-invasive breast lesions is less established compared to 
invasive breast carcinoma. Invasive ductal carcinoma, not otherwise specified (ductal 
NOS) comprises the largest group of invasive breast cancers. It is a heterogeneous 
Feature Categories 
Age ≤60years or >60years 
Tumour size ≤20mm or >20mm 
Lymphovascular vessel invasion Absent or present 
Lymph node involvement Absent or present 
ER status Positive or negative 
PR status Positive or negative 
HER2 status Positive or negative 
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group of tumours. About 80% of invasive cases is associated with the occurrence of 
ductal carcinoma in situ (DCIS).
[289]
 The growth patterns may be cribriform, 
micropapillary, papillary, solid and comedo types, and multiple architectural patterns 
can coexist in one lesion. Diagnostic criteria of benign and pemalignant features are 
summarised in Table 2.3.  
 
 
 
Table 2.4 Diagnostic criteria of the pathologic lesion.
[290]  
Lesion Diagnostic criteria 
Atypical ductal 
hyperplasia (ADH) 
A neoplastic intraductal lesion characterized by proliferation 
of evenly distributed monomorphic cells. Low grade DCIS 
must have been considered as a differential diagnosis 
Architectural features: proliferation of evenly distributed 
monomorphic cells, may exhibit micro papillae, tufts, fronds, 
arcades, rigid bridges, solid or cribriform pattern 
Cytological features: single small, round to ovoid nuclei which 
are perpendicular to the bridges, similar to low grade DCIS 
Ductal carcinoma in 
situ (DCIS) 
A neoplastic intra ductal lesion characterized by increased 
epithelial proliferation, subtle to marked cellular atypia. 
Low grade/ Grade 1  Architectural features: arcades, cribriform, solid and/or 
micropapillary pattern, necrosis is uncommon 
Cytological features: Monotonous, uniform rounded cell 
population which are larger than the adjacent normal 
epithelium, subtle increase in nuclear-cytoplasmic ration, 
equidistant or highly organized nuclear distribution, round 
nuclei, hyperchromasia may or may not be present 
Intermediate grade/ 
grade 2 
Architectural features: solid, cribriform or micropapillary 
pattern, some ducts may contain intra-luminal necrosis and 
amorphous calcifications which are distributed as for grade 1 
Cytological features: Pleomorphism between low and high 
grade DCIS but often similar to low grade, nucleoli often 
present but small, nuclear to cytoplasmicratio is often high 
High grade/ grade 3 Architectural features: micropapillary, cribriform or solid 
pattern. Typically larger than 5mm, comedo necrosis and 
amorphous calcifications are common 
Cytological features: Highly atypical, large cells: markedly 
pleomorphic, poorly polarized nuclei with irregular contour 
and distribution, coarse, clumped chromatin and prominent 
nucleoli, abnormal mitoses common. 
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2.4.4.2 Tumour Grading 
According to WHO criteria, grading of invasive carcinoma is based on histological 
features that are previously defined by Elston and Ellis.
[291]
 Invasive tumours of the 
breast are routinely graded based on tubule formation, nuclear polymorphism and 
mitotic counts. Each characteristic is scored from 1-3. The grading system gives an 
indication of the aggressiveness of the tumour. The total score after the three values 
are added together is then classified into a three tier system consisting of: well (3-5 
points), moderate (6-7 points) or poor (8-9 points) differentiation. 
Table 2.5 The tumour features that are assessed for tumour grade. 
 
2.4.4.3 Lymphatic, vascular and lymph node invasion 
Microscopically, lymphatic and vein are two structures that are very difficult to 
differentiate. Hence, the term lymphovascular is used to cover both structures. 
Lymphovascular invasion is the invasion of tumour cells into the blood vessel and/or 
lymphatic system. Lymphatic vessels are the main path for tumour cells to reach the 
Feature Score 
Tubule and gland formation 
     Majority of tumour (>75%) 
     Moderate degree (10-75%) 
     Little or none (<10%) 
 
1 
2 
3 
Nuclear pleomorphism 
     Small, regular uniform cells 
     Moderate increase in size and variability 
     Marked variation 
 
1 
2 
3 
Mitotic counts 
Dependent on microscope field diameter 
 
1-3 
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axillary lymph nodes.
[292]
 Therefore, lymph node metastases commonly have 
lymphovascular invasion.
[293]
 Lymph node invasion is considered as the main route 
of tumour cells to disseminate to other site. Thus, evaluation of the invasion provides 
prognostic information for the disease and aids in treatment management.
[294]  
 
2.4.4.4 Pathological Tumour Staging 
Pathological tumour staging describes how much a cancer has grown and spread. 
Classification of the anatomical extent of the disease is required to determine the 
appropriate treatment and indicates prognosis. Histological slides of patients’ breast 
cancer tissues are reviewed microscopically in conjunction with the original 
histopathological report. The TNM staging of the breast cancers is based on clinical 
(TNM or cTNM) and pathological (pTNM) data (Appendix A). The study included 
patients from stage I to IV disease.   
 
2.5 PATIENT FOLLOW UP 
Patient follow-up information is obtained from medical record information 
documented at outpatient visits with the treating surgeon, patients’ general 
practitioners and the cancer registry of New South Wale (NSW). Overall survival 
period is calculated from the date of surgical excision to the date of death or the date 
of last follow-up. The follow up information such as date of death or date of last 
follow up are obtained. Patients who are still alive are censored at the date of last 
follow up. Disease-free survival is defined as the time from the date of surgery until 
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recurrence.  Date of recurrence or date of last follow up is obtained and patients who 
do not have recurrence are censored at the date of last follow up. 
 
2.6 TISSUE MICROARRAYS 
2.6.1 Background 
The development and application of tissue microarray (TMA) technology has been 
established since it was first introduction in 1998.
[295]
  Multiple cases can be 
analyzed in a single histological section. High-density tissue microarrays are 
constructed using multiple cylindrical cores from different donor paraffin-wax 
embedded tissue blocks. Representative areas of interest are punch biopsied from the 
donor blocks after matching with the marked slides. The tissue cores then transferred 
immediately into premade holes in the recipient block. Cores are coordinated in a 
symmetrical array. The technique has been validated as a valuable and accurate 
method for analysis of protein expression for large cohorts of breast carcinomas.
[296]
  
It can be used with any technique that is applicable to paraffin embedded material. 
In-situ hybridization studies for genetic rearrangement and expression of RNA, or 
immunohistochemistry using, for protein expression can be performed on the 
TMAs.
[297]
 Several types of TMA can be generated depending on the research 
question which commonly include multitumor arrays, progression arrays and 
prognostic arrays.
[298] 
 
TMA core sizes can range from 0.6mm, 1mm and 2mm. As many as 1000 cores can 
be incorporated in a single TMA block if 0.6mm core is used.
[299]
 However, TMAs 
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may be limited by tumour heterogeneity that results in tissue sampling that is not 
representative of the tumour. This can be overcome by having more than one core of 
donor sample. Nevertheless, a study has been validated that even a single 0.6mm 
core can be representative in 95 – 97% of breast carcinoma cases.[300] It has been 
validated that tissue microarray is not significantly different from full-tissue sections 
on statistical analysis. Therefore TMAs can be considered as representative of full 
sections for high throughput analysis
[301]
 and a single core of the breast cancer will 
provide the same information as the full section.
[302]
   
 
 
 
 
 
 
 
 
           Figure 2.1: The different steps involved in TMA construction. 
 
 
Sources : Giltnane, J.M. and D.L. Rimm, technology insight: identification of biomarkers 
with tissue microarray technology. nature clinical practice. oncology, 2004. 1(2): p. 104-
11.
[303]
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2.6.1.1 Advantages of TMAs 
TMA is a useful technique for high throughput molecular profiling. It has the 
advantage of requiring minimal amount of reagents and hence low cost. 
Theoretically, a single section from TMA blocks can incorporate up to 1000 
tumours. Therefore, it enables reduction in use of reagents, manpower needs and 
general costs for large cohort analyses. In addition, it can produce consistency in 
assay which lowers interbatch variability.   
 
2.6.1.2 Limitations of TMAs 
There are some limitations with the use of this technique: 
a) Construction of the array blocks is time consuming as it is labour intensive 
[304]
  
b) The individual tissue cores can be lost or folded when sectioning and 
staining. Pre-treatment of the blocks for a short period of time in the oven and 
having multiple cores for a case can minimize the problem.  
c) Tumour heterogeneity is high in tumour and certain parts of interest of a 
tumour may not be represented in the arrayed cores. However, having 
multiple cores for each tumour of each case is validated to overcome the issue 
with heterogeneity.
[301]
  
d) The H&E slides are slightly expanded and may not match perfectly with 
donor blocks. Therefore, the representative area may be missed during tissue 
arraying. 
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2.6.2 Construction of Tissue Microarrays  
a) Marking areas of interest on the H&E slides 
To assess the role of senescence in breast cancer progression, a collection of tissue 
arrays consisting of human breast cancer tissues will be investigated. Tumour and 
control samples were obtained from formalin-fixed paraffin embedded tissue blocks 
from surgically resected specimens of breast cancer from Liverpool Hospital 
patients. Using the light microscope, appropriate representative areas of interest were 
marked with a felt tip pen on H&E stained sections of donor tissue slides to assist in 
obtaining suitable areas for incorporation into the arrays.  
 
b) Collecting samples from donor blocks and insertion into recipient blocks 
Studies that use 0.6mm punch usually have 3 cores while those that involve 1mm 
punch tended to use two cores. This study used 1mm punches with two cores of each 
representative area from primary tumours sampled. Tissue morphology of normal, 
benign, premalignant and malignant features from each patient was punched. If the 
feature was not available, the grid was left empty. The arrangement of cores start 
from normal features followed by benign features progressing to premalignant and 
ends with malignant areas as depicted in figure 2.2.    
 
Tissue cores were obtained from the matched donor tissue block using the 1mm 
puncher of the tissue arrayer instrument (Beecher). The array construction instrument 
utilizes two vertical punch biopsy devices. First a core punch (red punch) is used to 
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make a well in the recipient block, and then a marginally larger diameter punch (blue 
punch) is used to obtain tissue from the donor block and insert it into the recipient 
block. Arrays were aligned at least 3mm away from the block edges to prevent the 
paraffin from cracking. The cylindrical donor cores were inserted into a recipient 
paraffin block spaced 1mm apart.  
 
The punch biopsy device had depth stops so that the cores were aligned at a uniform 
depth within the recipient block. A core of human tissue was placed in the corner of 
the first row of arrangement at each TMA blocks to assist in orientation and to serve 
as the marker tissue. TMA blocks arrangement were recorded on a template to 
register the details of each representative feature based on the donor blocks code in 
which the unavailable features were left blank. This information was subsequently 
entered into the statistical database. 
 
c) Sectioning the TMA blocks 
The total number of microarray blocks constructed was 150. The cores were placed 
towards the center to avoid cracking the blocks. TMA blocks were pre-heat treated in 
order to ensure that the inserted cores were attached well with the recipient block. 
This technique involved 5 minutes in the oven (60
0
C) alternating with 5 minutes in 
the fridge (4
0
c) for 5 times. The blocks were then put in the 4
0
c fridge until cut. This 
step is to prevent or minimize folded or loss of donor cores when sectioning. 
Sections were cut from the arrays at 4-5µm thickness and mounted on superfrost 
ultra plus glass slides. The plus glass slides improve tissue adherence which prevent 
tissue loss in procedures using heat induced epitope retrieval. Each section was 
picked up in the same orientation in which the orientation marker was sited at down 
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i ii iii iv 
left away from the label (see figure 2.3). The section slides then put in the -20
0
C 
fridge until staining.  
 
 
 
 
 
 
 
 
Figure 2.2: Tissue arrangement of TMA block  
 
 
 
 
 
 
 
Figure 2.3: Standard configuration of arrays section on plus glass slide. 
 
Different patient 
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2.6.3 Validity of TMAs in IHC assessment of tumours  
Validity and reliability analysis between IHC-TMA sections with the conventional 
whole section shows strong concordance in various tumour types.
[296, 301, 302, 304, 305]
 
For breast cancer, the currently recommended markers, evaluation protocols and cut-
off values of whole section can be reliably applied to TMA section.
[306]
 Therefore, it 
is a validated technology as a tool to study a large number of tumours. It has been 
successfully used in several predictive and prognostic studies of breast 
carcinoma.
[307, 308]
 
 
2.7 IMMUNOHISTOCHEMISTRY 
2.7.1 Introduction 
Immunohistochemistry staining is a powerful tool that can provide details of 
distribution and localization of biomarkers which can potentially increase the 
understanding of protein expression in relation to the architectural and cytological 
features of biological tissue.
[309]
 Therefore, it serves as an important adjunct for the 
routine morphological assessment of tissues. It is use to study the link between 
protein expression profiles and cellular phenotypes as well as the divergent 
characteristics of normal to the abnormal tissue.
[310]
 IHC is one of any other 
translational studies that can prove whether RNA is successfully transcribed to 
protein level cause of the presence of in vivo inhibitory RNAs.
[311]
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2.7.2 Principles of Immunohistochemistry 
The basic principle of immunohistochemistry techniques involves the “lock and key” 
binding concept of the antibodies towards specific antigen. The interaction of 
antibody to antigen is made visible through a visualization step using reporter 
molecules that can produce colour-end product. The reporter molecules may be 
enzyme, cofactor or fluorophore such as peroxidase, alkaline phosphatase, biotin, 
fluorescein (FITC) and R-phycoerythrin. The application of peroxidase-labeled 
antibody has been utilized since it was introduced in 1968 to overcome the obvious 
limitation of fluorescence antibody technique including overmasking other antigens 
and tendency of the colour to fade rapidly.
[312]
 The antigen-antibody interaction may 
either directly use labelled primary antibody or indirectly use labelled secondary 
antibody. The primary antibody may be either polyclonal or monoclonal. Polyclonal 
antibodies have slightly different specificity to the different epitopes present on the 
antigen whereas monoclonal antibodies bind specifically to one epitope on an 
antigen.  
 
2.7.3 Production of Antibody 
Polyclonal antibodies are commonly less preferable compared to monoclonal 
antibodies for IHC staining as it has lower specificity and high nonspecific 
background staining.
[313]
 Monoclonal antibodies were produced from identical parent 
cell after humoral response is activated upon target antigen injection. The clonal B-
cells from this response is fused with neoplastic myeloma cells to form a hybridoma 
that can be grown in vitro or injected into the animal to produce the monoclonal 
antibody of interest.
[313]
 Formation of hybridoma allows sustainable production of 
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antibody without depending on the animal’s life as well as lack of interbatch 
variability.
[314]
 Nevertheless, it is less sensitive since it is only directed to one 
epitope.  
 
2.7.4 Overview of Different Methods of IHC Staining 
There are several methods of IHC staining technique that can be utilised to localise 
cellular antigens. Fundamentally, the technique is categorised into two general 
methods that involve direct or indirect staining method (Figure 2.4). The direct 
staining method utilises only a single step which is the simplest way to detect the 
antigen by using directly labelled primary antibody. It can save staining time but 
possess several disadvantages such as limited range of conjugated antibodies and 
being less sensitive. The other method involves multistep indirect staining. It makes 
use of an unlabelled primary antibody which needs to be localised by the conjugated 
secondary antibody. Some of primary antibody especially mouse produced 
immunoglobulin, needs an additional step of adding a linker which acts as a protein 
stabilizer before it can be localised by the secondary antibody. The Indirect method 
is more widely used due to detection of multiple different antibodies by the same 
secondary antibodies and is more sensitive than the direct method. 
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Figure 2.4: Illustration of the direct and indirect staining method 
 
 
2.7.4.1 Peroxidase Anti-peroxidase Vs Avidin-Biotin Methods of 
IHC 
Peroxidase anti-peroxidase (PAP) and avidin-biotin (ABC) technique are both further 
development of the indirect method with the involvement of a third layer of molecule 
complex (Figure 5). The third layer is a very stable peroxidase anti-peroxidase 
complex or avidin-biotin complex. The presence of the complex amplifies the signal 
thus providing greater sensitivity than the direct and indirect methods. The avidin-
biotin method is a more sensitive technique than the PAP method as biotinylation 
process is a mild conjugation thus preventing the loss of sensitivity of the secondary 
antibody.
[315]
 Avidin, is the chicken egg-white glycoprotein that can bind non-
immunologically to four molecules of biotin.  
Antigen 
Labelled Primary 
Antibody 
Labelled Secondary 
Antibody 
Coloured end 
product Substrate 
Direct 
Method
Indirect 
Method
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Figure 2.5 Peroxidase anti-peroxidase (PAP) and avidin-biotin (ABC) technique 
 
 
2.7.4.2 Polymer-HRP IHC Detection System 
Although the avidin-biotin method is the most sensitive technique, it has certain 
limitations. Endogenous biotin can be found in tissues especially in liver and kidney. 
Therefore, it can lead to non-specific background staining and give false positive 
results. The polymer-based method has been introduced to overcome this limitation. 
A dextran polymer is used as the backbone to conjugate multiple antibodies and 
enzymes. The sensitivity of this method is comparably greater than the PAP and 
ABC methods.
[316]
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Figure 2.6 Polymer-HRP IHC detection system.  
 
2.7.5 Pitfalls in IHC staining 
Immunohistochemistry staining is a sensitive and technically complex method for 
studying tissues but there are specific limitations. Pre-analytic factors such as time to 
fixation, method of tissue processing, time of fixation and type of fixative contribute 
to the formation of protein cross-linkage.
[317]
 This process results in masking the 
antigen epitopes and limits their accessibility. It is recommended specimens are fixed 
in 10% of neutral buffered formalin within 1 hour after resection for 6 to 72 
hours.
[285]
 Appropriate and efficient antigen retrieval is required to undo the protein 
linkage by the fixative. False positive reaction may occur due to production of 
endogenous substances involved in IHC staining. Non-specific binding caused by the 
non-immunological attachment of the antibody to certain sites of tissue by 
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hydrophobic or electrostatic forces can be overcome with normal serum. Endogenous 
peroxidase should be blocked with hydrogen peroxide prior to incubation of the 
primary antibody while endogenous biotin needs to be pretreated with unconjugated 
avidin.
[313]
 Evaluation of an antibody clone specificity is necessary to avoid false 
positive signals.
[318]
 Therefore, multiple tests should be conducted aimed at 
optimization of the immunoreaction. The antibody specificity used in this thesis has 
already validated by western blotting and/or peptide blocking experiments performed 
by the manufacturer. Recommended positive and negative controls specified by the 
manufacturer were run in order to revalidate the specificity of the antibody.  
 
2.7.6 Antigen Retrieval 
Antigen retrieval is important in exposing the hidden epitopes during the fixation 
process thus increase the sensitivity of the staining. Antigen retrieval typically 
incorporates either heat-based technique or, less commonly enzymatic-digestion-
based technique. Heating methods include microwave oven, steamer or water bath 
while enzyme-based techniques involve proteolytic enzymes to break the protein 
cross-links. Evidence-based practice involves deparaffinized tissue sections 
treatment in 97
0
C water bath for 40 minutes, enhanced primary antibody detection by 
2-40 times compared to conventional antigen-retrieval procedures.
[319]
 Buffers pH 
and ionic strength also influence the effectiveness of heat-induced retrieval.  
 
  Ch 2. Materials and Methods 
 
 
 
78 
 
2.7.7 Rationale of Methodology 
Among many other translational techniques, IHC method is a well-established 
technique and readily adaptable to clinical practice. It can be applied to routinely 
processed tissue specimens that are obtained for diagnostic purposes from patients. It 
can be used as a complementary technique to conventional analysis of hematoxylin 
and eosin, therefore it functions as an adjunct for diagnosis. It can distinguish 
malignant features of variable grades.  In addition IHC is effective, and saves on cost 
and time.   
 
2.7.8 Method of IHC Staining Used in this Thesis 
 The sections were pre-heated in the oven at 600C for at least 30 minutes to make 
it stick well to the glass slides and to melt the wax. 
 Water bath was pre-heated to 980C along with the antigen retrieval buffer inside 
the slides rack container. 
 The array sections were deparaffinised in xylene 3 times (10 minutes each) and 
rehydrated through graded decreasing concentrations of alcohol. 
 The sections were then introduced into water prior to incubation in the pre-heated 
antigen retrieval buffer. Optimum retrieval was achieved depending on each 
antibody clone. It is either the citratre buffer pH 6.1 (EnVision
TM
 FLEX Target 
Retrieval Solution, Low pH DM829) or TRIS/EDTA pH 9.0 (Envision
TM
 Flex 
Target Retrieval Solution High pH Dm828). Incubation time vary depending on 
the tissue and antibody used (see table 1). 
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 Retrieval buffer container then taken out with the slides still remain inside for 
them to cool down to a buffer temperature of 65
0
C. It took approximately 3-5 
minute for the temperature to cool down to 65
0
C. 
 The slides were immediately taken out of the antigen retrieval buffer solution and 
transferred to the DAKO TBST wash buffer 1X concentration (Envision
TM
 
FLEX Wash Buffer DM831) in the coplin jar. 
 The slides were then marked around the array sections with the DAKO pen. This 
was to ensure immunoreaction will take place on the tissue itself and to save 
usage of consumables.  
 The slides were then returned back into the coplin jar containing the TBST wash 
buffer 1X for 5 min. 
 Endogenous peroxidase was blocked with hydrogen peroxide in phosphate buffer 
(Envision
TM
 FLEX Peroxidase-Blocking Reagent DM821) for 20 min at room 
temperature. The slides were then rinsed in wash buffer. 
 Primary mouse antihuman antibodies were applied to the section (slides). 
Incubation time varies depend on the type of antibody used (see table 2.5). The 
amount or volume of antibody required will depends on the size of the section.  
The antibodies were diluted in Dako Antibody diluent Tris buffer (Envision
TM
 
FLEX Antibody Diluent DM830). After that washed in wash buffer.  
 Dako Mouse linker (EnvisionTM FLEX +Mouse Linker DM824) was then 
added to each of section for 30 min then rinsed with wash buffer. Only mouse 
antibody needs the addition of a linker. A linker was used to amplify the antigen 
signal thus enhance the staining intensity. This was followed by washing in the 
wash buffer. 
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 Dako secondary antibody (EnvisionTM FLEX/HRP DM822) was used to detect 
any primary antibody-antigen complex. Slides were incubated for 30 minutes. 
Dextran backbone was coupled with horseradish peroxidase and goat secondary 
antibodies which can detect both the mouse and rabbit immunoglobulins. 
 The immunoreaction complex was visualized using the standard enzymological 
techniques. The peroxidase catalyses the reaction between DAB 
(diaminobenzidine) chromogen (Envision
TM
 FLEX DAB + Chromogen) with 
the substrate (Envision
TM
 FLEX Substrate Buffer) producing the brown 
coloured end product.  
 DAB   +    H2O2        oxidized DAB    +    2H2O  
                   (Substrate)       (Brown end product)     
 
 
Table 2.6 Details of antibodies and staining conditions. 
Primary 
Antibody 
Clone Supplier Dilution Antigen retrieval 
solution 
Incubation 
time 
(minutes) 
P21 
SX118 
Monoclonal 
Dako 1:25 Tris/EDTA pH9 45  
P14 
Q8N726 
Polyclonal 
Sigma 1:50 
Citrate buffer 
pH6 
60  
DEC1 
BHLHE40 
8553 
Polyclonal 
IMGENEX 1:25 Tris/EDTA pH9 120 
DcR2 
EPR3588(2
) 
Monoclonal 
Abcam 1:100 Tris/EDTA pH9 90 
P16 
E6H4
TM 
 
Monoclonal 
Roche 
Neat pre-
prepared 
solution from 
manufacturer 
Pre-
prepared solution 
from 
manufacturer 
20 
p53 
DO-1 
Monoclonal 
Invitrogen 1:800 
Pre-
prepared solutio
n from 
manufacturer 
20 
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2.8 CONTROLS  
This thesis used 2 types of controls to ensure the specificity of the IHC staining: 
a) A known positive control that stains positively. Lack of staining means a 
negative result in the test specimen may be a false negative.  
b) An omission negative control that stains negatively. This is obtained by 
omitting the primary antibody from IHC staining of the test specimen. Any 
positive staining is a false positive result suggesting either endogenous 
enzyme activity or non-specific absorption of the secondary antibody or other 
reagents. 
 
 
     
 
Table 2.7 Controls used for each tumour markers.  
 
Marker Positive controls Negative controls 
P21 
Normal stomach, normal breast, 
breast carcinoma 
The primary antibody was 
replaced by the antibody 
diluent on the same 
positive controls tissue 
P14 Human placenta, breast carcinoma 
DEC1 Brain, breast carcinoma 
DcR2 
Testis, placenta, stomach, breast 
carcinoma 
P16 Cervical cancer 
p53 Colorectal cancer 
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2.9 SCORING OF IMMUNOHISTOCHEMICAL STAINING  
Although IHC staining is widely used in diagnostic work, there is no accepted 
standardized method of interpretation and there is a general lack of published studies 
that have assessed the reproducibility of various scoring techniques. The discrepancy 
in results and reports of immunostains were consequences of the methodologic 
divergence. Standardization of initial steps of tissue processing and immunostaining 
technique can still be achieved but not the interpretation.
[320]
 Basically, the 
interpretation can be classified into qualitative assessment (assessment irrespective 
the degree of positivity) or quantitative assessment (estimation or exact percentage 
and intensity of positive cells).
[321]
 Generally, our study used semiquantitative 
assessment by estimating the intensity and percentage of positive cells. Assessment 
of IHC staining was performed without knowledge of the patient’s clinical details. 
An average score was obtained from the multiple biopsy samples of each case. 
 
2.9.1 Cut off Values for IHC Staining 
There is no universally accepted standardized method of quantifying IHC staining 
and there is a general lack of published studies that have assessed the reproducibility 
of various scoring technique especially in tissue microarrays study. Therefore, we 
adopted the scoring technique that has been accepted and published (Table 2.7), and 
which is relevant to the respective tumour marker. The hormone receptor (ER and 
PR) and HER2 status were taken from the original histopathological report. HER2 
was assessed by immunoperoxidase technique. For 2+ result will followed FISH 
confirmation test of HER2 overexpression.  
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Table 2.8 The cut off values of each tumour markers used in the thesis 
 
 
Marker Scoring Technique Cut Off Point Ref. 
P14 
Intensity: 
0 = no staining 
1 = weak staining 
2 = moderate 
staining 
3= strong staining 
 
Distribution: 
0 = no 
staining 
1 = <1% 
2 = 1-10% 
3 = 11-33% 
4 = 34-66% 
5 = 67-100% 
Final score: 
Addition of intensity and 
distribution score.  
 
Negative ≤ 2 
Positive ≥ 3 
[243] 
P21 Percentage of nuclear reactivity ≥5% 
[322-
324] 
P16 
Intensity: 
0 = no staining 
1 = weak staining 
2 = moderate 
staining 
3= strong staining 
Distribution: 
0 = no 
staining 
1 = <10% 
2 = 10-50% 
3 = 51-80% 
4 = >80% 
Final score 
Multiplication of intensity 
and distribution score.  
 
0–4: weakly positive,  
5-6: moderately positive,  
8–12: strongly positive. 
[325] 
p53 Percentage of nuclear reactivity ≥10% 
[167, 
326-
328] 
DEC1 
Intensity: 
0=negative 
1=weak 
2=moderate 
3=strong 
 
Distribution: 
0=<5% 
1=5-25% 
2=26-50% 
3=51-75% 
4=>75% 
Final score:  
Multiplication of the two 
score. 0- 12 
Negative= 0-4 
Weakly positive (+)= 5-8 
Strongly positive (++)= 9-12 
[329] 
DcR2 
Intensity: 
0=negative 
1=weak 
2=moderate 
3=strong 
Distribution: 
0=<10% 
1=10-40% 
2=40-70% 
3=>70% 
Final score: 
Addition of intensity and 
distribution score  
Negative ≤1 
Positive ≥ 2 
[330] 
Hormone 
receptor 
Percentage of nuclear reactivity 
Negative <1% 
Weakly positive 1-10% 
Positive >10% 
Patholo
gy 
report 
HER2 
Percentage of protein expression 
(IHC) 
Negative 0-1+ (<10%) 
Equivocal 2+ (≥10%) 
Positive 3+ (≥30%) 
Patholo
gy 
report 
Gene amplification 
Non amplified, diploid 1-2 
copies 
Non amplified, polysomy 
2.5-5 copies 
Low level amplification >5 
copies  
High level amplification ≥10 
copies 
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2.10 STATISTICAL ANALYSIS 
2.10.1General 
All analysis in this thesis has been analysed using the IBM SPSS Statistics 21.0 (© 
Copyright IBM Corporation 1989, 2012). P values of <0.05 were regarded as 
statistically significant. Associations between expression of each of the proteins and 
clinicopathological data were examined using the Pearson chi-square. Dichotomous 
variables were assessed using 2x2 tables. Continues variables such as patient age and 
tumour size were dichotomized based on previous studies by other researcher. 
Assumptions testing for chi-square test are random sampling, independence of 
observations and expected frequency is 5 or more.  If assumptions of Pearson chi-
square are violated, the Fisher exact test is used for 2x2 tables and Fisher-Freeman-
Halton test for RxC tables.
[331]
  Overall survival and recurrence-free survival were 
analysed using the Kaplan-Meier curves to estimate the likelihood of survival (or 
some other outcome of interest) at a specific point in time for the patient group. Log-
rank test was used to compare the subgroups, in which comparison of two groups 
used pooled over strata and multiple comparisons (three or more groups) used 
pairwise over strata. Univariate and multivariate analyses were performed using the 
Cox proportional hazard regression test. Proportional hazards assumptions were 
checked using the hazard function plot and log-minus-log plot and residuals were 
checked using the Schoenfeld residuals. The assumption of time-independent effects 
was not violated. The clinical endpoint overall survival was defined as time from 
date of surgery until death by any reason and recurrent free survival as time from 
date of surgery until any recurrence (locoregional or distant). Patients with no 
recurrence (for recurrence free survival) or who were still alive (for overall survival) 
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at last follow up were censored. Missing data were analyzed using available-case 
analysis. 
 
2.10.2 Survival Analyses 
2.10.2.1 Background 
Survival analysis provides an estimate of the likelihood of survival (or some other 
outcome of interest) at a specific point in time for a group of patients. Survival 
curves provide a graphical representation of the variation of survival rates with time. 
Patients who are observed until the end point of interest is reached (e.g. death) are 
termed ‘uncensored cases’, while patients who survived longer than the follow-up 
period or who are lost to follow-up are said to be ‘censored cases’.[332] Statistical 
methods have been developed that take into account both uncensored and censored 
cases including the Kaplan-Meier method
[333]
 and the life table (actuarial) method. 
Kaplan-Meier and Life Tables are two methods devised to calculate cumulative 
incidence among persons with differing lengths of follow-up time. 
 
In the life table method of survival analysis, the time period a group is observed for 
is divided into fixed intervals and for each interval; an estimate is made of the 
proportion of patients surviving the time period. The cumulative survival rate is 
calculated based on the product of the probability of surviving an interval and the 
probability of surviving previous intervals. The median survival time is determined 
as the time taken for half of the patients to die (or reach the end point of interest), so 
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it can only be calculated if at least half of the patients die. The Kaplan-Meier method 
provides similar information to the life table method but is calculated based on the 
proportion of cases surviving to the time when each death occurs, rather than to fixed 
intervals of time. These methods make the assumption that censored patients do not 
systematically differ from uncensored cases.  
 
The Cox proportional hazards model was developed to assess the effects of multiple 
variables on survival time when some of the observations are censored (unknown). 
[334]
 This method provides an estimate of the relative influence of multiple factors or 
covariates upon outcome and so is a form of multivariate analysis (MVA), while the 
Kaplan-Meier and life table methods are univariate analyses. Care must be taken in 
interpretation of the results as different survival may reflect differences in the patient 
population not evaluated by MVA rather than the effects of the molecular marker.  
 
2.10.2.2 Survival Analyses in This Thesis. 
Kaplan-Meier survival analysis was conducted to estimate the likelihood of survival 
at a specific point in time for the patient group. The log rank test was used to assess 
differences in survival curves by testing the null hypothesis that subgroups of 
patients would have equivalent survival. Comparison of two groups used pooled over 
strata and multiple comparison (three or more groups) used pairwise over strata. 
Multivariate analysis was used to identify independent predictors of patient 
prognosis by evaluating prognostic associations of markers with overall survival 
while adjusting for the effects of relevant clinical and pathological factors. 
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Multivariate analyses were performed using the Cox proportional hazard regression 
test. Variables of multivariate test were selected according to the principle of fit. 
Log-minus-log plot, hazard function plot and partial residuals were applied to check 
model assumption. The assumption of time-independent effects was not violated. 
The clinical endpoints for overall survival were defined as time from date of surgery 
until death by any reason and disease-free survival described as time from date of 
surgery until any recurrence (locoregional recurrence and/or a distant recurrence, 
whichever came first). The follow up information such as date of death, date of 
recurrence or date of last follow up were obtained. Patients who were still alive (for 
overall survival) or no recurrence (for disease-free survival) at the latest follow up 
were censored. Three-year observed survival rates were calculated to provide an 
estimate of the proportion of patients surviving at least 3 years from the time of 
surgery, regardless of the cause of death. Missing data were analyzed using 
available-case analysis. Mortality hazard ratios (HR) or relative risk and 
corresponding 95% confidence intervals (range of two standard errors on either side 
of the HR) were estimated using a Cox proportional hazard model with a backward 
stepwise procedure. 
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CLINICOPATHOLOGICAL 
FEATURES OF INVASIVE 
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3.1 INTRODUCTION 
The well-established prognostic and predictive markers have been universally used 
to guide the clinical management of breast cancer patient for optimal treatment. 
Although surgical excision is the mainstay treatment, stratification of the patient 
based on prognostic and predictive markers have driven towards individualized 
adjuvant therapy. The likelihood of patient’s longevity and disease-free post-surgical 
survival can be measure through these individual prognostic parameters. Thus, in this 
chapter details the patient’s demographic, clinical and pathological characteristics. 
The information was then compared to other studies to examine the similarities of the 
populations studied to ensure that the TMA patients are a representative sample.  
 
3.2 RESULTS 
3.2.1 Patients demographic 
One thousand and eighty (1080) adult female patients with newly diagnosed breast 
cancer at Liverpool Hospital between year 2000 and year 2011 were studied 
retrospectively. The mean age at diagnosis was 60.1 ± 13.7 years (mean ± Standard 
deviation, SD) with median of 59.0 years. The patients ranged from young adult to 
elderly with age range of 27 to 102 years (Figure 3.1). Overall survival and disease-
free survival were determined in l033 and 1023 patients, respectively, with a median 
follow-up of 5 years. 
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3.2.2 Tumours clinical and pathological characteristics 
3.2.2.1 Pathologic lesion  
Tumours were chosen based on their histological classification according to the 
World Health Organization (WHO) Histological of tumours of the breast. Cases 
classified as infiltrating/invasive ductal carcinoma (IDC) were used as the primary 
subjects involved in this study as IDC is the commonest breast lesion diagnosed in 
the South Western Sydney area. IDC cases were then re-examined using light 
microscopy to stratify the morphology based on their histological features. This 
study examined 1080 patients of invasive ductal carcinoma series with concomitant 
appearance of 778 (72.0%) premalignant (ductal carcinoma in situ), 553 (51.2%) 
benign and 1053 (97.5%) normal morphology found to be available in the TMAs.  
 
3.2.2.2 Tumour size 
The mean tumour size was 21.5 ± 13.9 mm (mean ± SD), with a median of 18.0mm 
which varied from 1 to 112 mm. Figure 3.2 shows the tumour size frequency 
distribution curve which are skewed to the left. Tumour size was not significantly 
associated with patient’s age. Larger tumour size was more likely associated with 
lymphovascular invasion (Χ 2=65.61, p<0.0001) and lymph node invasion (Χ2=67.35, 
p<0.0001) compared to smaller tumours. ER (Χ 2=24.34, p<0.0001) and PR (Χ 
2
=18.75, p<0.0001) were expressed more in small tumour size while HER2 
expression did not associate significantly with tumour size (Χ 2=0.662, p=0.42).  
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Figure 3.1 Histogram of patient’s age at diagnosis amongst breast cancer cases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Distribution of tumour sizes among patients. 
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3.2.2.3 Tumour grade 
The majority of tumours were moderately differentiated (40.8%) while 35.0% were 
poorly differentiated and 24.2% were well differentiated. Tumour grade was 
significantly associated with other clinicopathological characteristics such as patient 
age, tumour size, stage, lymphovascular invasion (LVI), lymph node invasion (LNI), 
estrogen receptor (ER), progesterone receptor (PR), and HER2 (Table 3.1). The 
younger patients (40%) tended to have more aggressive tumour compared to older 
patients (35%) (Χ2=16.05, p<0.0001). Larger tumours are 46% more likely to be 
more aggressive than smaller tumours 28% (Χ2=52.98, p<0.0001) (Figure 3.3).  
 
Early stage cancer was associated with less aggressive growth, whereas advanced 
stage cancer was correlated with more aggressive growth (Χ2=80.55, p<0.0001). The 
more aggressive the tumour, the more likely it tends to invade the lymph and blood 
vessels (LVI) (Χ2=46.71, p<0.0001). In addition, aggressive cancer was significantly 
more likely to metastasize to lymph node (LNI) (Χ2=21.88, p<0.0001) (Figure 3.4).  
 
ER and PR positive tumours were less aggressive compared to the negative tumours; 
otherwise HER2 positive tumour was more aggressive compared to HER2 negative 
tumour (ER, Χ2=210.96, p<0.0001; PR, Χ2=134.85, p<0.0001; HER2, Χ2=52.04, 
p<0.0001) (Figure 3.5). 
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Table 3.1 Association of grade with clinicopathological characteristics. 
*P<0.005 statistically significant 
  
 
 
 
 
 
Characteristics Differentiation, No (%) N Χ 2 p-value 
  well moderate poor    
Age 
<60 
115 
(20) 
230 
(40) 
227 
(40) 
1080 16.05 <0.0001* 
 
≥60 
146 
(29) 
211 
(42) 
151 
(35) 
Size 
<20 
197 
(31) 
267 
(42) 
177 
(28) 
1080 52.98 <0.0001* 
 
≥20 
64 
(15) 
174 
(40) 
201 
(46) 
Stage 
I 
155 
(34) 
196 
(44) 
100 
(22) 
1080 80.55 <0.0001* 
 
II 
94 
(19) 
193 
(38) 
216 
(43) 
 
III 
10 
(9) 
47 
(41) 
58 
(50) 
 
IV 
2 
(18) 
5 
(46) 
4  
(36) 
LVI 
Absent 
208 
(29) 
299 
(42) 
204  
(29) 
1080 46.71 <0.0001* 
 
Present 
53 
(14) 
142 
(39) 
174  
(47) 
LNI 
Absent 
190 
(28) 
282 
(42) 
207  
(31) 
1080 21.88 <0.0001* 
 
Present 
71 
(18) 
159 
(39.7) 
171  
(43) 
ER 
Negative 
7 
(3) 
48 
(21) 
172  
(76) 
1022 210.96 <0.0001* 
 
Positive 
240 
(30) 
362 
(46) 
193  
(24) 
PR 
Negative 
39 
(12) 
91 
(28) 
200  
(61) 
1023 134.85 <0.0001* 
 
Positive 
209 
(30) 
319 
(46) 
165  
(24) 
HER2 
Negative 
154 
(28) 
223 
(40) 
184  
(33) 
673 52.04 <0.0001* 
 
Positive 
1 
(1) 
40 
(36) 
71  
(63) 
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Figure 3.3 Bar charts of histological grade vs. general characteristics. a) grade vs. 
age b) grade vs. size.  
 
a) 
b) 
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Figure 3.4 Bar charts of histological grade vs. extent of disease. a) grade vs. stage b) 
grade vs. LVI c) grade vs. LNI 
 
 
 
c) b) 
a) 
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Figure 3.5 Bar charts of histological grade vs. hormone receptors. a) grade vs. ER b) 
grade vs. PR c) grade vs. HER2. 
 
 
 
 
a) b) 
c) 
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3.2.2.4 Extent of the Disease 
Tumours were staged using the American Joint Committee on Cancer (AJCC) 
Tumour-Node-Metastasis classification. The majority of tumours were stage II with a 
total of 503 (46.6%) patients followed by 451 (41.8%) patients with stage I disease. 
A total of 115 (10.6%) patients had stage III while the other 11 (1%) patients were 
stage IV (Figure 3.6). The group included 401 patients with regional lymph node 
metastases. Node positive breast cancer were significantly associated with staging (Χ 
2
= 527.90, p<0.0001), tumour grade (Χ 2= 21.88, p<0.0001), tumour size (Χ 2= 67.35, 
p<0.0001) and HER2 (Χ 2=11.80, p<0.0001). There was no significant association 
between nodal metastases and age, ER and PR status.  
 
 
 
 
 
 
 
 
 
 
 
 
 
                               Figure 3.6 Tumour stages included in the group 
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3.2.3 Survival Analysis of Patients 
 
Using the Kaplan-Meier method, the estimated mean overall survival period for the 
entire group of breast cancer patients was 12.2 years (95% CI 11.8-12.6) with a total 
of 151 (14.6%) deaths and 880 (85.4%) still alive during the follow up period. The 1 
year, 2 year, 3 year and 5 year survival rates were 98.5%, 96.5%, 93.1% and 87.0%, 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 Survival probabilities among breast cancer patients with invasive ductal 
carcinoma (Kaplan-Meier survival curve). N = 1031 with 151 having died and 880 
still alive (marked with +). As less than 50% of the observations are uncensored, the 
median survival time cannot be estimated from Kaplan-Meier curve. 
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Relative survival rates of each clinicopathological covariate were determined to 
assess its relationship with the survival ability (Table 3.2). There was no significant 
difference in survival rates between age group (Figure 3.8). However, covariates 
such as tumour size, grade, lymphovascular invasion, lymph node invasion, estrogen 
receptor, progesterone receptor and tumour stage showed significant difference in 
overall survival between relative groups. Smaller tumours have a better survival rate 
than larger size tumours (p = 0.000 log rank test) (Figure 3.9).  
 
Well differentiated tumours have the same longevity as the moderately differentiated 
tumours (p=0.067 long rank test), and significantly better survival than poorly 
differentiated tumours (p=0.000 log rank test). Patients with moderately 
differentiated tumours also have longer survival compared to poorly differentiated 
tumours (p=0.005 log rank test) (Figure 3.10). Lymphovascular invasion was 
recognized as a significant predictor of shorter overall survival (p = 0.000 log rank 
test) (Figure 3.11). In addition, lymph node invasion also exhibited worse survival 
rates (p=0.000 log rank test) (Figure 3.12). Hormone receptor positivity of estrogen 
and progesterone were both shown as significant good predictors of longevity (p= 
0.000 log rank test respectively) (Figure 3.13 and Figure 3.14 respectively). HER2 
expression showed no difference in survival rates (Figure 3.15). Advanced stage of 
tumour had significant impact on survival with advanced cancers having the worse 
overall survival (p<0.05 log rank test) compared to other stages (Figure 3.16).  
Factors showing prognostic significance by univariate analysis (or close to 
significance in the case of age) were incorporated into multivariate analysis. It was 
found that lymph node invasion, progesterone receptor, age and tumour size were 
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significant factors (Table 3.3). Each unit increase in age and pathological tumour size 
is expected to increase the risk of dying by a factor of 1.02. In addition, positive 
lymphovascular invasion increase the risk of dying by a factor of 2.29. Risk of dying 
is decreased by half when progesterone receptor is positive. 
 
 
Table 3.2 Relationships between clinicopathological variables with patient outcome 
 
 
 
Characteristics Number of 
patients 
% of patients 5 year relative 
survival rates 
(%) 
p-value (log 
rank test) 
Age <60 
≥60 
541 
481 
52.9 
47.1 
88.7 
85.6 
0.118 
Tumour Size <20 
≥20 
606 
416 
59.3 
40.7 
91.0 
81.7 
<0.0001 
 
Grade Well 
Moderate 
poor 
242 
422 
358 
23.7 
41.3 
35.0 
94.9 
88.8 
80.1 
0.067 
0.005 
<0.0001 
LVI Positive 
Negative 
352 
670 
34.4 
65.6 
76.4 
93.4 
<0.0001 
 
LNI Positive 
Negative 
382 
640 
37.4 
62.6 
78.3 
92.8 
<0.0001 
 
ER Positive 
Negative 
751 
216 
77.9 
22.4 
91.1 
73.1 
<0.0001 
 
PR Positive 
Negative 
652 
316 
67.4 
32.6 
91.5 
78.3 
<0.0001 
 
HER2 Positive 
Negative 
110 
532 
17.1 
82.9 
82.2 
88.8 
0.281 
 
Stage 1 
2 
3 
4 
425 
473 
113 
11 
41.6 
46.3 
11.1 
1.0 
94.6 
87.3 
63.4 
33.8 
<0.0001 
<0.0001 
0.007 
<0.0001 
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Table 3.3 Cox multivariate regression analysis of clinicopathological variables. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 Survival probability based on Age (Kaplan-Meier curve, p=0.118, log 
rank test). 
 
 
 
 
 
Covariates B p value Hazard Ratio 95% CI 
Age 0.20 0.004 1.02 1.01-1.03 
Tumour size 0.017 0.002 1.02 1.01-1.03 
Lymphovascular invasion 0.829 <0.0001 2.29 1.50-3.51 
Progesterone receptor -0.57 0.01 0.57 0.37-0.87 
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Figure 3.9 Survival probability based on tumour size (Kaplan-Meier survival curve, 
p<0.0001 log rank test). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 Survival probability based on Nottingham grade (Kapan-Meier survival 
curve, well vs moderate p=0.067, well vs poor p<0.0001 and moderate vs poor 
p=0.005 log rank test). 
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Figure 3.11 Survival probability based on lymphovascular invasion (Kaplan-Meier 
survival curve, p<0.0001 log rank test) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12 Survival probability based on nodal invasion (Kaplan-Meier survival 
curve, p< 0.0001 log rank test) 
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Figure 3.13 Survival probability based on expression of estrogen receptor (Kaplan-
Meier survival curve, p<0.0001 log rank test). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14 Survival probability based on expression of progesterone receptor 
(Kaplan-Meier survival curve, p<0.0001 log rank test). 
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Figure 3.15 Survival probability based on HER2 expression. (Kaplan-Meier survival 
curve, p=0.281 log rank test). 
 
 
 
 
 
 
 
 
Figure 3.16 Survival probability based on cancer stage (Kaplan-Meier survival 
curve, Stage 1 vs. stage 2 p<0.0001, stage 2 vs. stage 3 p<0.0001, stage 3 vs. stage 4 
p=0.007 and stage 1 vs. stage 4 p<0.0001). 
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3.3 DISCUSSION 
3.3.1 IDC Patients Characteristics 
Breast cancer is an age-related disease predominantly seen in women 50 years of age 
and above. It has also been reported that low-risk group males have recently shown a 
slight increase in new cases over a 27-year period.
[335]
  However, we have excluded 
male patients from our study as the incidence rate is negligible, accounting for less 
than 1% over an 11 year period. Exclusion of male subjects is also to avoid gender-
bias. Our study found the mean age at diagnosis to be 60.1 ± 13.7 years (mean ± 
Standard deviation, SD) with median of 59.0 years.  The youngest patient was 27 
years old and the oldest was 102 years old with age distribution marginally higher in 
the less than 60 year old group than in the over 60 year old. The demographic 
features of our cohort are consistent with the published data. According to statistics 
reported by Australian Institute of Health and Welfare & National Breast and 
Ovarian Cancer Centre in 2008, the incidence rate increased continuously until age 
65-69 and then decreased past the age of 70.
[335]
 The incidence was highest at the age 
group of 60 to 64 years.
[336]
 The rate is doubling about every ten years until 
menopause in which the rate of increase slows dramatically. The metabolic system of 
older people is less efficient than young people in combating the disease. Several 
factors might contribute to the high incidence and aggressiveness of cancer in elderly 
including their body system having decreased DNA metabolism and DNA repair 
process thus enhancing the likelihood of getting cancer. The presence of 
comorbidities has possibly led to functional impairment in older patients with breast 
cancer, colorectal cancer and prostate cancer. Recommendations for prevention, 
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screening, therapy or other clinical approaches are always affected by ageism rather 
than evidence-based medicine.
[337]
  
 
3.3.2 Tumours Characteristics  
3.3.2.1 Histological features of invasive ductal carcinoma 
A large group of 1080 breast cancer patients of invasive ductal carcinoma, not 
otherwise specified (NOS) has been included in this study. In order to meet our aim 
to construct a large tissue microarray group we selected this type of breast tumour as 
it is the most common histological type of invasive carcinoma of the breast.  
Pathologists will usually diagnose it by default as the strict criteria for inclusion in 
the special types have not been met. It comprises about 40-75% of all breast cancer 
cases
[338]
 whereas special-type cancers such as the lobular, medullary, mucinous, 
tubular, tubular mixed and mixed comprise approximately 20-30% of invasive 
cancer.
[5]
 This type of invasive carcinoma also meets our inclusion criteria as other 
intraductal features may also appear concomitantly thus allowing for the examination 
of breast cancer tissue progression. It was reported that the DCIS features commonly 
appeared in up to 80% of invasive carcinoma cases.
[289]
 In this cohort, there are 
72.0% cases with concurrent premalignant in situ features and 51.2% with benign 
hyperplasia. The proportion of intraductal to invasive component can vary from as 
low as zero to 100%.
[339]
  In addition to ductal changes, other histological types may 
exist depending on the cancer cell distribution. Invasive breast cancer has been 
reported to occasionally exhibit an admixture of foci of other histologic types in 
approximately 28% cases in a series of 1000 cases.
[340]
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3.3.2.2 Tumours Characteristics 
The greatest mean dimension of the breast tumours in this series is 21.5 ± 13.9 mm 
with median of 18.0mm which range from 1 to 112 mm. The majority of the tumours 
are small size (less than 20mm) at diagnosis.
[308]
 In Australia, high awareness of 
women and a well organised breast screening programme has enabled the detection 
of high number of small size breast lesions including benign cysts. It was reported in 
2011 that 61.1% of all invasive breast cancers detected were small.
[341]
 We found that 
larger tumour size is more likely to be associated with lymphovascular invasion and 
lymph node invasion compared to the smaller tumours. This finding is in common 
with another study which also linked lymph node negativity with the smaller size.
[342]
  
There is a linear relationship between tumour diameter and the percentage of cases 
with positive lymph node involvement.
[343]
 Any detectable tumour irrespective of 
size is always followed up by screening of lymph node metastases via 
mammography which can aid in making any decision on axillary lymph node 
dissection.
[344] 
Distant metastasis may establish after the invasion of tumour cells into 
tissues surrounding the primary site, including invasion of the lymphovascular 
system and mobilization in capillary which ends in the distant organs. It is suggested 
that small tumours of less than 2mm may have already been involved in vascular 
invasion years before detection.
[345]
  
 
ER and PR are more commonly expressed in small tumours whereas HER2 
expression is not significantly associated with tumour size. Similarly hormone 
receptor is significantly decreased in larger tumours.
[346]
 The insignificant 
relationship of HER2 might be contributed to by the unavailability of HER2 data in 
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the system for patients from 2000 to 2005 as this tumour marker at that time was not 
routinely tested in patients for diagnosis and treatment decision of the disease.  
 
 
Tumours in our study were mostly moderately differentiated followed by poor and 
well differentiated tumours. Tumour grade was significantly associated with other 
clinicopathological characteristics such as patient age, tumour size, stage, 
lymphovascular invasion, lymph node invasion, estrogen receptor, progesterone 
receptor, and HER2. It was found that younger patients (39.7%) tend to have poor 
differentiated tumours compared to older patients (39.9%). Other study also found 
young women tended to have more aggressive features of poorly differentiated 
tumour cell.
[347]
 The more aggressive the tumour, the more likely it tends to invade 
the lymphatic and blood vessels. We also observed aggressive tumour tended to have 
nodal metastasis (42.6%). This was supported by other findings which found that 
grade I tumours tend to be associated with lymph node metastatsis, whereas in 
contrast,  grade III  tumours are correlated with positive nodal metastasis.
[348]
 ER and 
PR positive tumour are shown to be less aggressive whereas HER2 positive tumours 
are more aggressive. Similarly, a study of Asian breast cancer patients found ER and 
PR expression is significantly decreased in more aggressive tumours..
[346]
 
 
3.3.3 Extent of the Disease 
The patients studied in this thesis have disease stages ranging from early stage to 
advanced stage IV. Stage II is the largest group (46.6%) followed by stage I disease 
(41.8%). The patients with the lowest incidence are the ones with stage III (10.6%) 
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and stage IV (1%) diseases. These findings are in agreement with another large 
surveillance study in USA which reported higher incidence of local and regional 
breast cancer but decreased in distant disease.
[349]
 Only 37.1% of the tumours 
examined had regional lymph node metastasis in that study. Lymph node invasion 
was significantly correlated with tumour staging and grading. Poorly differentiated 
tumours were more likely to have nodal invasion (42.6%). However, we did not see 
any statistically significant relation between nodal status and age, ER, PR and HER2 
status.  
 
3.3.4 Survival among Breast Cancer Patients 
The survival probabilities from breast cancer is generally poor with decreasing trend 
as the cancer developed from pre-invasive to more advanced stage.
[350]
 The overall 
group 5-year survival was significantly affected by patient demographic and 
pathological factors of the tumour. The effect of tumour size, grade, invasion status, 
hormone status and cancer stage all have constant significant impact on survival 
ability in breast cancer patients. The findings in this thesis are in common with those 
in a large scale study which reported that 5-year relative survival is only slightly 
higher in younger patients (<65 years) than in older patients (≥65 years).[351] Patients 
with smaller tumours (<20mm) have greater chances to survive longer than those 
with larger tumours (≥20 mm). This finding is similar to a cancer statistical analysis 
conducted in U.S showing larger tumour have a more negative effect on survival.
[349]
 
Carter et al. reported that patients with smaller tumours (<2cm) survive better than 
those with larger tumours because of nodal involvement.
[343]
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This thesis showed poorly differentiated tumours have the highest probability of 
death compared to the well and moderate tumour grades, similar to a study by 
another group, where higher tumour grade negatively affects the survival of breast 
cancer patients.
[349]
 Lymphovascular and lymph node invasion both respectively have 
a negative effect on survival. This is in agreement with a study that found lymph 
node involvement has an inverse relationship with survival status.
[343]
  
 
The ER, PR and HER2 are the only markers that are essential to the therapy decision 
making. These three markers are used as prognostic factor as well as predictive 
markers.
[352]
 Expressions of estrogen and progesterone receptors are both good 
predictors of high longevity (P = 0.000 log rank test respectively) compared to 
negative expression. The 5 year survival is about 13-18% better for women with ER 
and PR positive breast cancers. Our finding is identical with a study which reported 
the survival of ER and PR positive breast cancer patients is greater than those with 
negative ER and PR expression. The magnitude of survival difference begins to 
reduce and may disappear after five years.
[353]
 This is attributed to the recurrence of 
ER- earlier than ER+ which lead to only a slight difference in survival rate after 10 
years. However, it is recently found that PR status is not a significant independent 
prognostic factor. There is no association between PR and ER- or ER+ which raises 
questions concerning the routine testing of PR in breast cancer.
[354]
 Our HER2 
expression data did not prove any difference in survival rates. This might not be 
representative of the whole group, as HER2 data from 2000 to 2005 were 
unavailable. Nevertheless, HER2 is a strong independent prognostic factor. Higher 
amplification of HER2 is significantly associated with shorter survival.
[355]
 It can be 
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used as a long term prognostic factor in predicting poor survival of breast cancer 
patients.
[356]
  
 
Advancement of tumour growth had significant impact on survival where advanced 
cancer has the worse overall survival (p<0.05 long rank test comparison of each 
stage). Distant metastases dramatically decrease the survival among breast cancer 
patients. The 5-year survival percentage of stage I (94.6%) reduced to 33.8 % of 
stage IV tumour. Our finding is supported by the Surveillance, Epidemiology and 
End Results (SEER) program of breast cancer results which reported that as the 
cancer progresses to higher stage, the survival rates significantly decline after 5 year 
of diagnosis.
[357]
  The similarity of prognosis in this thesis finding with that observed 
in Australia and overseas verify that the group is a representative sample. 
  
3.4 CONCLUSION 
- The tumours included in this study are mostly small in size, moderately 
differentiated, early stage tumour, ER and PR positive, HER2 negative and 
absence of lymphovascular and lymph node invasion. 
- Bad prognostic factors are large size, poor differentiation, late stage, negative 
ER and PR, as well as presence of lymphovascular invasion and lymph node 
metastasis.  
- The associations established by the parameters are in agreement with other 
breast cancer population studies. Therefore, the data in this thesis can be 
regarded as representative.  
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4.1 INTRODUCTION 
P14
ARF
 (P14) is the alternative transcript product of the INK4a/ARF locus of 
chromosome 21, which also encodes the tumour suppressor P16.
[358]
 Although both 
of the tumour suppressors share the same exons, they are not isoforms, do not share 
the same acid amino homology and are completely unrelated proteins with distinct 
function.
[359]
 Fundamentally, P14 is known as a tumour suppressor protein as it is the 
critical activator of p53 cell cycle regulatory pathway.
[360]
 Activation of the P14 
would activate different suppressor pathways through the activation of p53 protein. It 
is the important key regulator of p53 activation and therefore plays an important role 
in the initiation of human protective mechanisms. Thus, this chapter is to assess the 
status of expression level of P14 in breast cancer development. In addition, the 
association of the protein overexpression with important clinicopathological factors 
was also examined. Estimation of the likelihood to survive was also investigated. 
Cox univariate and multivariate was conducted to assess prognostic value of the P14 
expression. 
 
4.2 RESULTS 
There were 1080 cases of primary breast invasive ductal carcinoma available for 
assessment of P14 expression. 29 (2.7%) cases of IDC features were missing which 
were lost during cutting section and staining process. Additionally, TMA cores with 
DCIS, ADH and normal features were lost in 39/778 (5.3%), 58/553 (10.5%) and 
101/1053 (9.59%) cases respectively due to the same processing reason. Expression 
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of P14 was assessed semi-quantitatively. Immunoreactivity in the nucleus and 
cytoplasm were individually graded. Intensity and distribution of the 
immunoreactivity were recorded. Intensity score 0 (no staining), 1 (weak staining), 2 
(moderate staining) or 3 (strong staining) were added to the distribution score 0 (no 
staining), 1 (<1%), 2 (1-10%), 3 (11-33%), 4 (34-66%) or 5 (67-100%) which give a 
final score ranging from 0-8. Scores of ≥ 3 were considered increased expression 
according to a previous study by others.
[243]
 In our study, we found expression of P14 
was mostly in the cytoplasm with occasionally insignificant nuclear staining (Figure 
4.2).  
 
All breast specimens are handled according to the same protocol at the South Area 
Western Pathology Service. The use of standardized fixation and handling protocols 
ensured that the differences in protein expression as detected on 
immunohistochemistry is not simply as a result of differences in fixation. All breast 
specimens are fixed in 10% neutral buffer formalin at at pH 7.0 to 7.4, in which 4mm 
tissue blocks are fixed for at least 24 hours but no more than 72 hours. This is in 
accordance of the guidelines by the American Society of Clinical Oncology 
(ASCO)/College of American Pathologists (CAP) guidelines for 
immunohistochemistry or insitu hybridisation. 
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4.2.1 Molecular expression of P14 
4.2.1.1 P14 expression in normal breast tissue 
P14 overexpression was found in 66.7% (635/952) of the matching normal breast 
tissue from the respective invasive ductal carcinoma cases P14 (Figure 4.1). 
Overexpression in the normal tissue was characterised by higher distribution of 
positivity in the epithelial cells but with weak to moderate staining (Figure 4.2). 
Occasionally, immunoreactivity in surrounding tissue was shown in the nucleus of 
the lymphocytes. 
 
4.2.1.2 P14 expression in benign breast tissue 
Positive staining for P14 was observed in TMA cores of matching benign breast 
tissues derived from the respective invasive ductal carcinoma cases. Of the 495 cases 
of the examined cohort with benign breast conditions available for assessment, the 
benign tissues of 329 (66.46%) cases were overexpressed for P14 (Figure 4.1). There 
was slight increment in the percentage of overexpression group in comparison to the 
matching normal tissues.  
 
4.2.1.3 P14 expression in ductal carcinoma insitu (DCIS)  
Expression of P14 was localised to the cytoplasm in DCIS with only occasional cases 
with nuclear expression. Clear staining with no nonspecific background staining 
affirms the specificity of the antibody (Figure 4.2). 80.65% of the DCIS were 
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categorised as higher expression of the P14 tumour suppressor and 19.35% belongs 
to negative expression (Figure 4.1).  
 
4.2.1.4 P14 expression in invasive ductal carcinoma (IDC)  
More than half of the total invasive ductal carcinoma cases showed positive staining.  
Most of the positive cancer cells showed higher distribution in the tissue with weak 
to moderate intensity. 802 out of 1051 cases had been classified as higher expression 
of P14 with 29 of the cases lost during tissue staining process (Figure 4.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Proportion of P14 immunohistochemical staining score in each 
pathological lesion. 
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Figure 4.2 Immunohistochemical staining for P14 of the breast tissue cytoplasm. 
(a) Normal, positive; (b) ADH, positive; (c) DCIS, positive; (d) IDC, positive 
(Left: magnification x 100, Right: magnification x400). 
(a) 
(b) 
(c) 
(d) 
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4.2.2 Association of P14 expression with breast cancer progression 
Table 4.1 shows the association of P14 expression and breast tissue progression and 
analysed using the Pearson Chi Square test. The expression of P14 indicates a highly 
significant association with the progression of normal to benign lesions to DCIS and 
IDC. High P14 expression in normal breast tissue is more likely to be associated with 
invasive cancers with more aggressive features (chi-square, P<0.0001). Additionally, 
50.0% (228/456) of the cases with high P14 expression in the normal tissues were 
more likely to develop higher expression in matching benign tissues compared to the 
group with low P14 staining in the normal tissues (chi-square, P<0.0001). 
Furthermore, expression of P14 was significantly increased in pre-invasive lesion, 
DCIS. 58.5% (224/383) of the cases in which the benign tissues were increased for 
P14 were also more likely to have high expression of P14 in the DCIS (chi-square, 
P<0.0001).  
 
We found a positive linear relationship between P14 overexpression and the 
progression of normal breast tissue to benign (ADH), pre-invasive (DCIS) and 
invasive (IDC) lesions. Higher expression in early development was predicted to 
have higher expression of P14 in the fully developed cancer. Equally important, the 
finding also supported that P14 expression in DCIS was significantly associated with 
expression in IDC lesions. 69.3% (498/719) of the P14 overexpressed DCIS cases 
eventually develop P14 overexpressed invasive tumours (P<0.0001). 
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Table 4.1 Association of P14 expression with breast cancer progression. Chi square 
P-value indicates the differences between: (a) Normal vs. ADH; (b) ADH vs. DCIS; 
(c) DCIS vs. IDC and (d) IDC vs. Normal.  
 
 
 
4.2.3 Correlation of P14 expression with clinical and pathology 
covariates 
The Pearson Chi-square was used to test for any associations between P14 
expression and various clinicopathological variables (Table 4.2). High P14 
expression was significantly associated with differentiation of the tumour cell. 
Moderate tumour cell differentiation was found to be correlated with high expression 
of P14 (Chi-square, P=0.004) (Figure 4.3). In addition, high P14
ARF
 was associated 
with estrogen receptor positivity (Chi-square, P=0.008) (Figure 4.4).  Estrogen 
receptor positive cells were more likely to have high P14 expression than negative 
expression. There was no significant correlation with other variables of age, stage, 
lymphovascular invasion, lymph mode invasion, PR and HER2. 
 
P14 Expression 
Low 
(≤2) 
High 
(≥3) 
P-value (chi 
square) 
Normal Breast Tissue 
Low 
High 
95 
58 
75 
228 
<0.0001
a
 
Atypical Ductal Hyperplasia 
(ADH) 
Low 
High 
57 
28 
74 
224 
<0.0001
b 
Ductal Carcinoma In Situ 
(DCIS) 
Low 
High 
79 
85 
57 
498 
<0.0001
c 
Invasive Ductal Carcinoma  
(IDC) 
Low  
High 
117 
190 
95 
525 
<0.0001
d 
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Table 4.2 Relationship between P14 expression and clinicopathological 
characteristics. 
       *Statistically significant (P<0.05).  
 
 
 
 
 
  
P14 Expression 
 Low 
(≤2) 
High 
(≥3) 
 P-value 
Age 
≤60 years 
>60 years 
130 
119 
428 
374 
0.749 
Size 
≤20mm 
>20mm 
137 
112 
486 
316 
0.118 
Grade 
Well 
Moderate 
Poor 
79 
88 
82 
173 
336 
293 
0.004* 
Stage 
I 
II 
III 
IV 
95 
125 
26 
3 
342 
366 
87 
7 
0.569 
LVI 
Absent 
Present 
168 
81 
520 
282 
0.445 
LNI 
Absent 
Present 
154 
95 
508 
294 
0.670 
ER 
Negative 
Positive 
40 
204 
184 
566 
0.008* 
PR 
Negative 
Positive 
76 
168 
245 
506 
0.668 
HER2 
Negative 
Positive 
164 
24 
378 
82 
0.114 
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Figure 4.3 Bar chart of P14 expression and tumour differentiation (P<0.05)  
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Bar chart of P14 score and estrogen receptor (P<0.05)  
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4.2.4 Recurrence and survival  
For patients with low P14 expression, the estimated mean survival time was 11.52 ± 
SE 0.35 with a total of 25/236 (15.6%) deaths and 211/236 (84.4%) still alive during 
the follow up period. Survival rates for 1 year, 2 years, 3 years and 5 years were 
98.7%, 97.4%, 94.3% and 85.9%, respectively. Patients with high score of P14 
showed estimated mean survival time of 12.14 ± SE 0.23 with a total of 122/766 
(15.9%) deaths and 644/766 (84.1%) still alive during the follow up period. Survival 
rates for 1 year, 2 years, 3 years and 5 years were 98.1%, 95.8%, 92.4% and 86.7%, 
respectively.   
 
There was no statistically significant difference between the overall survival rates of 
patients with low or high P14 expression. A non-significant trend for high P14 
expression was associated with poorer overall survival using Kaplan-Meier survival 
analysis (Log rank test, OS, P=0.456) (Figure 4.5). Probability for the cancer to recur 
was significantly associated with high P14 expression. We found that high P14
ARF 
expression was correlated with increased risk of relapse (Log rank test, DFS, 
P=0.038) (Figure 4.6). Low P14 expression group showed 6.3% (15/237) recurrence 
while the high P14 expression group have high percentage of relapse of 13.7% 
(104/757).  5 Years recurrence rate for the low group is 92.0% whereas the high 
group is 88.4%. 
 
Multivariate analyses were conducted to assess the relationship between established 
clinicopathological features and senescence biomarker expressions with overall 
survival and disease free survival using the Cox hazard regression test. Variables of 
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multivariate test were selected according to principle of fit. We found P14 
overexpression was a significant prognostic factor in predicting disease recurrence 
(Cox regression, p=0.016). Hazard of relapse is increased 3.556 times when the 
tumour is P14 positive (Table 4.3). However, we were not able to show the 
significance of P14 expression in predicting the likelihood of dying (Cox regression, 
p>0.05).  
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Figure 4.5 Probability of survival according to P14 expression in IDC cases 
(Kaplan-Meier survival curve, p=0.456 log rank). Low P14 expression    
(immunoscore ≤2) n=25 (blue line), High P14 (≥3) n=122 (green line). There 
were a total of 855 censored cases. 
 
 
 
 
 
 
 
 
 
Figure 4.6 Probability of recurrence according to P14 expression in IDC cases 
(Kaplan-Meier analysis, p=0.038 log rank test). High P14 (green line) tumour is 
associated with increased risk of relapse.   
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Table 4.3 Univariate and multivariate Cox regression analysis of P14 expression 
Variable 
Univariate analysis Multivariate analysis 
RR 95% CI P-value
‡
 RR 95% CI P-value
‡
 
Overall survival (OS) 
Age 1.367 0.992 - 1.883 0.056 1.660 0.995-2.771 0.052 
Tumour size 1.892 1.373 - 2.607 <0.0001* 0.881 0.465-1.669 0.698 
Grade 2.368 1.485 - 3.775 <0.0001* 0.924 0.364-2.343 0.867 
Staging 16.302 7.523 - 35.327 <0.0001* 23.421 5.680-96.564 <0.0001* 
LVI 3.143 2.262 - 4.368 <0.0001* 1.933 1.076-3.473 0.027 
LNI 2.429 1.758 - 3.354 <0.0001* 0.817 0.400-1.670 0.579 
ER 0.377 0.270 - 0.527 <0.0001* 0.363 0.163-0.806 0.013 
PR 0.399 0.288 - 0.554 <0.0001* 1.067 0.492-2.315 0.869 
HER2 1.382 0.765 - 2.496 0.283 0.729 0.376-1.414 0.350 
P14 1.179 0.765 - 1.818 0.456 1.096 0.595-2.018 0.769 
Disease-free survival (DFS) 
Age 0.815 0.568 - 1.170 0.267 1.163 0.642-2.107 0.618 
Tumour size 1.975 1.379 - 2.829 <0.0001* 0.987 0.461-2.116 0.974 
Grade 4.093 2.246 - 7.460 <0.0001* 2.447 0.756-7.925 0.136 
Staging 12.790 4.922 - 33.238 <0.0001* 6.593 1.314-33.081 0.022 
LVI 4.003 2.747 - 5.833 <0.0001* 2.434 1.218-4.865 0.012 
LNI 2.798 1.945 - 4.024 <0.0001* 1.276 0.517-3.149 0.596 
ER 0.293 0.200 - 0.427 <0.0001* 0.616 0.258-1.472 0.276 
PR 0.432 0.297 - 0.629 <0.0001* 0.774 0.330-1.816 0.556 
HER2 1.649 0.859 - 3.167 0.133 0.758 0.368-1.564 0.454 
P14 1.767 1.026 - 3.044 0.040* 3.556 1.266-9.994 0.016 
‡
Cox Hazard Regression Test 
*Statistically significant 
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4.3 DISCUSSION 
Alterations of ARF proteins that mainly regulate the cell cycle at the G1/S phase have 
been involved in a wide range of tumours including breast carcinoma. Our findings 
presented in this chapter explain the distribution of ARF markers in a sequence of 
developed breast cancer tissue. We also presented the linkage of the P14 protein 
expression with patient’s survival and its potential prognostic utility. 
 
4.3.1 Characteristics of P14 overexpression in primary breast 
carcinoma 
 
In our study, expression of P14 protein was seen in the cytoplasm and rarely in the 
nuclei of the breast tumour cells; most cases only exhibited cytoplasmic staining. 
Despite the fact that ARF is predominantly a nucleolar protein, P14 immunostaining was 
found to be predominantly in the cytoplasmic region in the breast tissues in this study. 
Our findings are in agreement with previously documented malignant breast cancer 
lesion which reported cytoplasmic P14 as an important prognostic factor in breast 
tumorigenesis.
[243]
 This is supported by a study of prostate cancer progression which 
reported high levels of cytoplasmic P14 as the cells progress to malignant tumour.
[361]
 
Moreover, cytoplasmic P14arf was evident in several ranges of primary tumours of non-
small cell lung cancer, oral squamous cell carcinoma, pancreatic tumours and prostate 
cancer as well as breast cancer.
[361-365]
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Despite the exclusively nucleolar localization in most cancer studies, abnormal 
cytoplasmic accumulation might have significant role in tumorigenic event. 
Relocalisation of P14 from the nucleus to the cytoplasm may possibly be related to 
functional inactivation as it was shown for other tumour suppressors such as P21 and 
p53.
[366-368]
 As a measurement of P14 function, we have assessed its association with the 
downstream effector of p53 and P21. Functional distortion is explained by its inability to 
activate downstream effector. Interestingly, we found increased P14 protein expression 
associated with negative expression of P21 (Pearson chi square p=0.027, data not 
shown). Increased P14 protein expression also appears to be associated with negative 
expression of p53, although this association is statistically insignificant. These findings 
may suggest the inactivation of P14-dependent tumour suppressive functions and 
activation of its oncogenic features due to the relocalisation from nucleus to cytoplasm. 
P14 gene is rarely inactivated in breast tumour by mutation.
[369]
                                                                             
Other study has supported that altered subcellular distribution of P14 is a sign of 
distortion of the structure and function of ARF protein.
[175] 
In vitro evidence has 
suggested the localisation of the ARF protein to the cytoplasm is associated with Pex19p 
protein.
[370]
 These 33-kda proteins act as a p19ARF-binding protein that is involved in 
the extrusion of the p19ARF from the nucleus.
[371]
 It does not seem likely that this is a 
consequence of nonspecific or false positive staining; a distinct cytoplasmic signal has 
been obtained with the same antibody and under the same conditions in non-tumoral 
placenta, the recommended positive control from the manufacturer. In addition, the 
immunohistochemical detection technique employed in this study has been optimised so 
that it is most effective in reversing the formalin-induced protein cross-linking. The hot 
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water bath used ensures less tissue loss of the arrayed cores because it obviates the need 
of vigorously boiling the buffer solution, while effectively reversing protein cross-
linking.
[372]
                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
4.3.2 The association of P14 expression with breast cancer progression 
 
It is hypothesized that senescence-associated markers are intensified in premalignant but 
not in malignant lesions; it can then be applied as a defining feature to help in diagnosis 
and prognostication of a cancer.
[207]
 We have demonstrated increased expression of P14 
from normal to premalignant breast tissues followed by a slight decrease in malignant 
tumour cells. Although our study showed a pattern of increase expression of P14, a 
study by others found uniform P14 expression among all benign and malignant 
meningioma tumours.
[373]
 Nevertheless, the finding of high P14 expression in both 
premalignant and malignant lesions is also seen in prostate cancer progression.
[361]
 In 
contrast, other studies have documented no significant difference in P14 expression 
between premalignant and malignant lesions in breast cancer and cervical carcinoma.
[374, 
375] 
 
 
We found the expression of P14 increases from normal to ADH to DCIS, then slightly 
reduced from DCIS to IDC. These results appear to indicated that the expression of the 
senescence marker, P14, gradually increases as the tissues become more proliferative as 
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a natural response of a tumour suppressor gene to counteract the growth, peaking at the 
pre-invasive stage. However, when the lesion becomes invasive (i.e. tumour cells are so 
called 'immortable' and can divide indefinitely) the tumour cells most likely escape 
senescence by acquiring mutations that either directly/indirectly negate tumour 
suppressor gene function, hence resulting in the plateauing of senescence marker levels 
seen in the malignant state. It has previously been shown that P14
 
overexpression is 
present in both invasive and non-invasive breast cancers 
[243]
.   
 
The inactivation of P14 has been reported to correlate with coexistent P53 mutation.
[376]
 
Malfunction of the P14 is indicated by manifestation of underexpressed P14 mRNA 
which is associated with at least one genetic or epigenetic alteration. Senescence is 
known for its antiproliferative effect against genome instability 
[377]
 It is claimed that the 
senescence pathway initially act as a protector against hyperproliferative tumour but 
concomitantly nurture adjacent cells to become aggressive. Additionally, senescent cells 
show increased expression for mitogenic, antiapoptotic and angiogenic factors which 
help in promoting tumour formation.
[378]  
 
 
4.3.3 P14 expression and associated clinical and pathological 
parameters  
 
Interestingly, P14 overexpression in invasive ductal carcinoma is associated with 
established prognostic factors such as high tumour grade and positive estrogen receptor. 
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To our knowledge, such associations have not been reported in human breast cancer. 
Nevertheless, other cancer studies have documented P14 overexpression in association 
with aggressive tumour behavior and suggested it as a sign of malfunction of the major 
cell-cycle regulatory pathways.
[379] 
In contrast, another study found impairment of the 
major cell-cycle regulatory is associated with the loss of P14 in combination with p53 
overexpression.
[380]
 There is no conclusive explanation for the significant association of 
overexpression P14 with positive estrogen receptor although another study has 
documented downregulation of P14
 
expression as a mediator of tumorigenesis in the 
presence of ER upregulation.
[381]
  
 
However, P14 protein positivity has been reported to be associated with vascular 
invasion, nodal metastasis, and perineural invasion.
[382]
 On the other hand, low 
expression of P14 mRNA appears to be correlated with deep invasion of tumour, lymph 
node metastasis and a high TNM stage of the tumour.
[383]
 Low expression of P14 has 
been linked to hypermethylation of the P14 gene which is believed to be the major 
inactivation mechanism in breast cancer.
[384]
 
 
Moreover, all other parameters were not statistically significant correlated with P14 
expression. In other aspect, other researchers have illustrated decreased expression of 
P14 in breast cancer were significantly related with presence of progesterone receptors 
and peritumoral vessel involvement; otherwise overexpressed P14 was associated with 
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negative ERBB2.
[385]
 In vitro study has demonstrated Her-2 promotes mammary 
tumorigenesis via the Hdm2-mediated p53 degradation by inactivation of ARF.
[386]
  
 
4.3.4 Survival, recurrence free survival and prognostication.  
 
This thesis did not show P14
 
is a statistically significant factor for the prediction of 
overall patient survival. However, it is a significant prognostic factor in predicting the 
likelihood of the disease to recur.  In contrast to our finding of cytoplasmic P14 
expression associated with increased risk of relapse, a study by Vestey et al. found that 
the presence of cytoplasmic P14 confers significant survival advantage in breast cancer 
patients
[387]
. This contradictory finding may be related to the dual function of P14, in 
which it acts as a tumour suppressor in some tumours but exhibits oncogenic activity in 
others 
[215-217]
. Moreover, senescent cells have been shown to change their surrounding 
tissue environment which can in turn promote tumour formation in the adjacent cells 
[224]
.  
 
It is reported overexpression of nucleolar P14 protein is associated with high growth 
activity, aggressive tumour as well as poor survival ability.
[379]
 The association of P14 
with bad prognostic factor may be related to aberrant P53. The cell cycle arrest pathway 
will be blocked if any major cell cycle regulator is absent. It is found that induction of 
P14 in a breast cancer that carries wild-type P53-gene increases the sensitivity of tumour 
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cells to conventional chemotherapeutic drug which increases cytotoxic activity.
[388]
 In 
this thesis, association of overexpression of cytoplasmic P14 with increased risk of 
relapse may be related to functional inactivation because of the protein localisation.  
 
4.4 CONCLUSION 
 
- There is significantly increased expression of P14 in a large group of breast 
cancer patients. 
- Overexpression of cytoplasmic P14 seems to occur at an early stage in the multi-
step process of breast tumourigenesis and these alterations precede the 
development of invasive cancer. 
- Overexpression of cytoplasmic P14 is an independent prognostic molecular 
marker in predicting the likelihood of the tumour to recur and may be useful to 
provide additional prognostic information in the clinical setting. 
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CHAPTER 5 
P21/WAF1/CIP1 EXPRESSION 
IN BREAST  
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5.1 INTRODUCTION 
P21/WAF1/CIP1 (P21) is a cyclin-dependent kinase inhibitor of CDK1 and CDK2. It is 
a protein that is encoded by the CDKN1A gene located on chromosome 6 (6p21.2). P21 
belongs to the Cip and Kip family which includes P27 and P57.
[389]
 It mediates multiple 
tumour suppressor pathways to promote anti-proliferative activities through either p53-
dependent or p53-independent growth arrest pathway. However, it is the major 
determinant of tumour protection by p53.
[390]
 P21 tumour suppressor activity was first 
genetically discovered after Cdkn1a
-/-
 mice developed spontaneous tumours.
[391]
 
Determination of P21 in a large cohort may help to assess the nature of P21 in the 
progression of breast tumour. Therefore, in this chapter we will assess P21 protein 
expression and the relationship with breast cancer development as well as the 
clinicopathological parameters. Survival analysis was conducted to assess the clinical 
significance of P21 expression in relation to patient survival in breast cancer. 
 
5.2 RESULTS 
This study included 1080 cases of primary invasive ductal carcinoma for the assessment 
of the expression of the senescence protein marker, P21. A total of 1080 malignant 
lesions (IDC) of which 778 had accompanying premalignant lesions (DCIS), 553 with 
matching benign lesions (ADH) and 1053 with normal matching tissues, were available 
and incorporated into the tissue microarray (TMA) blocks. Tissue losses from tissue 
microarray section were high accounting for 5.8% loss in the normal tisues, 9.8% in 
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ADH, 4.0% in DCIS and 1.2% in IDC. Protein expression was analysed semi-
quantitatively by estimating the percentage of immunoreactive nuclear staining only.  
Cytoplasmic staining is disregarded. Scores of more than 5% were considered increased 
expression.
[322-324]
 The expression of P21 was predominantly in nuclear and occasional 
faint cytoplasmic staining was present (Figure 5.2).  
 
5.2.1 Protein expression of P21 
5.2.1.1 P21 expression in normal breast tissue 
We found P21 protein expression was downregulated in normal breast tissue. The 
majority of cases belonged to low expression group, which accounted for 99.6%, 
whereby only 0.4% showed increased P21 expression (Figure 5.1). It showed scattered 
positive cells of the epithelial cells. Occasionally, surrounding tissue showed 
immunoreactivity in the nucleus of the connective tissue.  
 
5.2.1.2 P21 expression in the benign lesion, ADH 
Benign breast tissue, ADH, showed the same pattern staining as the matched normal 
tissues. The tissue expressed scattered positive cells in the ductal region (Figure 5.2). 
Generally, loss of P21 expression in the breast tissue epithelium was seen in ADH. 
98.6% of ADH exhibited negative expression of P21 protein and only 1.4% 
demonstrated positivity (Figure 5.1). 
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5.2.1.3 P21 expression in the premalignant lesion, DCIS  
P21 expression in DCIS was predominantly in the nucleus with only non-specific faint 
cytoplasmic staining (Figure 5.2). The protein expression score varied from as low as 
0% to as high as 70%. In general, 94.9% of the DCIS tissue demonstrated low 
expression while only 5.1% of the cases had high expression of P21 protein (Figure 5.1). 
 
5.2.1.4 P21 expression in IDC  
The expression of P21 protein was mainly localised in the nuclei of tumour cells with 
occasional presence of faint cytoplasmic staining (Figure 5.2). Nevertheless, the tumour 
cells mainly showed low expression of P21 (94.8%) with minor positive expression in 
5.2% (score range 5%-60%) of the cases (Figure 5.1). The intensity of the staining was 
ranged from moderate to strong nuclear staining. A few scattered positive cells were 
occasionally present in the adjacent tissue. 
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     Figure 5.1 Proportion of P21 expression in different breast tissue progression. 
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Figure 5.2 Example of P21 immunoreactivity in a series of breast lesions. 
(a) Normal, positive; scattered distribution of positive cells (b) ADH, 
positive; Distinct nuclear staining with appearance of minor faint 
cytoplasmic staining (c) DCIS, positive; High expression of P21 protein in 
the epithelium of DCIS (d) IDC, positive; High expression of P21. Left: 
High-power magnification (×100) (a-d). Right: show higher-power (×400) 
views of the same fields. 
(a) 
(c) 
(d) 
(b) 
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5.2.2 Association of P21 expression in breast cancer progression 
 
In general, P21 protein expression in the breast cancer tissue was downregulated. Loss 
of P21 protein expression was predominant in each stage of breast cancer 
development. The expression of P21 was significantly associated with the breast 
cancer progression (Table 5.1). As the breast tissue progressed from normal into 
neoplastic phenotype, there was slight increment in the P21 protein expression, 
however it was still less dominant than cases with no P21 expression. The distribution 
of P21 in tumour cells was heterogenous with positive cells often appearing in 
clusters. Only 5.2% of the IDC cases showed tumour cells with positive 
immunoreactivity in the nucleus. 
 
Normal tissue was less likely to express the P21 protein and remain silent in the 
benign lesion (P<0.0001). Moreover, the matching normal tissue that was negative for 
P21 was more likely to be associated with low expression in the malignant tissue 
(P<0.0001) (Table 5.1). 91.7% of the DCIS cases with lower expression in tended to 
have decreased P21 expression in the matching malignant tissues (P<0.0001). Plateau 
changes in the level of P21 expression was observed with progression from 
premalignant (5.1%) to malignant lesions (5.2%). We found a positive linear 
relationship of P21 expression with the progression of breast tissue to the malignant 
phenotype. Lower expression in early development was predicted to have lower 
expression in the developed cancer. 
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Table 5.1 Association of P21 expression with breast cancer progression. Chi square P-
value indicates the differences between: (a) Normal vs. ADH; (b) ADH vs. DCIS; (c) 
DCIS vs. IDC and (d) IDC vs. Normal. Percentage represent ratio of positive or 
negative to the total number of cases. 
 
 
5.2.3 Correlation of P21 with clinical and pathological covariates 
The relationship between P21 protein expressions with clinicopathological variables 
was evaluated using the Pearson Chi-square test (Table 5.2). The expression of P21 
was significantly correlated with tumour grade. Loss of P21 expression was associated 
with moderate differentiation (chi square p<0.0001 (Figure 5.3). There were no 
significant association between P21 expression with other prognostic indicators such 
as age, tumour size, staging, lymphovascular invasion, lymph node involvement, 
positivity of ER, PR and HER2. 
 
P21 Expression 
Negative 
(≥5%) 
Positive 
(<5%) 
P-value 
Normal Breast Epithelial 
988 
(99.6%) 
4 
(0.4%) 
<0.0001
a
 
Atypical Ductal Hyperplasia (ADH) 
492 
(98.6%) 
7 
(1.4%) 
<0.0001
b
 
Ductal Carcinoma In Situ (DCIS) 
709 
(94.9) 
38 
(5.1%) 
<0.0001
c
 
Invasive Ductal Carcinoma  (IDC) 
1004 
(94.8%) 
55 
(5.2%) 
<0.0001
d
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Table 5.2 Associations of P21 expression with clinicopathological parameters. Only 
cell tumour differentiation showed statistical significant associations with P21 
expression. No other significant results were seen. 
 
  P21 Expression 
 Negative  
(<5%) 
Positive 
(≥5%) P-value 
Age 
≤60 years 
>60 years 
536 
468 
29 
26 
0.924 
Tumour size 
≤20mm 
>20mm 
595 
409 
35 
20 
0.520 
Differentiation 
Well 
Moderate 
Poor 
256 
398 
350 
2 
33 
20 
<0.0001* 
Stage 
I 
II 
III 
IV 
425 
463 
107 
9 
21 
27 
6 
1 
0.853 
Lymphovascular 
invasion 
Absent 
Present 
662 
342 
34 
21 
0.531 
Lymph Node 
invasion 
Absent 
Present 
638 
366 
31 
24 
0.282 
ER 
Negative 
Positive 
205 
745 
15 
36 
0.188 
PR 
Negative 
Positive 
300 
651 
21 
30 
0.151 
HER2 
Negative 
Positive 
527 
100 
21 
6 
0.386 
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Figure 5.3 Bar chart of tumour cell differentiation vs. P21 score of malignant feature  
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5.2.4 Recurrence and Survival  
Overall survival and disease free survival was analysed used Kaplan-Meier log rank 
test. The estimated mean overall survival for low P21 expression group was 12.16 ± 
SE 0.22 with a total of 142/957 (14.8%) dead and 815/957 (85.2%) still alive during 
the follow up period. The 1 year, 5 year and 10 year survival rate was 98.5%, 86.7% 
and 74.2% respectively.  
 
Patients with high P21 score showed estimated mean overall survival time 12.14 ± SE 
0.62 with a total of 6/54 (11.1%) and 48/54 (88.9%) still alive during follow up period. 
The 1 year, 5 year and 10 year survival rate was 98.1%, 92.4% and 84.2% 
respectively. 12.2% (116 recurrent cases out of 949) of the patients of the low P21 
expression group experienced recurrence while only 7.4% (4 recurrent cases out of 54) 
of patients from high P21 expression group experienced recurrence. There was no 
statistically significant difference of the overall survival and disease free survival 
between low and high P21 expression (OS, P=0.299; DFS, P=0.169) (figure 5.4).  
 
Univariate and multivariate cox regression analysis did not find P21 expression as a 
significant prognostic factor for invasive ductal breast carcinoma patients (p > 0.05, 
RR 0.347, 95% CI 0.048-2.523) (Table 5.3). 
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Figure 5.4 Patient’s survival ability conferring to P21 expression of malignant 
features. Above, probability to survive after diagnosis did not prove any significant 
result (Kaplan-Meier survival curve, P>0.005). Bottom, probability of the tumour to 
recur did not show significant finding (Kaplan-Meier recurrence curve, P>0.05). 
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Table 5.3 Univariate and multivariate cox regression analysis of P21 expression 
Variable 
Univariate analysis Multivariate analysis 
RR 95% CI P-value
‡
 RR 95% CI P-value
‡
 
Overall survival (OS) 
Age 1.367 0.992 - 1.883 0.056 1.628 0.969-2.733 0.065 
Tumour size 1.892 1.373 - 2.607 <0.0001* 0.799 0.423-1.512 0.491 
Grade 2.368 1.485 - 3.775 <0.0001* 0.970 0.383-2.457 0.948 
Staging 16.302 7.523 - 35.327 <0.0001* 32.404 7.475-140.475 <0.0001* 
LVI 3.143 2.262 - 4.368 <0.0001* 2.153 1.188-3.902 0.011* 
LNI 2.429 1.758 - 3.354 <0.0001* 0.746 0.363-1.533 0.424 
ER 0.377 0.270 - 0.527 <0.0001* 0.363 0.166-0.793 0.011* 
PR 0.399 0.288 - 0.554 <0.0001* 1.029 0.485-2.182 0.940 
HER2 1.382 0.765 - 2.496 0.283 0.710 0.364-1.384 0.314 
P21 0.650 0.287 - 1.475 0.303 0.230 0.030-1.761 0.157 
Disease-free survival (DFS) 
Age 0.815 0.568 - 1.170 0.267 1.127 0.620-2.050 0.695 
Tumour size 1.975 1.379 - 2.829 <0.0001* 0.899 0.418-1.930 0.784 
Grade 4.093 2.246 - 7.460 <0.0001* 2.748 0.848-8.906 0.092 
Staging 12.790 4.922 - 33.238 <0.0001* 8.405 1.576-44.814 0.013* 
LVI 4.003 2.747 - 5.833 <0.0001* 2.753 1.386-5.469 0.004* 
LNI 2.798 1.945 - 4.024 <0.0001* 1.178 0.477-2.910 0.723 
ER 0.293 0.200 - 0.427 <0.0001* 0.576 0.247-1.343 0.202 
PR 0.432 0.297 - 0.629 <0.0001* 0.808 0.351-1.861 0.616 
HER2 1.649 0.859 - 3.167 0.133 0.739 0.352-1.549 0.423 
P21 0.503 0.185 - 1.366 0.177 0.307 0.039-2.396 0.260 
‡
Cox Hazard Regression Test 
*Statistically significant 
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5.3 DISCUSSION 
5.3.1 Characteristics of P21 expressions in primary breast carcinoma 
P21 is a cyclin-dependent kinase inhibitor (cyclin-dependent kinase interacting protein 
1, CIP 1) which is consisted of two protein-binding domains, the N- and C-terminal.
[392]
 
The C-terminal is responsible for its nuclear localization, which then binds with 
proliferating cell nuclear antigen (PCNA) to inhibit DNA replication.
[393]
 Nuclear 
translocation of P21 is positively modulated by calmodulin and negatively by AKT-
dependent phosphorylation.
[394, 395]
 Nuclear localization is strongly associated with its 
activity as a growth inhibitor whereas cytoplasm relocalization of P21 is correlated with 
functional inactivation.
[367]
 In the present study, we reported a strong prominent 
characteristic of nuclear staining with occasional cytoplasmic staining of P21 protein 
expression. However, the nuclear expression of P21 was predominantly down regulated. 
Only 5.2% of the IDC cases presented the activated P21 protein. This finding suggested 
that the tumour cells have escaped the growth arrest by the down regulation of cell cycle 
inhibitor. The aggressive tumour cells manage to overcome the inhibition of weak P21 
activation. Several mechanisms may be responsible for P21 altered induction. It could 
possibly be due to alterations of the WAF1/CIP1 gene or altered P53 induction. 
Recently, p21 gene mutation has been reported to be significant in breast cancer.
[396]
                                      
Bukholm et al. found that down regulation of P21 expression was associated with P53 
abnormalities.
[397]
 On the other hand, alteration of P21 can occur without P53 
abnormalities suggesting that other mechanisms might be involved in turning off the P21 
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gene.
[324]
 This inactivation of P21 protein might be associated with PCNA ubiquitination 
that is related to inactivation of DNA repair activity.
[398] 
 
5.3.2 P21 expression in the breast lesions 
In the present study, we showed P21 was primarily reduced in expression and hence, 
down regulated. We examined a pattern of gradual increased expression of P21 from 
normal to benign to premalignant then plateauing from premalignant to malignant, 
although the percentage is small. The expression of P21 protein between normal, benign, 
premalignant and malignant breast tissues were significantly associated. In comparison, 
a similar study with a small cohort reported that there was no significant difference 
between the expression of P21 protein in the normal and benign breast disorder with a 
significantly higher p21 mRNA expression in benign compared to normal tissues.
[399]
 
Another study has shown that P21 was significantly reduced in the invasive uterine 
cancer compared to normal and precancerous lesions which suggested P21 inactivation 
is an early event of tumourigenesis.
[400]
 Nevertheless, another breast cancer study reveals 
a high expression profile of P21 protein in the tumour cells which suggested that high 
P21 expression in the breast cancer cells is probably activated due to genetic instability 
of the DNA resulting in the cell cycle arrest at  G1/S checkpoint.
[401]
 Hence, studies on 
expression of P21 in breast cancer have revealed conflicting results, as some studies 
show increased expression while others are correlated with the reduction of P21 in the 
breast tumour. P21, which is also known as wild-type p53 activated fragment-1 (WAF 
1), is a critical downstream effector of p53. It has important role in the regulation of cell 
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cycle, gene transcription, DNA repair and modulation of apoptosis.
[402]
 Despite its 
activity as a tumour growth inhibitor, P21 is found to paradoxically induce cell cycle 
progression. In a recent finding, P21 was found to be involved in the breast tumour 
progression via the formation of the transcriptional complex with stat3, progesterone 
receptor and ErbB-2 upon induction by the synthetic progesterone.
[244]  
 
5.3.3 Association of P21 expression with clinicopathological parameters  
Aberrations of P21 in breast tumour cells were analyzed used Pearson chi square test. 
We demonstrated a significant inverse association between P21 expressions with tumour 
grade in breast cancer. The absence of P21 was correlated with poor tumour 
differentiation. This finding was comparable with the theory of  P21 overexpression 
having the ability to induce differentiation in a wide range of cancerous and normal cells 
via vitamin D and its analogue.
[403]
 Therefore, loss of P21 results in the inability to 
ensure proper differentiation in cells. In contrast, others have indicated high expression 
was clinically significantly associated with poorly differentiated tumour.
[167, 324, 404]  
High 
P21 expressing tumours may actually be more aggressive than their pathological or 
biological features.
[401]
 There were no significant associations between P21 expression 
and other clinicopathological parameters such as age, tumour size, staging, 
lymphovascular invasion, lymph node involvement, ER, PR and HER2 status.  
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5.3.4 Survival, recurrence free survival and prognostication. 
Functionally, P21 plays an important role in the regulation of cell cycle, gene 
transcription, DNA repair and modulation of apoptosis.
[402]
 P21 has dual role in cancer, 
as on one hand it inhibits tumour growth while on the other it induces cancer 
progression. Increased expression of P21 is commonly associated with growth-arrest of 
terminally differentiated cells,
[405]
 albeit high expression of P21 will possibly induce 
breast tumourigenesis by the formation of transcriptional complex with stat3, 
progesterone receptor and ErbB-2.
[244]
 Still, the significance of cyclin-dependent kinase 
inhibitor P21 expression in human breast cancer is uncertain with limited and conflicting 
data. While some studies report direct relationship between P21 expression and poor 
prognostic factors,
[167, 323, 324]
 others have shown correlation between P21 expression and 
good prognosis.
[406-408]
 Although aberrant P21 protein can occur at high frequency, other 
investigators have found P21 expression to be insignificant in breast cancer 
development.
[409-411] 
It is suggested that P21 is not an important prognostic factor in 
breast cancer. We were also unable to show any significant correlation between P21 
expression and overall and disease free survival suggesting it might be not be 
significantly involved in the breast cancer progression. 
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5.4 CONCLUSION 
- There was significant low expression of P21 in a large retrospective breast cancer 
cohort 
- Low level of P21 occurs at an early stage in the multi-step process of breast 
tumourigenesis and this aberration precedes the development of invasive cancer. 
- P21 is negatively associated with breast tumour differentiation.  
- P21 is not an important prognostic factor in breast cancer. 
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CHAPTER 6 
P16INK4A EXPRESSION IN 
BREAST  
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6.1 INTRODUCTION 
P16
INK4A
 (P16) is a well-established tumour suppressor that has been found to play an 
important role in the progression of human cancers. P16 is involved in cell cycle arrest 
related cellular senescence in premalignant tumour, yet its investigation has so far been 
restricted to animal models.  In this chapter, the expression profile of P16 in a series of 
primary human breast cancer is presented. Additionally, its association with 
clinicopathological data as well as the linkage of protein expression with patient survival 
and its potential prognostic utility are evaluated.  
 
6.2 RESULTS 
Tissue availability for P16 analysis on the TMAs is very high with tissue lost ranging 
from only from 3.0% to 9.5% (normal, 9.11%; benign, 9.04%; premalignant, 5.40% and 
malignant 3.26%). Protein expression was assessed semi-quantitatively. 
Immunoreactivity in the nucleus and cytoplasm was individually graded. Intensity and 
distribution of the immunoreactivity were recorded. P16
INK4a
 was scored based on the 
study by Karin Milde-Langosch: 
[325]
 intensity score (0 = no staining, 1 = weak staining, 
2 = moderate staining, 3 = strong staining) was multiplied with distribution score (0 = no 
staining, 1 = <10%, 2 = 10-50%, 3 = 51-80%, 4 = >80%). Final score was categorized 
into 0–4: weakly positive, 5-6: moderately positive, 8–12: strongly positive. Generally, 
P16 expression was predominantly in the nucleus and less commonly in the cytoplasm. 
 Ch 6. P16INK4A Expression Profiles 
 
 
 
154 
 
6.2.1 Molecular expression of P16 
6.2.1.1 P16 expression in normal breast tissue 
Nuclear and cytoplasmic staining was seen in small proportions. P16 immunoreactivity 
of normal mammary epithelium was variable in intensity but generally displayed weak 
nuclear reactivity. Majority of the normal tissue showed no P16 staining. There was 
strong nuclear staining in a few cases, which account for 2.4% of the total cases. If 
present, immunoreactivity signals in the nuclei were intense and diffuse. The                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
majority of the normal tissues had weak cytoplasmic staining.  
 
6.2.1.2 P16 expression in benign breast lesion, ADH 
Immunostaining signals in the nuclei showed various patterns but could be 
morphologically classified into mixed patterns with diffuse and dot type signal. 
Occasionally, there was weak background staining of the stroma. P16 staining pattern in 
ADH was the same as that in normal breast tissue. In general, in ADH, the epithelial 
cells exhibited mostly weak nuclear reactivity (65.7%) with sporadic of strong 
immunostaining (7.9%) (Figure 6.1). If present, strong positive staining cells were 
heterogeneously scattered among the many negative cells within the lesion. Cytoplasmic 
staining was rare. 
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6.2.1.3 P16 expression in the premalignant lesion, DCIS.  
P16 expression in DCIS was predominantly in the nucleus with only incidental faint 
cytoplasmic staining. The nuclear immunostaining score varies from as low as 0% to as 
high as 100%. The lesions exhibited clear and diffuse positive P16 staining. Strong P16 
expression was seen in 20.7% of the DCIS cases, moderate in 29.9% and weak in 49.3% 
cases (Figure 6.1).  
 
6.2.1.4 P16 expression in IDC  
P16 expression in the IDC cells was mainly localised to the nucleus with minimal 
insignificant staining in the cytoplasmic region. Diffuse and strong P16 
immunoreactivity was frequently seen throughout the tumour (Figure 6.2). Occasional 
positive cells were seen in the adjacent tissue. In some cases, the tumours displayed 
weak and moderate P16 immunoreactivity with heterogeneously scattered positive.  
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Figure 6.1 The proportion of cases with P16 intensity score in each category of lesions.  
 
 
 
 
 
Strong
Moderate
Weak
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
Normal ADH DCIS IDC
Strong
Moderate
Weak
 Ch 6. P16INK4A Expression Profiles 
 
 
 
157 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 Examples of P16 immunoreactivity in a series of breast lesions mirroring the 
progression in breast cancer development. (a) Normal, positive; focal distribution of 
positive cells (b) ADH, positive; mixed patterns of diffuse and dot type signal (c) DCIS, 
positive; strong and diffuse staining (d) IDC, positive; High distribution of P16 
immunoreactivity throughout the tumour cells. Left: High-power magnification (×100) 
(a-d). Right: show higher-power (×400) views of the same fields. 
(a) 
(d) 
(c) 
(b) 
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6.2.2 Association of P16 expression during breast cancer development 
 
P16 expressions were predominantly seen in the nucleus and less commonly in the 
cytoplasm. Malignant lesions with strong immunoreactivity showed uniform staining of 
all tumour cells, whereas tumours with weak and moderate P16 staining often showed 
heterogeneous staining pattern (Figure 6.2). The staining intensity of the cells and the 
number of positive cells increased from normal to premalignant DCIS, then 
plateau/slight increase from DCIS to malignant IDC. Nuclear P16 expression was 
significantly associated with breast cancer development (chi square, p<0.05, Table 6.1). 
 
Table 6.1 is a summary of the relationship between P16 expression and breast 
pathological lesions. In the present study, normal tissue is found to be less likely to 
express the P16 protein and remain weak in the benign lesion (chi square, p<0.0001). In 
addition, the matching normal tissue that is weakly stained for P16 is more likely to be 
associated with weak expression in the IDC (chi square, p<0.0001). In general, increased 
strong expression was observed from normal to DCIS with slight plateau from DCIS to 
IDC. Statistically, strong staining in DCIS is more likely to increase expression in the 
corresponding IDC (chi square, p<0.0001). Positive linear relationship was observed 
with higher expression in early development resulting in higher expression in the later 
stage. 
 
  
 Ch 6. P16INK4A Expression Profiles 
 
 
 
159 
 
 
 
Table 6.1 Association of P16 expression with breast cancer progression. Chi square P-
value indicates the differences between: (a) Normal vs. ADH; (b) ADH vs. DCIS; (c) 
DCIS vs. IDC and (d) IDC vs. Normal. Percentage represent ratio of positive or negative 
to the total number of cases. 
 
 
6.2.3 Correlation of P16 with clinical and pathology covariates 
We also assessed the significance of P16 expression in relation with clinicopathological 
variables using the Pearson Chi-square (Table 6.2). This study found a highly significant 
association between P16 expression with tumour grade, estrogen receptor and 
progesterone receptor (chi square, p<0.0001 respectively).  Increased expressions of P16 
were associated with the unfavourable prognostic factors of poor tumour differentiation 
and ER and PR negativity. There was no significant association observed with other 
prognostic indicators of age, tumour size, staging, lymphovascular invasion, lymph node 
involvement and positivity of HER2.  
 
P16  Expression 
Weak 
(0-4) 
Moderate 
(5-6) 
Strong 
(8-12) 
P-value 
Normal 738 (76.3%) 206 (21.3%) 23 (2.4%) <0.05
a 
ADH 333 (65.7%) 134 (26.4%) 40 (7.9%) <0.0001
b 
DCIS 364 (49.3%) 221 (29.9%) 153 (20.7%) <0.0001
c 
IDC 635 (60.9%) 182 (17.5%) 225 (21.6%) <0.05
d 
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Table 6.2 Association of P16 markers with clinicopathological variables.  
 
 
  
P16 Expression 
 
Weak 
(0-4) 
Moderate 
(5-6) 
Strong 
(8-12) 
P-value
‡
 
Age 
≤60 years 
>60 years 
327 
307 
97 
86 
129 
96 
0.331 
Tumour size 
≤20mm 
>20mm 
385 
249 
107 
76 
126 
99 
0.4449 
Grade 
Well 
Moderate 
Poor 
178 
261 
195 
49 
83 
51 
29 
74 
122 
<0.0001* 
Stage 
I 
II 
III 
IV 
267 
292 
68 
7 
79 
82 
20 
2 
92 
108 
24 
1 
0.975 
LVI 
Absent 
Present 
430 
204 
117 
66 
134 
31 
0.074 
LNI 
Absent 
Present 
397 
237 
117 
66 
142 
83 
0.947 
ER 
Negative 
Positive 
81 
520 
28 
145 
110 
100 
<0.0001* 
PR 
Negative 
Positive 
149 
452 
48 
126 
121 
89 
<0.0001* 
HER2 
Negative 
Positive 
361 
60 
80 
23 
98 
17 
0.124 
‡ Pearson χ2 
* Statistically significant p<0.05   
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6.2.4 Recurrence and survival  
 
Patients’ survival as influenced by P16 protein expression was analysed using Kaplan-
Meier test. The comparisons between subgroup of more than 3 used pairwise log rank 
test.  The estimated mean overall survival for the group with weak P16 expression was 
13.129 ± 0.219 years with a total of 60 deaths (n=607, 9.88%) and 547 patients still alive 
(n=607, 90.12%) during the follow up period. The 1 year, 3 year and 5 year survival rate 
was 98.7%, 95.4% and 90.0% respectively.  The group with moderate P16 expression 
was reported to have 17.16% death (n=169, death=29) and 82.84% patients still alive 
(n=169, alive=140) with estimated mean overall survival of 10.893 ± 0.470 years. The 1 
year, 3 year and 5 year survival rate was 99.4%, 94.1% and 87.1% respectively.  
 
In addition, the group with strong P16 expression has an estimated mean survival of 
9.984 ± 0.377 years with a total of 57 deaths (n=217, 26.27%) and 160 still alive 
(n=217, 73.73%) during the follow up period. The 1 year, 3 year and 5 year survival rate 
was 95.8%, 84.3% and 75.6% respectively. A total of 117 cases had tumour relapse. 
Recurrent rate for weak, moderate and strong expression group was 7.74% (n=607, 
event=47), 12.73% (n=165, event= 21) and 23.0% (n=213, event=49) respectively. The 
differences between P16 expression group were statistically significant for both overall 
survival (Kaplan-Meier, p<0.05) and disease-free survival (Kaplan-Meier, p<0.05) 
(Figure 6.3). 
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Univariate and multivariate cox regression analysis showed P16 was a significant 
prognostic factor in predicting overall survival and disease-free survival. Univariate 
analysis showed strong P16 expression were significantly associated with decreased OS 
(p=0.000, HR 2.498, 95% CI 1.739 - 3.588) and DFS (p=0.000, HR 2.943, 95% CI 
1.970 - 4.396) (Table 4). Multivariate analysis showed that strong P16 expression was 
an independent factor for overall survival (p=0.011, HR 2.321, 95% CI 1.213-4.440) and 
disease free survival (p=0.001, HR 3.335, 95% CI 1.586-7.012). 
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Figure 6.3. Survival probability based on p16 marker Above: Overall survival 
probability (Kaplan-Meier curve, Weak vs. Moderate p=0.022, Moderate vs. Strong 
p=0.079, Strong vs.  Weak p=0.000). Bottom: Disease free survival probability (Kaplan-
Meier curve, Weak vs. Moderate p=0.081, Moderate vs. Strong p=0.013, Strong vs.  
Weak p=0.000 
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      Table 6.3 Univariate and multivariate cox regression analysis of P16 expression 
Variable 
Univariate analysis Multivariate analysis 
RR 95% CI P-value
‡
 RR 95% CI P-value
‡
 
Overall survival (OS) 
Age 1.367 0.992 - 1.883 0.056 1.791 1.066-3.011 0.028* 
Tumour size 1.892 1.373 - 2.607 <0.0001* 0.900 0.474-1.709 0.748 
Grade 2.368 1.485 - 3.775 <0.0001* 0.929 0.344-2.507 0.884 
Staging 16.302 7.523 - 35.327 <0.0001* 28.246 6.654-119.906 0.000 
LVI 3.143 2.262 - 4.368 <0.0001* 1.796 0.991-3.256 0.054* 
LNI 2.429 1.758 - 3.354 <0.0001* 0.827 0.399-1.716 0.611 
ER 0.377 0.270 - 0.527 <0.0001* 0.462 0.196-1.089 0.077 
PR 0.399 0.288 - 0.554 <0.0001* 1.242 0.561-2.746 0.593 
HER2 1.382 0.765 - 2.496 0.283 0.921 0.467-1.815 0.811 
P16 2.498 1.739 - 3.588 <0.0001* 2.321 1.213-4.440 0.011* 
Disease-free survival (DFS) 
Age 0.815 0.568 - 1.170 0.267 1.248 0.684-2.276 0.471 
Tumour size 1.975 1.379 - 2.829 <0.0001* 1.041 0.475-2.281 0.920 
Grade 4.093 2.246 - 7.460 <0.0001* 3.371 0.900-12.618 0.071 
Staging 12.790 4.922 - 33.238 <0.0001* 7.421 1.456-37.823 0.016* 
LVI 4.003 2.747 - 5.833 <0.0001* 2.385 1.189-4.783 0.014* 
LNI 2.798 1.945 - 4.024 <0.0001* 1.462 0.569-3.756 0.431 
ER 0.293 0.200 - 0.427 <0.0001* 0.890 0.348-2.280 0.809 
PR 0.432 0.297 - 0.629 <0.0001* 0.959 0.398-2.309 0.925 
HER2 1.649 0.859 - 3.167 0.133 0.965 0.460-2.023 0.924 
P16 2.943 1.970 - 4.396 <0.0001* 3.335 1.586-7.012 0.001* 
‡
Cox Hazard Regression Test 
*Statistically significant 
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6.3 DISCUSSION 
Cellular senescence is an age-related irreversible cell cycle arrest at the G1 phase upon 
intrinsic or extrinsic induction.
[227]
 P16 is involved in the oncogene-induced senescence 
pathway through the well-established P16 
INK4a
 –Rb pathway [199]. Many in vivo and in 
vitro studies have demonstrated the inhibition of neoplastic cell proliferation by the 
senescence process 
[189, 215, 221]
.
 
Induction of either p53 or P16 in response to abnormal 
mitogenic signalling promotes premature senescence, suggesting that it is a mechanism 
of tumour suppression
[189]
. It has been found that loss of P16 in the normal cell promotes 
hyperplasia which can lead to increased risk of tumour development.
[240] 
 
6.3.1 Expression of P16 in primary breast carcinoma 
 
P16 is a nuclear protein encoded by MTS1/CDKN2/P16 gene of human chromosome 
9.
[412]
 In this study, P16 expression was mostly found in the nucleus. Less commonly, 
P16 expression was seen in the cytoplasmic region. Abnormalities of P16 can be found 
in a wide range of human malignancies as well as in breast cancer. P16 expression 
appears to be upregulated from normal, benign to premalignant lesions and then 
plateauing in the invasive lesion. It was reported that up regulation of P16 in DCIS 
patients is a sign of increased risk to subsequently develop invasive breast cancer, 
particularly when in combination with Ki-67 and COX-2 markers.
[413]
 However, P16 
overexpression in benign atypical hyperplasia lesions does not significantly associate 
with high risk to subsequent development of breast cancer.
[414]
 We reported higher P16 
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expression in the early development was correlated with higher expression in the later 
development. This finding might suggests lesion with high P16 is more likely to develop 
subsequent malignant lesion.  
 
Upregulation of P16 may be a consequence of either abrogate Rb signalling or a 
response to cellular stress.
[415, 416]
 To date, increased P16 expression in both pre-
malignant and malignant tissues have been seen in several other human cancers, such as 
esophageal
[417]
 and prostate carcinoma
[361]
. Pathophysiologically, overexpression of 
senescence markers in a tumour cell may indicate that the tumour cell has been activated 
to enter the senescence program, but it may also reflect disruption of a downstream 
mediator of the regulatory pathway 
[418]
. Abnormally high level of P16 was proposed as 
a result of pRb inactivation or low pRb expression.
[419]  
On the other hand, a recent study 
reported replicative senescence may contribute to the stabilisation and increased 
expression of P16 in senescent cells 
[420]
. 
 
6.3.2 The association of P16 with clinicopathological parameters 
 
Association of P16 marker expression with well-established prognostic marker were 
assessed using Pearson chi-square test.  To our knowledge, P16 protein biomarker was 
rarely reported to have any significant association with clinical and pathological data of 
breast cancer patients 
[421, 422]
 until recently when a small cohort study found P16 
overexpression was associated with more a malignant phenotype.
[325]
 Similarly, our 
study has shown that increased P16 protein expression in malignant breast tissue 
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correlates with unfavourable prognostic factors of poor tumour differentiation and ER 
and PR negativity. The significance of P16 had been established at the genetic level 
which found association of high P16 mRNA levels with grading, ER negativity, lymph 
node involvement, and increased risk of relapse.
[419]
 Abrogation in the suppression 
pathway could possibly associate with bad outcome, which might explain the finding of 
P16 upregulation correlated with bad prognostic factors. Invasive lesion may escape the 
cell cycle regulatory by acquiring mutations that either directly/indirectly negates 
tumour suppressor gene function. It was reported the inactivation of P16 may 
contributed by homozygous deletion, mutation, or promoter methylation.
[238]  
 
 
6.3.3 Prognostic significance of P16 
 
In the present study, we found that high P16
INK4a
 protein expression is a sign of poor 
overall survival and disease free survival. Upregulation of P16 is shown to have shorter 
survival and increased risk of relapse in breast cancer patients. A similar finding was 
seen in other human breast cancer study.
[422]
 The poor survival outcome of a high P16 
protein expression is especially relevant when high P16 is associated with the 
unfavourable well-established prognostic factor. In addition, the finding was supported 
by a genetic study which reported association between overexpression of P16
 
mRNA 
with loss of survival advantage in primary breast cancer.
[419]
 However, other studies 
have shown contradictory findings in which amplification of P16 protein expression was 
correlated with better prognosis.
[423]
 We found P16 protein remains a significant 
prognostic factor in predicting ability to survive amongst breast cancer patients after 
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Cox multivariate analysis was conducted. The association of P16 with worse prognosis 
may be related to abrogated tumour suppressor pathway as it is evident that intact 
response to cellular stress are strongly associated with a disease free prognosis.
[424]
 P16 
biomarker may help in stratification of early detected pre-invasive DCIS, thus detection 
of P16 may be useful in the management of patients early before invasion occurs. 
 
 
6.4 CONCLUSION 
Based on the above, following conclusions are reached: 
1. Significantly increased expression of P16 in a large group of breast cancer 
patient. 
2. P16 nuclear expression was less common in the early development of normal and 
benign hyperplasia but high expression can be seen in the premalignant and 
malignant lesions. 
3. P16 overexpression is associated with unfavourable prognostic factors such as 
poor tumour differentiation and ER and PR negativity. 
4. Overexpression of P16 protein expression is associated with poor overall 
survival and disease free survival.     
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CHAPTER 7 
p53 EXPRESSION IN BREAST  
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7.1 INTRODUCTION 
p53 protein has been described since 1979 as a virus-associated tumour antigen, an 
oncogene and finally an important tumour suppressor.
[425]
 Physiologically, wild-type p53 
is a tumour suppressor gene that mediates cell cycle regulatory pathways either via cell 
cycle arrest, apoptosis or cellular senescence.
[426]
 Abnormalities of the gene may give 
rise to a cancer after accumulation of many mutations in the same cells.
[427]
 Although it 
has been thoroughly investigated by scientists, the protein expression of p53 protein has 
not been studied in relation with the senescence biomarker properties. Similar to the 
previous chapter, the content in this chapter would include the expression profiles of 
p53, the association with clinicopathological parameters as well as its value as a 
prognostic factor. 
 
7.2 RESULTS 
We reported high frequency of accessible tissue in TMA section with low number 
missing tissue cores. The tissue loss ranged from 3.0% to 7.0% (normal, 6.17%; benign, 
7.23%; premalignant, 3.86% and malignant 1.77%). Assessment of p53 
immunoreactivity was based on established method. Protein expressions were analysed 
semi-quantitatively by estimating the percentage of immunoreactivity in the nucleus and 
disregarding the cytoplasmic staining. Score of more than or equal to 10% were 
considered to have an increase in expression.
[167, 326-328]
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7.2.1 Expression of p53 
7.2.1.1 p53 expression in normal breast tissue 
Our study showed p53 is predominantly expressed in the nucleus and less commonly in 
the cytoplasmic. The percentage of staining for individual tissue cores ranged from 0% 
to 60%. Positive staining (score of ≥10%) was seen 5.8% of the total cases. If present, 
the immunoreactivity of p53 in the nuclei exhibited weak and focally positive signals.  
 
7.2.1.2 p53 Expression in ADH 
p53 immunoreactivity in hyperplastic mammary epithelium of the lesion ADH was 
variable in intensity but was largely weak nuclear reactivity. Nevertheless, the 
immunoreactivity is stronger compared to normal mammary tissue. Nuclear staining was 
seen in only 11.1% of the total cases. The percentage of staining for individual tissue 
cores ranged from 0% to 90%. Occasionally, there was weak background staining of the 
stroma. Cytoplasmic staining was less commonly seen. 
 
7.2.1.3 p53 Expression in DCIS  
p53 protein expression in DCIS tissue was predominantly in the nucleus and incidental 
faint cytoplasmic staining. The percentage of staining for individual tissue cores ranged 
from as low as 0% to as high as 100%. The staining pattern was clear and diffuse. 
Positive staining can be seen in 28.3% of the total cases.   
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7.2.1.4 p53 Expression in IDC  
Malignant tumour cells in individual tumour tissue cores showed nuclear 
immunoreactivity ranging from 0% to 100%.  Positive staining (score of more than 
10%) can be seen in 27.0% of the total cases. Malignant lesions frequently showed 
diffuse nuclear immunostaining (Figure 7.5d). Occasionally positive cells were seen in 
the adjacent tissue. 
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Figure 7.1 The proportion of p53 staining in normal breast tissue.  5.8% (57/988) of the 
total cases were positive stained and 94.2% (931/988) were negative. 
 
 
 
 
 
 
 
 
 
 
Figure 7.2 The proportion of p53 staining in ADH.  11.1% (57/513) of the cases were 
positive and 88.9% (456/513) were negative. 
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Figure 7.3 The proportion of p53 staining in DCIS. Positive group were accounted as 
28.3% (212/748) whereas negative group accounted as 71.7% (536/748). 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4 The proportion of p53 staining in IDC. 27.0% (284/ 1053) were positive for 
P53 and 73.0% (769/1053) negative.
  Ch 7. p53 Expression Profiles 
 
 
 
175 
 
 
 
Figure 7.5 Example of p53 immunoreactivity in progression series of breast cancer 
development. (a) Normal: Left, negative; Middle, positive (x100); Right, clear and 
distinct nuclear staining (x400)  (b) ADH: Left, negative; Middle, positive (x100); 
Right, positive dot type signal (x400); (c) DCIS: Left, negative; Middle, positive (x100); 
Right, strong and diffuse staining of nucleus and cytoplasmic region (x400) (d) IDC: 
Left, negative; Middle, positive nucleus throughout tumour cells; Right, strong dot 
signal positive immunoreactivity (x400). 
   
   
   
   
(a) 
(b) 
(c) 
(d) 
  Ch 7. p53 Expression Profiles 
 
 
 
176 
 
7.2.2 p53 expression in breast cancer development  
The association of p53 protein expression and the different breast lesions was assessed 
using chi square test. We found strong association of p53 protein expression with each 
type of breast lesion. Generally, the expression of p53 appears to increase from normal 
to ADH to DCIS, and then slightly decreases from DCIS to IDC.  
 
Table 7.1 is the summary of the relationship between breast lesions and p53 expressions. 
In the present study, we found the matching normal tissue that is positively stained is 
more likely to be further positively expressed in ADH (p<0.0001). However, p53 is 
more likely to be reduced in expression in IDC (p=0.032). DCIS are more likely to have 
greater p53 expression than invasive lesions (p<0.0001). 
 
 
Table 7.1 Association of p53 expression with breast cancer progression. Chi square P-
value indicates the differences between: (a) Normal vs. ADH; (b) ADH vs. DCIS; (c) 
DCIS vs. IDC and (d) IDC vs. Normal. Percentage represent ratio of positive or negative 
to the total number of cases. 
 
 
 p53  Expression 
Negative Positive χ2 p-value 
Normal 931 (94.2%) 57 (5.8%) 52.289 <0.0001
a
 
ADH 456 (88.9%) 57 (11.1%) 12.304 <0.0001
b
 
DCIS 536 (71.7%) 212 (28.3%) 318.556 <0.000
c
 
IDC 769 (73.0%) 284 (27.0%) 4.583 0.032
d
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7.2.3 Correlation of p53 with Clinical and Pathology covariates 
 
The significance of p53 protein expression in breast tumour was assessed in relation to 
standard prognostic factors. We found p53 protein expression was significantly 
associated with age, grade, staging, lymphovascular invasion (LVI), estrogen receptor 
(ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 
(HER2). However, the marker did not significantly associate with tumour size and 
lymph node metastases (LNM). p53 upregulation was associated with poor prognostic 
indicators such as poor differentiation, late stage tumour, present of lymphovascular 
invasion and negative ER and PR as well as positive HER2. However, p53 upregulation 
was associated with older age. 
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Table 7.2 Association of p53 markers with clinicopathological variables.  
 
  
p53 protein Expression 
 
Negative (%) Positive (%)  χ2 P‡ 
Age 
≤60 years 
>60 years 
381(68.2) 
388 (78.5) 
178 (31.8) 
106 (21.5) 
14.360 <0.0001* 
Tumour size 
≤20mm 
>20mm 
468 (74.9) 
301 (70.3) 
157 (25.1) 
127 (29.7) 
2.674 0.102 
Grade 
Well 
Moderate 
Poor 
238 (92.6) 
333 (77.8) 
198 (53.8) 
19 (7.4) 
95 (22.2) 
170 (46.2) 
124.019 <0.0001* 
Stage 
I 
II 
III 
IV 
341 (77.3) 
338 (69.1) 
83 (73.4) 
7 (70.0) 
100 (22.7) 
151 (30.9) 
30 (26.6) 
3 (30.0) 
7.980 0.046* 
LVI 
Absent 
Present 
528 (76.4) 
241 (66.6) 
163 (23.6) 
121 (33.4) 
11.669 0.001* 
LNI 
Absent 
Present 
494 (74.4) 
275 (70.7) 
170 (25.6) 
114 (29.3) 
1.708 0.191 
ER 
Negative 
Positive 
107 (48.4) 
621 (80.2) 
114 (51.6) 
153 (19.8) 
88.636 <0.0001* 
PR 
Negative 
Positive 
188 (58.7) 
541 (80.0) 
132 (41.3) 
135 (20.0) 
50.124 <0.0001* 
HER2 
Negative 
Positive 
404 (74.1) 
58 (55.8) 
141 (25.9) 
46 (44.2) 
14.352 <0.0001* 
   ‡ Pearson χ2 
   * Statistically significant p<0.05 
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7.2.4 Recurrence and survival  
 
The differences in overall survival and disease free survival for patients with different 
levels of p53 expression was analysed using Kaplan-Meier log rank test. The estimated 
mean overall survival for negative the p53 group was 12.363 ± 0.232 with a total of 105 
deaths (n=735, 14.29%) and 630 patients still alive (n=735, 85.71%) during the follow 
up period. The 1 year, 3 year and 5 year survival rate was 98.5%, 94.0% and 87.5%, 
respectively. The positive p53 group had 42 deaths (n=269, 15.61%) with 227 patients 
still alive (n=269, 84.39%) during the follow up period. The 1 year, 3 year and 5 year 
survival rate was 97.7%, 89.4% and 84.0%, respectively. 
 
There were a total of 119 tumour relapse cases consisting of 78 p53 negative cases and 
41 p53 positive cases. Recurrence rate for negative group was 10.70% (n=729, 
event=78) and 15.36% (n=267, event=41) for the positive group. The estimated mean 
disease free survival for the p53 negative group was 12.061 ± 0.191 and p53 positive 
group was 10.777 ± 0.442. Kaplan Meier analysis did not show significant difference in 
overall survival in relation to p53 expression (χ2= 2.425, p=0.119). Nevertheless, p53 
expression was significantly associated with increased risk of relapse (χ2= 9.532, 
p=0.002). Univariate cox regression analysis showed p53 was a significant prognostic 
factor in predicting disease free survival (HR 1.805 95% CI 1.23-2.639 p=0.002) but not 
overall survival. However, when multivariate analysis incorporating the 
clinicopathology parameters was conducted, p53 did not show any significant findings 
for both overall and disease free survival. 
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Figure 7.6 Survival probability based on p53 marker survival. Above: Overall survival 
(Kaplan-Meier curve, negative vs. positive, p=0.119). Bottom: Disease free survival 
probability (Kaplan-Meier curve, negative vs. positive, p=0.002)
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    Table 7.3 Univariate and multivariate cox regression to estimate the hazards ratio of p53 expression.  
Variable 
Univariate analysis Multivariate analysis 
RR 95% CI P-value RR 95% CI P-value 
Overall survival (OS) 
Age 1.367 0.992 - 1.883 0.056 1.608 0.958-2.698 0.072 
Tumour size 1.892 1.373 - 2.607 <0.0001* 0.778 0.403-1.502 0.455 
Grade 2.368 1.485 - 3.775 <0.0001* 0.855 0.360-2.029 0.722 
Staging 16.302 7.523 - 35.327 <0.0001* 24.939 6.008-103.513 <0.0001* 
LVI 3.143 2.262 - 4.368 <0.0001* 2.079 1.156-3.738 0.015* 
LNI 2.429 1.758 - 3.354 <0.0001* 0.790 0.387-1.614 0.518 
ER 0.377 0.270 - 0.527 <0.0001* 0.313 0.137-0.716 0.006* 
PR 0.399 0.288 - 0.554 <0.0001* 1.124 0.514-2.459 0.769 
HER2 1.382 0.765 - 2.496 0.283 0.718 0.370-1.396 0.329 
p53 1.329 0.928-1.902 0.121 0.604 0.335-1.091 0.095 
Disease-free survival (DFS) 
Age 0.815 0.568 - 1.170 0.267 1.106 0.609-2.007 0.741 
Tumour size 1.975 1.379 - 2.829 <0.0001* 0.870 0.396-1.909 0.728 
Grade 4.093 2.246 - 7.460 <0.0001* 3.030 0.925-9.930 0.067 
Staging 12.790 4.922 - 33.238 <0.0001* 6.697 1.355-33.096 0.020* 
LVI 4.003 2.747 - 5.833 <0.0001* 2.694 1.362-5.326 0.004* 
LNI 2.798 1.945 - 4.024 <0.0001* 1.255 0.513-3.069 0.619 
ER 0.293 0.200 - 0.427 <0.0001* 0.517 0.214-1.245 0.141 
PR 0.432 0.297 - 0.629 <0.0001* 0.837 0.355-1.975 0.685 
HER2 1.649 0.859 - 3.167 0.133 0.748 0.359-1.559 0.439 
p53 1.805 1.23-2.639 0.002* 0.675 0.352-1.295 0.237 
* Statistically significant p<0.05 
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7.3 DISCUSSION 
7.3.1 Expression of p53 in Primary Breast Carcinoma 
 
The p53 gene is a tumour suppressor localised to the short arm of chromosome 17 and 
encodes a 375 amino acid nuclear phosphoprotein. p53 is activated when cells are 
stressed or damaged.
[428]
 p53 plays an important role in protecting human genome 
stability.
[125]
 It protects cellular integrity via three primary responses: cell cycle arrest, 
cellular senescence or apoptosis.
[429]
 Alteration of p53 has been involved in a wide range 
of human cancers including breast carcinoma. The activation of the p53 gene occurred 
early in the development of breast cancer. p53 expression appears increased in 
progressively more advanced stages of the development of breast cancer, peaking at the 
premalignant DCIS stage, followed by a slight drop in the invasive lesion. These 
observations may be explained by the tumour suppressive function of p53 reacting to 
cellular stress signals such as abnormal proliferation or DNA damage. Therefore, the 
tumour suppressor upregulation is a natural response to counteract the abnormal growth. 
However, invasive cancer may be formed after the cells surpass the cell cycle regulatory 
when mutations occur in the tumour suppressor gene itself. It is reported that mutations 
of p53 are one of the most common known genetic alterations in human cancer.
[328, 430-
432]
  More than 75% of the mutations do not affect the translation of p53 protein, but 
mutant p53 protein loses its wild-type functions.
[433]
 Mutant p53 is more stable 
compared to the short-lived wild-type p53.
[434]
 The long presence of mutant p53 itself 
may have an oncogenic effect on the cells.
[435]
 p53 positivity in immunohistochemistry 
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staining is highly associated with mutant p53 gene.
[436, 437]
 The latest finding have shown 
p53 immunoreactivity, by either manual or automated scoring method, can be used to 
predict missense mutations in breast carcinomas with high accuracy.
[438]
 However, p53 
upregulation in IHC may detect both mutated p53 and stabilized wild-type p53 and not 
p53 deletions.
 [439]
 Despite the wealth of publications on IHC and association with 
mutation, it remains unknown whether the upregulation of p53 in this study is 
representative of the wild-type or mutant p53 protein as the antibody used in this study 
can react with the mutant and wild form of p53 at the epitope aa 20-25. Further 
confirmatory mutational study should be conducted to confirm the mutation status as the 
genetic abnormalities need to be more clearly defined. We have also ruled out the non-
functional activity of cytoplasmic p53 protein as our finding showed the p53 protein 
expression primarily localised in the nucleus.   
 
7.3.2 The Association of p53 with clinicopathological parameters      
 
The association of p53 expression with clinicopathological parameters was assessed 
using Pearson chi-square. The clinical significance of p53 protein in breast cancer was 
determined by assessing its relation to the existing standard prognostic factors. We 
found p53 expression was highly associated with the clinical and pathological 
parameters of breast cancer patients. Our study showed that p53 overexpression was 
significantly associated with poor prognostic factors such as poor differentiation, late 
stage tumour, presence of lymphovascular invasion and negative ER and PR as well as 
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positive HER2. Only a few studies reported relationship between p53 protein expression 
with favourable clinicopathological parameters (young age
[440]
), while most studies have 
shown relationship between p53 protein expression with unfavourable indicators (large 
tumour size, high grade tumour, advanced tumour stage, negative hormone receptor 
status, lymph node invasion
 [441-444]
). Silvestrini et al. confirmed that tumors 
overexpressing p53 are most frequently negative for estrogen receptor and that they tend 
to be large.
[445]
 The relationship between absence of p53 and good prognostic indicators 
may be due to wild-type p53 having a short half-life of 5-20 minutes in most cells and is 
thus usually undetectable by standard immunohistochemical staining.
[434]
 On the other 
hand, mutant p53 is more stable and accumulates in the nucleus due to elongated half-
life or by binding with other oncogene proteins. However, an elevated level of mutated 
p53 does not give protection to the cellular integrity, and thus is directly linked to 
unfavourable prognostic factors. This finding may suggest that the upregulation of p53 
is associated with mutant p53 protein. Nevertheless, we suggest mutational study to be 
conducted to confirm the type of protein expression in this cohort. 
. 
7.3.3 Prognostic significance of p53 
 
In brief, prognostic factor may be defined as any factor that provides information on 
clinical outcome independent of treatment, and can be used to separate poor from 
favourable groups.
[439]
 Despite the extensive biological and clinical studies, and reports 
on p53 that may have promising value in predicting the outcome of a specific cancer 
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type, P53 is not yet widely accepted and used as a prognostic factor in the clinical 
setting.  This is because most studies analyzing P53 have not taken therapy into 
consideration which may result in analytical and statistical bias.
[439]
 Regardless, p53 has 
been found to be the most affected gene in breast cancer 
[151]
  and is highly associated 
with breast cancer basal-like and HER2-enriched subtypes.
 [117]
 
 
The importance of p53 overexpression in predicting worse survival outcome has been 
reported in several small group breast cancer studies.
[446-448]
 In the present study, we 
found p53 protein overexpression is correlated with increased risk in developing the 
disease later but not with the patient survival. Similar finding had been shown 
previously by others which found that overexpression of p53 has worse outcome for 
disease-free survival and the overall survival.
[326, 328, 449, 450]
 The prognostic value of p53 
overexpression has been associated with clinical breast cancer subtype of luminal A
[451]
,  
node-positive
[452] 
and metastatic breast cancer
[453]
.
 
Moreover, other researchers have 
shown that p53 overexpression is a specific poor prognostic factor for lymph node 
metastasis, triple negative and HER2+/p53+ breast cancer.
[444, 454, 455]
 p53 
overexpression is reported to be related to aggressive tumour thus possibly explaining its 
association with poor prognosis. Furthermore, the association of p53 gene mutation with 
p53 protein overexpression may contribute to the abrogation of the suppressor pathway 
thus leading to aggressive tumour behaviour. Additionally, the poor prognosis may be 
possibly explained by its association with endocrine therapy resistance and lower 
chemotherapy sensitivity.
[451, 456]
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7.4 CONCLUSION 
Based on the above, following conclusions are reached: 
 
1. Significantly increased expression of p53 in a large cohort of breast cancer 
patient. 
2. P53 expression was less common in the early development of breast cancer, 
specifically in normal breast tissue and ADH; however overexpression of nuclear 
P53 protein was seen in the premalignant and malignant lesions. 
3. p53 overexpression was significantly associated with poor prognostic factors 
such as poor differentiation, late stage tumour, present of lymphovascular 
invasion and negative ER and PR as well as positive HER2. 
4. p53 overexpression appears to be a univariate predictor of poor disease-free 
survival. 
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SENESCENCE DE NOVO 
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8.1 INTRODUCTION 
DcR2 (decoy receptor 2) is one of two TRAIL non-cell-death-inducing receptors. DcR2, 
also known as TRAIL-R4, is a truncated receptor for tumor necrosis factor (TNF)-
related apoptosis-inducing ligand (TRAIL or Apo2L). This protein is well known for its 
anti-apoptotic activity by inhibiting the ligand formation between TRAIL and the death 
receptors especially DR5.
[457]
 DEC1 (differentiated embryo-chondrocyte expressed gene 
1) is also known as stimulation of retinoic acid 13 (Stra13, in mouse) or split and hairy 
related protein-2 (Sharp2, in rat).
[458]
 DEC1 protein is basic helix loop-helix (BHLHB2) 
transcription factor that can be triggered by numerous extracellular stimuli such as 
growth factors, serum starvation, hypoxia, hormones, nutrient, cytokines, light and 
infection. Biologically speaking, it is involved in a wide range of signaling pathways 
including development, cell differentiation, cell growth, cell death, oncogenesis, 
immune systems, circadian rhythm, and homeostasis
[459] Of the putative functions of 
DcR2 and DEC1, both de-novo markers were recently found to be candidate genes for 
premature cellular senescence.
[263]
 This chapter looks into the expression profiles of 
DcR2 and DEC1 in a series of breast lesions in the progression to malignancy as well as 
their association with well-established clinicopathological covariates. In addition, we try 
to look at its clinical significance as a prognostic factor.  
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8.2 RESULTS 
Tissue microarray is associated with higher risk of tissue loss during tissue staining 
process compared to whole tissue section slide. We reported tissue loss for DcR2 
staining as high up as 11%. The range was from 3% to 11% (normal, 10.92%; benign, 
11.21%; premalignant, 9.64% and malignant 3.73%) whereas tissue loss during DEC1 
staining process ranged from 2% to 9% (normal, 8.74%; benign, 9.40%; premalignant, 
4.37% and malignant 2.0%). 
Protein expressions were assessed semi-quantitatively by estimating the percentage of 
positive-stained cells. Intensity and distribution of the immunoreactivity were recorded. 
Scoring for DcR2 was performed and adapted as described previously:
[330]
 the intensity 
score (0=no staining, 1=weak staining, 2=moderate, 3=strong) was added to the 
distribution score (0 = <10% staining, 1 = 10-40% staining, 2 = 40-70 % staining, 3 = 
>70% staining), resulting in a final score ranging from 0 to 6. Increased expression was 
defined as ≥2. DEC1 immunoreactivity in the nucleus and cytoplasm were individually 
graded. The scoring was based on a study by Xu et al.: intensity score (0 = no staining, 1 
= weak staining, 2 = moderate staining, 3 = strong staining) was multiplied with 
distribution score (0=<5%, 1=5-25%, 2=26-50%, 3=51-75% and 4=>75%). Final score 
was categorized into 0–4: negative, 5-8: weakly positive, 9–12: strongly positive. 
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8.2.1 Protein Expression of Senescence de-novo Marker 
8.2.1.1 DcR2 protein 
8.2.1.1.1 DcR2 Expression in normal breast tissue 
DcR2 was seen primarily in the cytoplasmic region of the normal breast epithelium. 
DcR2 imparts a dot-like pattern of staining in the nucleus. Most positive stained normal 
tissues have a weak staining intensity. If present, strong positive stains were 
heterogeneously scattered among the many negative cells within the lesion. 13.9% of 
normal breast tissue were absent of DcR2 activation (score 0%). Occasionally, positive 
weak staining can be seen in the surrounding tissue. 
 
 
  
Figure 8.1 DcR2 immunoreactivity in the normal morphology. Left at low 
magnification of 100X and right at high magnification of 400X 
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8.2.1.1.2 DcR2 Expression in ADH 
Immunostaining signals in the benign lesion, ADH, showed various staining intensity 
and high degree of distribution. Majority of the benign tissue is present with the DcR2 
protein activation whereas only 5.0% of the lesion were absent of DcR2 activation 
(score 0%). The signal is much stronger than in the normal tissue. Irregularly, in strong 
staining the protein was masking over the nuclear region. Occasionally, there was weak 
background staining of the stroma.  
 
 
 
 
 
  
Figure 8.2 DcR2 immunoreactivity in the benign hyperplasia lesion. Left at low 
magnification of 100X and right at high magnification of 400X 
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8.2.1.1.3 DcR2 Expression in DCIS  
The DcR2 protein is stained in the cytoplasmic region of DCIS. The nuclear region 
appeared to express blue dot type signal. Occasionally, a few cells have strong staining 
in the cytoplasm compared to the adjacent cells which may form a ring shape of 
concentrated dark brown around the nuclear region. If the signals were too strong, the 
protein may mask over the nuclear compartment. DcR2 activation scores varied from as 
low as 0% to as high as 100% in individual tissue cores. The surrounding background 
might show positive staining.  
 
 
 
 
 
  
Figure 8.3 DcR2 immunoreactivity in the premalignant in situ lesion. Left at low 
magnification of 100X and right at high magnification of 400X 
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8.2.1.1.4 DcR2 expression in IDC  
Most of the DcR2 immunoreactivity was seen in the cytoplasm with minor protein 
expression masking over the nucleus. The nuclear immunoreactivity appeared as a blue 
dot signal. Commonly, in IDC cases with strong DcR2 immunoreactivity, the staining 
was seen throughout the tumour cells. DcR2 activation scores in individual tissue cores 
ranged from as low as 0% to as high as 100%. Occasional positive cells were seen in the 
adjacent tissue.  
 
 
 
 
 
  
Figure 8.4 DcR2 immunoreactivity in the malignant invasive lesion. Left at low 
magnification of 100X and right at high magnification of 400X 
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8.2.1.2 DEC1 protein 
8.2.1.2.1 DEC1 Expression in normal breast tissue 
Protein expression of DEC1 gene was seen in the nuclear region accompanied by diffuse 
staining in the cytoplasm. DEC1 protein expression was high even in normal breast 
tissue.  The score varied from 0% to 90% for both nuclear and cytoplasmic 
immunoreactivity. It appeared the immunoreactivity of DEC1 gene was homogenous in 
the breast tissue. Frequently, positive cells were seen in the adjacent tissue. 
 
 
 
 
  
Figure 8.5 DEC1 immunoreactivity in the normal breast tissue. Left at low 
magnification of 100X and right at high magnification of 400X 
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8.2.1.2.2 DEC1 Expression in ADH 
The intensity of the staining was stronger compared to normal breast tissue. 
Immunoreactivity of DEC1 can be seen in the nucleus and cytoplasmic region. A strong 
granular pattern of DEC1 staining was seen within the cytoplasm. A few of the adjacent 
cells were positively stained. Lymphocytes were seen to have strong activation of DEC1 
which we used as internal positive control.  
 
 
 
 
 
 
 
  
Figure 8.6 DEC1 immunoreactivity in the benign lesion. Left at low 
magnification of 100X and right at high magnification of 400X 
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8.2.1.2.3 DEC1 expression in DCIS  
 
In DCIS, nuclear immunoreactivity ranged from 0% to 100%.  Most were seen to 
display moderate intensity. As seen in ADH, DCIS cases showed a strong granular 
pattern of DEC1 staining within the cytoplasm. Lymphocytes and neutrophil in the 
adjacent background were also positively stained. Occasionally, the stroma was also 
positively stained. 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 8.7 DEC1 immunoreactivity in the premalignant DCIS. Left at low 
magnification of 100X and right at high magnification of 400X 
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8.2.1.2.4 DEC1 expression in IDC  
Malignant tumour cells exhibited homogenous staining of DEC1 protein. A strong 
granular staining can be seen in the cytoplasm. Occasionally, a ring shape staining 
around the nucleus may be seen. We also observed a varying degree of nuclear 
immunoreactivity. Frequently, diffuse staining throughout malignant tumour cells was 
seen. 
 
 
 
 
 
 
 
  
Figure 8.8 DEC1 immunoreactivity in the malignant breast tissue. Left at low 
magnification of 100X and right at high magnification of 400X 
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8.2.2 Association of protein expression with breast cancer development 
 
8.2.2.1 DcR2 in the progression to breast cancer 
The expression of DcR2 protein in a series of breast lesions representative of  
progression to malignancy showed increase in DcR2 expression from normal to ADH to 
DCIS, which then plateaued/slightly increase from DCIS to IDC (Table 8.1). The 
association between DcR2 expression and breast cancer progression was assessed by the 
Pearson chi-square test. In general, positive-stained cells in the precursor lesions were 
more likely to continue to overexpress the protein in the more advanced lesion. 
Overexpression of DCR2 in benign breast lesions seem to be associated with high 
DCR2 in the matching normal tissue (chi-square, P<0.0001). In addition, the positive 
benign tissue was more likely to have high expression of DcR2 in the premalignant 
lesion (chi-square, P<0.0001). Equally important, the finding also supported that DcR2 
expression in premalignant was highly associated with expression in the malignant 
counterpart. A total of 89.5% (611/683) of the positive DCIS cases eventually develop 
positive IDC (chi-square, P<0.0001). The difference in DcR2 expression was 
statistically significant when IDC was compared to non-malignant tissues (chi-square, 
P<0.0001). 
 
 
 
 Ch 8. DcR2 & DEC1 Expression Profiles 
 
 
 
199 
 
 
 
 
 
Table 8.1 Association of DcR2 expression with breast cancer progression. Chi square P-
value indicates the differences between: (a) Normal vs. ADH; (b) ADH vs. DCIS; (c) 
DCIS vs. IDC and (d) IDC vs. Normal. Percentage represent ratio of positive or negative 
to the total number of cases. 
 
 
 
 
 
 
 
 DcR2 immunoreactivity 
 Negative 
<10% 
Positive 
≥10% 
χ2 P-value 
Normal 371 (39.6%) 567 (60.4%) 79.500 <0.0001
a
 
ADH 91 (18.5%) 400 (81.5% 28.629 <0.0001
b 
DCIS 53 (7.5%) 650 (92.5%)) 148.045 <0.0001
c 
IDC 63 (6.1%) 969 (93.9%) 16.141 <0.0001
d 
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8.2.2.2 DEC1 vs. breast tissue progression 
DEC1 expression was localised in both the nucleus and cytoplasm. The staining was 
uniformly homogenous in normal, benign, premalignant and malignant breast tissues. 
The majority of the breast tissues have weak activation of the DEC1 gene. The staining 
appeared to increase from normal to benign to premalignant lesions, and then decreased 
from premalignant to malignant tissues in both the nucleus and cytoplasm; however, in 
each tissue the percentage of staining was small. The association between activation of 
DEC1 and breast tissue progression was assessed by Pearson Chi-square (Table 8.2 and 
Table 8.3). We found the association of DEC1 expression between each breast lesion 
was statistically significant. A linear relationship was found in which lower DEC1 
expression in the breast lesions at the early stages of breast cancer development was 
predicted to have lower expression in the fully developed cancer. Precursors with weak 
DEC1 expression were more likely to develop immunoreactivity in the later stage of 
progression. This type relationship was seen when comparison was made between 
normal vs. benign, benign vs. premalignant, premalignant vs. malignant and malignant 
vs. normal tissues (chi-square, P<0.0001 respectively).  
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 DEC1 nuclear immunoreactivity 
 Negative 
(0-4) 
Weak 
(5-8) 
Strong 
(9-12) 
P-value 
Normal 91 (9.5%) 869 (90.4%) 1 (0.1%) <0.0001
a
 
ADH 43 (8.6%) 455 (90.8%) 3 (0.6%) <0.0001
b 
DCIS 79 (10.6%) 654 (87.9%) 11 (1.5%) <0.0001
c 
IDC 125 (11.9%) 912 (86.9%) 13 (1.2%) <0.0001
d 
Table 8.2 The association of DEC1 nuclear protein expression in breast lesions 
representing the different stages of breast cancer development. Chi square P-value 
indicates the differences between: (a) Normal vs. ADH; (b) ADH vs. DCIS; (c) DCIS 
vs. IDC and (d) IDC vs. Normal. Percentage represent ratio of positive or negative to 
the total number of cases. 
 
 
Table 8.3 The association of DEC1 cytoplasmic protein expression in breast lesions 
representing the different stages of breast cancer development. Chi square P-value 
indicates the differences between: (a) Normal vs. ADH; (b) ADH vs. DCIS; (c) DCIS 
 
DEC1 cytoplasm immunoreactivity 
 Negative 
(0-4) 
Weak 
(5-8) 
Strong 
(9-12) 
P-value 
Normal 77 (8.0%) 883 (91.9%) 1 (0.1%) <0.0001
a
 
ADH 34 (6.8%) 461 (92.6%) 3 (0.6%) <0.0001
b 
DCIS 42 (5.6%) 693 (92.9%) 11 (1.5%) <0.0001
c 
IDC 82 (7.8%) 953 (90.8%) 14 (1.3%) <0.0001
d 
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vs. IDC and (d) IDC vs. Normal. Percentage represent ratio of positive or negative to 
the total number of cases. 
8.2.3 Correlation of tumour marker with clinicopathological data 
 
8.2.3.1 DcR2 vs. clinicopathological covariates 
The clinical significance of DcR2 protein was further analysed by examining its 
correlation with well-established clinicopathological covariates (Table 8.4). We found 
DcR2 protein expression was significantly correlated with tumour grade, hormone 
receptors status and HER2. Overexpression of DCR2 was associated with moderate 
differentiation, positivity of hormone status (ER and PR) and HER2 negativity. There 
were no significant associations made with other prognostic indicators of age, tumour 
size, staging, lymphovascular invasion and lymph node involvement.  
 
 
8.2.3.2 DEC1 vs. clinicopathological covariates 
We also assessed the significance of DEC1 protein expression in relation to the clinical 
and pathological parameters (Table 8.5). Both nuclear and cytoplasmic 
immunoreactivity were not significantly associated with the well-established prognostic 
factors such as age, tumour size, staging, lymphovascular invasion, lymph node 
invasion, hormone receptors and HER2. 
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Table 8.4 Association of senescence-associated marker DcR2 with 
clinicopathological variables.  
 
 
 
  DcR2 protein Expression 
 Negative Positive χ2 P‡ 
Age 
≤60 years 
>60 years 
38 
25 
509 
460 
1.441 0.230 
Tumour size 
≤20mm 
>20mm 
36 
27 
574 
395 
0.107 0.743 
Grade 
Well 
Moderate 
Poor 
15 
16 
32 
234 
408 
327 
8.964 0.011* 
Stage 
I 
II   
III 
IV 
22 
33 
8 
0 
407 
449 
104 
9 
1.972 0.578 
LVI 
Absent 
Present 
40 
23 
633 
336 
0.088 0.767 
LNI 
Absent 
Present 
33 
30 
612 
357 
2.931 0.087 
ER 
Negative 
Positive 
28 
33 
187 
730 
21.700 <0.0001* 
PR 
Negative 
Positive 
29 
32 
281 
637 
7.578 0.006* 
HER2 
Negative 
Positive 
31 
13 
498 
90 
6.085 0.014 
‡ Pearson χ2 
* Statistically significant p<0.05 
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Table 8.5 Association of senescence-associated marker DEC1 with 
clinicopathological variables.  
 
 
  
DEC1 nuclear expression DEC1 cytoplasm expression 
 
negative Weak strong P
‡
 negative Weak strong P
‡
 
Age 
≤60 
years 
>60 
years 
66 
59 
483 
429 
7 
6 
0.997 
488 
34 
499 
454 
8 
6 
0.533 
Tumour 
size 
≤20mm 
>20mm 
77 
48 
537 
375 
7 
6 
0.783 
46 
36 
567 
386 
8 
6 
0.825 
Grade 
Well 
Moderate 
Poor 
30 
40 
55 
222 
377 
313 
4 
4 
5 
0.212 
26 
21 
35 
226 
394 
333 
4 
5 
5 
0.089 
Stage 
I 
II 
III 
IV 
55 
57 
13 
0 
379 
423 
101 
9 
3 
10 
0 
0 
0.352 
33 
43 
6 
0 
401 
436 
107 
9 
3 
11 
0 
0 
0.187 
LVI 
Absent 
Present 
83 
42 
597 
315 
9 
4 
0.942 
59 
23 
620 
333 
9 
5 
0.449 
LNI 
Absent 
Present 
80 
45 
575 
337 
6 
7 
0.441 
54 
28 
600 
353 
7 
7 
0.521 
ER 
Negative 
Positive 
32 
91 
190 
670 
1 
10 
0.352 
17 
64 
204 
696 
2 
10 
0.838 
PR 
Negative 
Positive 
43 
80 
277 
584 
2 
9 
0.496 
28 
53 
291 
610 
3 
9 
0.787 
HER2 
Negative 
Positive 
64 
8 
476 
99 
4 
0 
0.282 
47 
7 
492 
100 
4 
0 
0.510 
‡ Pearson χ2 
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8.2.4 Senescence de novo markers in disease recurrence and patient 
survival 
 
8.2.4.1 DcR2 and survival ability 
We analysed the differences in overall survival and disease free survival in relation to 
DcR2 expression using the Kaplan-Meier log rank test. The estimated mean overall 
survival for the negative group was 11.458 ± 0.566 with a total of 9 deaths (n=61, 
14.75%) and 52 patients still alive (n=61, 85.25%) during the follow up period. The 1 
year, 3 year and 5 year survival rate was 98.3%, 87.7% and 82.9%, respectively. The 
estimated mean overall survival for the positive group was 12.185 ± 0.217 with a total 
of 136 deaths (n=924, 14.72%) and 85.28% patients still alive during the follow up 
period. The 1 year, 3 year and 5 year survival rate was 98.4%, 93.4% and 87.0%, 
respectively. While the positive group showed a pattern of worse survival compared to 
negative group, it was not statistically significant (log rank test, p=0.765).  
 
 A total of 117 cases had tumour relapse, with 7 recurrence cases occurring in negative 
group and 110 cases occurring in positive group. Negative group showed 1 year, 3 year 
and 5 year disease free survival of 93.2%, 89.6% and 85.9%, respectively. In 
comparison, positive group showed 1 year, 3 year and 5 year disease free survival of 
98.5%, 93.3% and 5 90.1%, respectively. However, we found no significant differences 
in disease free survival between negative and positive group (log rank test, p=0.799) 
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Figure 8.9 Survival probability based on DcR2 protein expression Above: Overall 
survival (Kaplan-Meier curve, p=0.765). Bottom: Disease free survival (Kaplan-Meier 
curve, p=0.799) 
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8.2.4.2 DEC1 and patient survival  
The DEC1 protein expression was categorised into three different groups of negative, 
weak and strong. During the follow up period, the total cases of death in negative 
nuclear DEC1 group were 17 cases (n=119, 14.29%), whereas 126 cases (n=871, 
14.47%) and 2 cases (n=11, 18.18%) were stratified into the weak nuclear and strong 
nuclear groups respectively. The estimated mean survival for negative nuclear group, 
weak nuclear group and strong nuclear group was 11.724 ± 0.455, 12.203 ± 0.233 and 
11.012 ± 1.139 years, respectively. Nuclear expression survival rates in the three 
different groups were high. The 5 year survival rates in the negative and weak groups 
were 86.4% and 86.9% respectively. However, as low cases had strong nuclear 
expression, only the 10-year survival rate could be generated which was 60.6%. The 
overall survival differences in nuclear expression were not statistically significant. Log 
rank analysis reported the following results: negative vs. weak p=0.767, weak vs. strong 
p=0.902 and negative vs. strong p=0.817.  
 
The total numbers of cases available for disease free survival analysis were 993. We 
reported recurrence had occurred in 12 cases (n=116, 10.34%) in the negative group, 
103 cases (n=866, 11.89%) in the weak group and 1 case (n=11, 9.09%) in the strong 
DEC1 expression group. The estimated mean disease free survival for the  negative, 
weak and strong group was 12.221 ± 0.428, 11.773 ± 0.198 and 11.600 ± 1.039, 
respectively. We also found no significant differences in disease free survival for the 
 Ch 8. DcR2 & DEC1 Expression Profiles 
 
 
 
208 
 
different DEC1 expression groups. Log rank analysis reported the following results: 
negative vs. weak p=0.412, weak vs. strong p=0.677 and negative vs. strong p=0.825.   
 
Cytoplasmic expressions of DEC1 also showed no significant differences in overall 
survival and disease free survival. The estimated mean overall survival for negative, 
weak and strong groups was 11.802 ± 0.511, 12.199 ± 0.223 and 0.232 ± 1.228, 
respectively. The estimated mean disease free survival for negative, weak and strong 
groups was 11.925 ± 0.467, 11.814 ± 0.189 and 10.669 ± 1.296, respectively.  
 
8.2.4.3 Multivariate analysis of DcR2 and DEC1 marker 
Multivariate cox regression was used to analyse the impact of collective covariates in 
predicting survival. All the covariates were included in the test. However, we found no 
significance in DCR2 and DEC1 protein expression in predicting survival outcomes in 
breast cancer patients (Table 8.6).  
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Figure 8.11 Survival probability based on nuclear expression of DEC1 Left: Overall 
survival (Kaplan-Meier curve, negative vs weak p=0.767, weak vs Strong p=0.902, 
Strong vs negative p=0.817). Right: Disease free survival (Kaplan-Meier curve, 
negative vs weak p=0.412, weak vs Strong p=0.677, Strong vs negative p=0.825) 
 
 
 
 
 
 
 
 
 
 
Figure 8.12 Survival probability based on cytoplasmic expression of DEC1 Left: 
Overall survival (Kaplan-Meier curve, negative vs. weak p=0.265, weak vs. Strong 
p=0.502, Strong vs. negative p=0.249). Right: Disease free survival (Kaplan-Meier 
curve, negative vs. weak p=0.514, weak vs. Strong p=0.690, Strong vs. negative 
p=0.562).  
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Variable 
Univariate analysis Multivariate analysis 
RR 95% CI p-value RR 95% CI p-value 
Overall survival (OS) 
Age 1.367 0.992 - 1.883 0.056 1.724 1.008-2.950 0.047* 
Tumour size 1.892 1.373 - 2.607 <0.0001* 0.982 0.497-1.938 0.957 
Grade 2.368 1.485 - 3.775 <0.0001* 1.200 0.434-3.316 0.725 
Staging 16.302 7.523 - 35.327 <0.0001* 13.208 2.187-79.777 0.005* 
LVI 3.143 2.262 - 4.368 <0.0001* 2.093 1.100-3.981 0.024* 
LNI 2.429 1.758 - 3.354 <0.0001* 0.956 0.450-2.029 0.906 
ER 0.377 0.270 - 0.527 <0.0001* 0.286 0.128-0.641 0.002* 
PR 0.399 0.288 - 0.554 <0.0001* 1.211 0.559-2.627 0.627 
HER2 1.382 0.765 - 2.496 0.283 0.718 0.365-1.415 0.339 
DcR2 0.902 0.459-1.772 0.765 1.686 0.642-4.430 0.289 
DEC1 (nuclear) 1.194 0.275-5.174 0.813 0.779 0.181-3.355 0.737 
DEC1 (cytoplasmic) 2.281 0.589-8.831 0.233 1.761 0.236-13.140 0.581 
Disease-free survival (DFS) 
Age 0.815 0.568 - 1.170 0.267 1.202 0.650-2.223 0.557 
Tumour size 1.975 1.379 - 2.829 <0.0001* 1.237 0.532-2.877 0.622 
Grade 4.093 2.246 - 7.460 <0.0001* 3.528 0.947-13.142 0.060 
Staging 12.790 4.922 - 33.238 <0.0001* 1.388 0.136-14.153 0.782 
LVI 4.003 2.747 - 5.833 <0.0001* 2.935 1.403-6.140 0.004* 
LNI 2.798 1.945 - 4.024 <0.0001* 1.687 0.651-4.374 0.282 
ER 0.293 0.200 - 0.427 <0.0001* 0.444 0.180-1.092 0.077 
PR 0.432 0.297 - 0.629 <0.0001* 0.977 0.404-2.358 0.958 
HER2 1.649 0.859 - 3.167 0.133 0.735 0.346-1.561 0.422 
DcR2 0.905 0.422-1.944 0.799 1.358 0.449-4.111 0.588 
DEC1 (nuclear) 0.831 0.108-6.399 0.859 1.586 0.209-12.040 0.655 
DEC1 (cytoplasmic) 1.667 0.346-8.037 0.524 1.661 0.101-27.410 0.723 
Table 8.6 Multivariate analysis of DCR2 and DEC1 with clinicopathological parameters. 
* Statistically significant p<0.05
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8.3 DISCUSSION 
DcR2, also known as TRAIL-R4 or TRUNDD, is an anti-apoptotic receptor which has a 
substantially truncated cytoplasmic death domain.
[460]
 This plasma membrane-located 
receptor is expressed in the intracellular cytoplasmic compartment. Although 
compartmentalization of TRAIL receptor other than at their recognized locations may be 
related to its non-functional activity
[461]
, we cannot draw any conclusion from DcR2 
localization in the nuclear compartment. It is thought that DcR2 is as an oncogene for its 
anti-apoptotic effect. However, a recent study found that DcR2 is involved in the 
oncogene-induced senescence which is highly expressed in the premalignant stage but 
lost in malignant tumours.
[207] 
Senescent cells expressing high DcR2 protein show a less 
aggressive proliferation index, whereas loss of DcR2 expression in tumour cells is 
associated with high proliferation rate. The role of this de novo marker is in lung 
carcinogenesis of a mouse model. The clinical significance DcR2 has not been reported 
by other study in a breast cancer tissue progression series especially in a large 
retrospective group.  
 
We reported that DcR2 marker is highly expressed in the human breast tissue as early as 
in the normal tissues. Protein expression of DcR2 gradually increases as the normal 
breast tissue abnormally progresses into the premalignant lesion stage; but a plateauing 
in DcR2 expression is seen in the progression from premalignant to malignant stage. 
However, expression of DcR2 occurs in a high proportion of cases, accounting for 
93.9% of IDC. Association between DcR2 protein expression and breast tissue 
 Ch 8. DcR2 & DEC1 Expression Profiles 
 
 
 
212 
 
progression is highly significant. Interestingly, we reported significant difference when 
IDC was compared to non-malignant tissues (P<0.0001). Similar pattern had been 
reported by Zhang et al. in prostate carcinoma study which reported DcR2 protein is 
expressed more frequently in prostate carcinomas than in benign prostatic tissue.
[361]
 In 
contrast, Gottwald et al. reported DcR2 protein is less common  in endometrioid 
adenocarcinoma compared to normal endometrium.
[462]
  However, another cancer study 
has reported no clear differences were observed in the expression of DcR2 between 
colorectal neoplasms and normal mucosa.
[463]
 Overexpressed DcR2 is also seen in other 
human malignancies such as colon cancer and lung cancer.
[464, 465]
 Physiologically, 
DcR2 is frequently expressed in normal tissues, but often silenced by hypermethylation 
in a wide range tumour cells including breast cancer, cervical cancer, malignant 
mesothelioma, neuroblastoma and prostate cancer.
[269]
  
 
Interestingly, we found overexpressed DcR2 protein is associated with good prognostic 
factors such as moderate tumour differentiation, ER and PR positivity and HER2 
negativity. To our knowledge such association has not been reported previously. In 
endometrioid adenocarcinoma DcR2 is not related to tumour grading and staging.
[462]
 
This association may reflect the activation of senescence pathway but somehow favour 
the tumorigenesis.  It is reported that cellular senescence may activate the protective 
effect at the early stage of carcinogenesis but then evolved to stimulate neoplastic 
growth in later progression. In addition, the negative influence of overexpressed DcR2 
may be due to its anti-apoptotic effects.
[466, 467]
  DcR2 would compete with the death of 
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TRAIL receptors to bind with Apo2L but its ligand formation prevents apoptosis thus 
favouring tumour progression. It is not fully established whether activation of DcR2 
protein would favour senescence or apoptosis.  
 
The other hypothesis tested in this chapter is that DcR2 should correlate with patient 
survival. This could not be proven with our results for both overall and disease free 
survival. A similar observation is noted in endometrioid carcinoma, in which DcR2 
protein also appears to be prognostically unimportant prognostic factor.
[462]
 However, a 
breast cancer study conducted by Ganten et al. found high expression of TRAIL-R4  
significant correlates with decreased DFS and OS.
[270]
 The inverse relationship between 
DcR2 protein expression and survival outcome may be explained by its ability to cause 
TRAIL resistance in breast tumour cell lines leading to the failure of TRAIL based 
chemotherapeutic drugs.
[268]
 
 
DEC1 belongs to the basic helix-loop-helix (bHLH) transcription factors that function as 
a regulator of the cell cycle, differentiation, circadian rhythms and apoptosis upon 
exposure to various extracellular stimuli.
[468]
 In our study, we found that DEC1 
expression increases with progression from normal tissue to benign, and subsequently to 
premalignant and malignant lesions. DEC1 is expressed in both the nucleus and the 
cytoplasm. The nuclear and cytoplasmic localization of DEC1 has been seen in each 
stages of breast cancer development with progression from normal, ADH, DCIS and 
malignant invasive tissue. Liu et al. reported that DEC1 is mostly present in the nucleus 
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of normal tissue but detected in both nucleus and cytoplasm of invasive breast 
carcinoma.
[469]
 Similarly, Chakrabarti et al. also reported the staining of DEC1 only in 
nucleus of normal breast tissue while the expression localized in both nucleus and 
cytoplasm of in situ and malignant lesion.
[264]
 
 
 
The expression of DEC1 protein is increased gradually and significantly associates with 
tumour development. The overexpression of DEC1 increases from normal to ADH to 
DCIS but decreases from DCIS to IDC for both nuclear and cytoplasmic expression; 
however, in each tissue core the percentage staining is small.. Similarly, studies by other 
groups found an increase in the expression of DEC1 during progression from normal to 
in situ and invasive breast carcinoma.
[264]
 This is in common with the finding of high 
expression of DEC1 in tumour tissues when compared to normal tissues in human 
kidney and lung.
[265]
 These finding suggest that DEC1 may contribute to breast cancer 
progression to the invasive phenotype. It may additionally have a role in the stroma 
since expression was frequently observed in the adjacent background particularly in 
fibroblasts and white blood cells. 
 
The clinical significance of DEC1 in association with the well-established standard 
prognostic markers is not statistically significant. DEC1 does not appear to be important 
prognostic factor for breast cancer patients in our study. This is in agreement with breast 
cancer study by another group, which also found no significant prognostic value.
[264]
 On 
the other has, DEC1 overexpression appears to impart a survival advantage in patients 
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with esophageal squamous cell carcinoma.
[329]
 Multivariate analysis found DCR2 or 
DEC1 not to be important prognostic markers after adjusting the clinical and 
pathological covariates.  
 
8.4 CONCLUSION 
Based on the above, following conclusions are reached: 
 
1. The DcR2 protein expression is predominantly localised to the cytoplasm and to a 
lesser extent in the nucleus whereas DEC1 protein expression is in both the 
nucleus and cytoplasm. DEC1 protein is also frequently found in the stroma. 
2. High expression of DcR2 occurs at an early stage in the multi-step process of 
breast carcinogenesis and gradually increases in the subsequent more advanced 
morphological stage. 
3. In the majority of breast lesions, DEC1 protein is weakly expressed. Strong 
expression increases from normal to benign to premalignant and malignant 
lesions. 
4. Overexpression of DcR2 is associated with favourable prognostic factors such as 
moderate tumour differentiation, ER and PR positivity and HER2 negativity. 
However, DEC1 expression is not shown to have any significant association with 
the clinical and pathological covariates. 
5. DcR2 and DEC1 are not important prognostic markers for overall and disease free 
survival among breast cancer patients.  
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9.1 INTRODUCTION 
Multivariate analysis of all covariates was conducted using Cox regression based on 
principle of fit which included all the covariates in the test. The combined effect analysis 
included only the markers that are significant in the univariate analysis which are P16, 
P14 and p53. P16 score were dichotomised into two groups, negative (0-4) and positive 
(5-12). 
 
9.2 RESULTS 
9.2.1 Multivariate analysis of all covariates 
Our study found that staging, lymphovascular invasion and estrogen receptor status were 
the important prognostic factors for overall survival but none of the tumour markers 
showed significant correlation (Table 9.1). However, we found P14 and P16 along with 
lymphovascular invasion are the significant prognostic factors for disease free survival 
of breast cancer patients (Table 9.2).  
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Table 9.1 Multivariate analysis of all markers including the clinicopathological parameters on overall survival 
 
Variable 
Univariate analysis Multivariate analysis 
RR 95% CI P-value† RR 95% CI P-value† 
Overall survival (OS) 
Age 1.367 0.992 - 1.883 0.056 1.660 0.963-2.861 0.068 
Tumour size 1.892 1.373 - 2.607 <0.0001* 0.841 0.416-1.702 0.631 
Grade 2.368 1.485 - 3.775 <0.0001* 1.096 0.376-3.191 0.867 
Staging 16.302 7.523 - 35.327 <0.0001* 24.124 3.671-158.526 0.001* 
LVI 3.143 2.262 - 4.368 <0.0001* 2.063 1.080-3.942 0.028* 
LNI 2.429 1.758 - 3.354 <0.0001* 0.854 0.399-1.829 0.684 
ER 0.377 0.270 - 0.527 <0.0001* 0.319 0.124-0.824 0.018* 
PR 0.399 0.288 - 0.554 <0.0001* 1.272 0.562-2.879 0.563 
HER2 1.382 0.765 - 2.496 0.283 0.870 0.431-1.755 0.697 
P14 1.179 0.765 - 1.818 0.456 0.933 0.478-1.821 0.839 
p53 1.329 0.928-1.902 0.121 0.640 0.340-1.203 0.166 
P16 2.498 1.739 - 3.588 <0.0001* 1.937 0.944-3.973 0.071 
P21 0.650 0.287 - 1.475 0.303 0.368 0.048-2.839 0.338 
DCR2 0.902 0.459-1.772 0.765 1.541 0.584-4.065 0.382 
DEC1 (Nucleus) 1.194 0.275-5.174 0.813 0.778 0.173-3.501 0.744 
DEC1 
(Cytoplasm) 
2.281 0.589-8.831 0.233 
1.664 0.210-13.153 0.629 
* Statistically significant p<0.05 
† Cox proportional hazard regression 
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Table 9.2 Multivariate analysis of all markers including the clinicopathological parameters on disease free survival 
Variable 
Univariate analysis Multivariate analysis 
RR 95% CI P-value† RR 95% CI P-value† 
Disease free survival (DFS) 
Age 1.367 0.992 - 1.883 0.056 1.226 0.653-2.302 0.525 
Tumour size 1.892 1.373 - 2.607 <0.0001* 1.121 0.467-2.692 0.798 
Grade 2.368 1.485 - 3.775 <0.0001* 2.926 0.749-11.432 0.123 
Staging 16.302 7.523 - 35.327 <0.0001* 2.559 0.224-29.271 0.450 
LVI 3.143 2.262 - 4.368 <0.0001* 2.827 1.352-5.913 0.006* 
LNI 2.429 1.758 - 3.354 <0.0001* 1.511 0.569-4.013 0.408 
ER 0.377 0.270 - 0.527 <0.0001* 0.743 0.259-2.129 0.580 
PR 0.399 0.288 - 0.554 <0.0001* 0.919 0.367-2.301 0.857 
HER2 1.382 0.765 - 2.496 0.283 0.829 0.383-1.793 0.634 
P14 1.767 1.026 - 3.044 0.040* 3.783 1.106-12.940 0.034* 
p53 1.805 1.23-2.639 0.002* 0.798 0.396-1.610 0.529 
P16 2.943 1.970 - 4.396 <0.0001* 2.560 1.129-5.804 0.024* 
P21 0.503 0.185 - 1.366 0.177 0.433 0.056-3.365 0.424 
DCR2 0.905 0.422-1.944 0.799 1.349 0.436-4.166 0.603 
DEC1 (Nucleus) 0.831 0.108-6.399 0.859 1.435 0.188-10.937 0.728 
DEC1 
(Cytoplasm) 
1.667 0.346-8.037 0.524 0.869 0.050-15.106 0.923 
* Statistically significant p<0.05 
† Cox proportional hazard regression 
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9.2.2 Effect of combining tumour marker on outcome 
9.2.2.1 Effect of combining P16 and P14 expression on outcomes. 
The effects of combining P16 and P14 expression on outcomes are shown in Fig 9.1, 
and were analysed using univariable models. Relative to patients with P16 and P14 
negative cancers, patients with breast cancers displaying strong P16 and P14 expressions 
had an adjusted 3-fold increased risk of having disease recurrence (HR=3.283, 95% CI: 
1.569,6.869) and 2-fold increased risk of all-cause related death (HR=1.935, 95% CI: 
1.108,3.377) (Table 9.3). 
 
 
 
 
9.2.2.2 Effect of combining p53 and P16 expression on outcomes. 
The effects of combining p53 and P16 expression on patient’s outcome were analysed 
using univariable models. Combination of p53 and P16 showed significant differences 
in patient’s overall survival and disease free survival (Figure 9.2). The worst outcome 
was seen in patients with p53+/P16+ tumours. Relative to patients with p53 and P16 
negative cancers, patients with breast cancers displaying strong p53 and P16 expressions 
had an adjusted 4-fold increased risk of having disease recurrence (HR=3.748, 95% CI: 
2.251-6.239) and 3-fold increased risk of all-cause related death (HR=2.632, 95% CI: 
1.656-4.183) (Table 9.4). 
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9.2.2.5 Effect of combining P14 and p53 expression on outcomes. 
The effects of combining P14 and p53 expression on patient’s outcome were analysed 
using univariable models. Combination of P14 and p53 showed significant differences 
in patient’s disease free survival only (Figure 9.3). The worst outcome was seen in 
patients with P14+/p53+ tumours. Relative to patients with P14 and p53 negative 
cancers, patients with breast cancers displaying strong P14 and p53 expressions had an 
adjusted 3-fold increased risk of having disease recurrence (HR=3.103, 95% CI: 1.539-
6.256) (Table 9.5). 
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Figure 9.1 Survival probability based on joint effect of p16 and p14 expression. 
Left: Overall survival probability. P16+/P14+ vs. P16-/P14- (p=0.022) and 
P16+/P14+ vs. P16-/P14+ (p=0.000) showed significant differences on overall 
survival. The worst outcome was seen in patients with P16+/P14+. Right: Disease 
free survival probability, P16+/P14+ vs. P16+/P14- (p=0.034), P16+/P14+ vs. P16-
/P14+ (p=0.000) and P16+/P14+ vs. P16-/P14- (p=0.001) showed significant 
differences in DFS. The worst outcome was seen in patients with P16+/P14+ 
tumours.  
 
 
 
Table 9.3 Association of p16 and p14 status with overall and disease-free survival 
 
 
 
 Time to death Time to recurrence 
 HR 95% CI p- value† HR 95% CI p-value† 
a) Joint effect 
P16+/P14+ 1.935 1.108-3.377 0.020* 3.283 1.569-6.869 0.002* 
P16+/P14- 1.140 0.499-2.607 0.756 1.413 0.490-4.076 0.523 
P16-/P14+ 0.771 0.427-1.392 0.389 1.315 0.612-2.826 0.483 
P16-/P14- reference reference 
b) Stratified effect 
P16+/P14+ 1.681 0.840-3.362 0.142 2.406 1.042-5.560 0.040* 
P16+/P14- reference reference 
P16-/P14+ 0.787 0.435-1.424 0.429 1.179 0.545-2.551 0.675 
P16-/P14- reference reference 
* Statistically significant p<0.05 
† Cox proportional hazard regression 
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Figure 9.2 Survival probability based on joint effect of p53 and p16 expression. 
Left: Overall survival probability, p53+/P16+ VS. p53-/P16- (p=0.000), P53+/P16+ 
vs. p53+/P16- (p=0.008), P53+/P16- VS. p53-/P16+ (p=0.049) and P53-/P16+ vs. 
P53-/P16- (p=0.000) showed significant differences on overall survival. The worst 
outcome was seen in patients P53+/P16+ tumours. Right: Disease free survival, 
p53+/P16+ VS. p53-/P16- (p=0.000), p53+/P16+ vs. p53+/P16- (p=0.017) and p53-
/P16+ vs. p53-/P16- (p=0.000) showed significant differences in DFS. The worst 
outcome was seen in patients with P53+/P16+ tumours.  
 
Table 9.4 Association of p53 and p16 status with overall and disease-free survival 
 
 
 
 Time to death Time to recurrence 
 HR 95% CI p-value† HR 95% CI p-value† 
a) Joint effect 
p53+/P16+ 2.632 1.656-4.183 <0.0001* 3.748 2.251-6.239 <0.0001* 
p53+/P16- 1.090 0.589-2.015 0.784 1.706 0.912-3.190 0.094 
p53-/P16+ 2.031 1.379-2.991 <0.0001* 2.244 1.424-3.536 <0.0001* 
p53-/P16- Reference reference 
b) Stratified effect 
p53+/P16+ 2.364 1.228-4.551 0.010* 2.158 1.130-4.121 0.020* 
P53+/P16- reference reference 
P53-/P16+ 2.029 1.378-2.989 <0.0001* 2.220 1.408-3.499 0.001* 
P53-/P16- reference reference 
* Statistically significant p<0.05 
† Cox proportional hazard regression 
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Figure 9.3 Survival probability based on joint effect of P14 and p53 expression.    
Left: Overall survival, No significant difference was seen between each combination 
Right: Disease free survival probability based on joint effect of P14 and p53 
expression. P14+/p53+ VS. P14-/p53- (p=0.001) and P14+/p53+ vs. P14+/p53- 
(p=0.007) showed significant differences in DFS. The worst outcome was seen in 
patients with P14+/p53+ tumours.  
 
 
 
Table 9.5 Association of P14 and p53 status with overall and disease-free survival 
* Statistically significant p<0.05 
† Cox proportional hazard regression 
 
 
Time to death Time to recurrence 
HR 95% CI p-value† HR 95% CI p-value† 
a) Joint effect 
P14+/p53+ 1.595 0.891-2.858 0.116 3.103 1.539-6.256 0.002* 
P14+/p53- 1.263 0.749-2.129 0.382 1.759 0.904-3.423 0.096 
P14-/p53+ 1.505 0.624-3.633 0.363 1.495 0.468-4.771 0.497 
P14-/p53- reference reference 
b) Stratified effect 
P14+/p53+ 1.265 0.850-1.882 0.247 1.741 1.160-2.612 0.007* 
P14+/p53- reference reference 
P14-/p53+ 1.532 0.633-3.712 0.344 1.832 0.552-6.081 0.323 
P14-/p53- reference reference 
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9.3 DISCUSSION 
In this thesis, the original hypothesis stipulates that expression of cellular senescence 
biomarkers should correlate with patient survival. However, the results did not show 
that senescence biomarkers are significant prognostic predictor of overall survival for 
breast cancer patients. On the other hand, the results appear to show that p14 and p16 
are important adverse prognostic factors in relation to disease free survival breast 
cancer patients.  
 
A single prognostic factor is no longer sufficient in treatment decision making. The 
conventional approach of ‘one size fits all’ has shifted to personalized treatment 
based on molecular classification of breast tumour. Currently, there is increasing use 
of two or more biomarkers in the assessment of patient prognosis and response to 
treatment.
[470]
 The importance of the combined effect of P14, P16 and p53 as 
biomarkers is highlighted in this thesis. We have shown in this study that patients 
with breast cancers expressing both P16 and P14 expression have increased risk of 
poor clinical outcome in the form of disease recurrence and poor overall survival, 
although the effect on the latter is not as strong. Additionally, the combination of p53 
and P16 expression also results in worse clinical outcome for overall and disease-free 
survival. However, the combination of P14 and p53 has a significant association with 
increased risk of disease recurrence in breast cancer patients. 
 
While we able to show a few significant novel findings, we would not exclude there 
are some limitations that may hindered big potential of this study. The data analysis 
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might have been affected by the incomplete figures of HER2 expression in our 
cohort. We were a bit restricted for not able to perform HER2 staining on the missing 
results due to limitation on the budget and health complication. Although extra 
precautions have been taken while handling TMA blocks and sections, we still 
encountered tissue lost during cutting and staining process. However, it is minimal 
and may unlikely have impacted the analysis. To our observation, tissue containing 
high amount of fat tissue is most likely to be lost during the heat antigen retrieval 
steps. Other limitation is short follow up period when the survival rate among breast 
cancer patient is high. More than 50% of our cohort showed a good survival rate and 
still alive at the end of the study. Therefore, for future analysis on the TMA cohort 
should consider re-follow up the current status. 
 
 
9.4 CONCLUSION 
Based on the above, following conclusions are reached: 
 
1. Multivariate of all six senescence biomarkers with clinicopathological 
covariates shows that P14 and P16 are the important prognostic factors for 
disease free survival among breast cancer patients. 
2. A combination of two senescence markers such as the joint effect of 
P16+/P14+ and p53+/P16+ has significant correlation with poor overall and 
disease free survival, whereas a combination of P14 and p53 is only 
associated with worse outcome in disease free survival.  
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Breast carcinogenesis involves a multistage process. The disease develops following 
the evasion of various cell cycle check-points.  Deregulation of the latter is a 
common pathway in the development of many human cancers, in which the normally 
failsafe mechanisms are interrupted, resulting in genetic instability compounded by 
cell cycle progression 
[134]
.
 
Although there are many studies on the molecular 
characteristics of invasive breast cancer, the molecular events that occur during the 
development and progression of breast cancer precursors are less well established. 
Molecular mechanisms mediating the progression of in situ carcinoma to infiltrating 
breast cancer remain largely unknown. In this context, cellular senescence is a 
mechanism that is recently found to mediate the processes involved in tumour 
development. While cellular senescence protects the mutated cells by permanently 
halting cell cycle against cancer formation, senescent cells occur in the premalignant 
stage but are lost in malignant tumour.
[177]
 Senescence is therefore a defining feature 
of premalignant tumours that may prove valuable in the diagnosis and prognosis of 
cancer. However, this hypothesis has been restricted to oncogene-induced senescence 
in the animal model. Thus, there is a need to clarify the event in the primary human 
cancer. To our knowledge, few biological events have been recorded to explain the 
involvement of such preventive or prognostic biomarkers in human primary breast 
cancer development. 
 
This thesis set out to find the importance of epithelial senescence markers in human 
breast cancer progression. Thus to scrutinize its significance, tissue microarray 
(TMAs) from a large retrospective cohort of 1080 breast cancer patients were 
constructed. To establish a progression series of breast cancer tissues to mirror the 
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different stages of multistep breast cancer development, where available, matching 
tissues from normal breast, ADH, DCIS and IDC were obtained from each patient. 
Evaluation for the relationship between senescence markers and well-established 
clinical and pathological prognostic covariates was undertaken. The variation in 
expression levels of the molecular markers is likely to reflect the differences in 
biological behavior of breast cancer and molecular characteristics that may assist in 
identifying patients of greatest risk to develop breast carcinoma. Hence, detection of 
the molecular markers in precursor lesions may help in effective management of an 
early detected breast carcinoma. The use of TMAs can significantly improve the 
throughput of IHC analysis and enhance the time-consuming tissue scoring. 
Nevertheless, this technique has a few limitations. A high percentage of tissue loss 
can be seen during tissue sectioning and tissue staining despite the suggested pre-
treatment of the tissue block and the use of water-bath antigen retrieval. Moreover, 
there is a possibility that the desired tissue area has been missed especially when it 
comes to the miniscule size of the benign lesions that are available for examination. 
In addition, the lesion on slides is slightly more expanded than the actual tissue 
paraffin block. 
 
Following the Introductory and Methods chapters, Chapter 3 presents the overview 
of patient’s demographic and clinicopathological characteristics. The associations of 
clinical and pathological database are then compared with the established literature. 
The data derived from our study are consistent with the data of the well-established 
literature. Parameters such as large size, poor differentiation, late clinical stage, 
negative ER and PR, as well as presence of lymphovascular invasion and lymph 
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node metastasis are poor prognostic factors for breast cancer patients.
[343, 349, 352]
 
These results raise the prospect that this study group is representative of a sample of 
Sydney South West breast cancer population. Therefore, it may be used to assist 
future study specifically in regards to the Sydney South West population for better 
management breast cancer patients.  
 
To achieve the aims of this thesis, the IHC status of the senescence marker proteins 
of 1080 breast cancer patients were assessed. The senescence-associated tumour 
markers investigated in this thesis included P14, P16, P21, p53, DcR2 and DEC1. 
Interestingly, the findings in this thesis are consistent with the hypothesis that the 
markers will peak at the premalignant stage, with loss of expression in the malignant 
stage. It is observed that there is a pattern of plateauing of the marker expression 
from the premalignant to malignant stage. This finding may be related to the 
principle that any abnormal cell growth would naturally activate human protective 
mechanism such as cellular senescence. As the tissues become more proliferative the 
expressions of senescence-associated markers gradually increase to in attempt to 
reduce the growth. However, the lesion may acquire mutations resulting in the 
evasion of cellular senescence which inhibit further protein expression, therefore 
reflecting the plateau expression level of the markers. As a result, the tumour cells 
divide indefinitely becoming more aggressive and invading the surrounding tissue. 
Taken together, they support one of the main hypotheses of this thesis that 
senescence-associated molecular markers involved in the pathogenesis of breast 
cancer are aberrantly expressed in breast cancer tissue with the highest level of 
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expression at the premalignant stage although it does exclude loss of the markers in 
malignant lesion.  
 
The clinicopathological data of patients is retrieved and the well-established 
prognostic factors investigated in this study include age, tumour size, grade, staging, 
nodal status and hormonal receptor status. It is apparent that the majority of the 
women, including a significant proportion of young woman, presented with small 
and node-negative tumours, thus requiring earlier treatment management. Molecular 
classification using senescence-associated tumour markers may potentially 
supplement conventional clinicopathological data. The relationship between 
clinicopathological parameters and the senescence biomarkers are assessed in order 
to identify markers that are associated with favourable prognosis.  Interestingly, 5 of 
the markers showed a significant association with at least one of the 
clinicopathological parameters. However, one of the markers (DEC1) did not show 
any significant association with the parameters. The majority of the markers (P14, 
P16 and p53) exhibited overexpression of protein associated with adverse prognostic 
indicators. In contrast, overexpression of DcR2 is associated with good prognosis 
.On the other hand, P21 downregulation is correlated with adverse prognostic factors. 
We have no conclusive explanation for such significant associations, although these 
findings may inform that the tumour suppressor has been mutated in invasive lesion, 
losing its normal function, and therefore associated with poor prognosis.  
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One of the hypotheses in this thesis is that variation in expression levels of molecular 
markers reflect the differences in biological behaviour of primary breast cancer and 
thus can provide prognostic information beyond that provided by conventional 
pathological tumour assessment and staging. Additionally, the prognostic 
information may also be used to indicate a need for more frequent clinical follow-up. 
Interestingly, of the 6 tumour markers studied in this thesis, 3 show significant 
correlation with patient survival. Univariate analysis shows that alterations of P14, 
P16 and p53 expression are important markers of disease recurrence in invasive 
breast carcinoma. High expression of these markers is a sign of increased risk for the 
tumour to recur. P16 is the only tumour marker that is associated with poor patient 
overall survival in which high P16 expression predicts adverse outcome on patient 
overall survival. 
 
Multivariate analysis is used to assess the significance of any prognostic information 
independent of that obtained from other known prognostic information. Interestingly, 
low P14 and P16 expression are independent prognostic factors of improved disease-
free survival, although not all markers in this group show clear evidence of an 
independent association with patient overall survival. The combinations of P16 with 
P14, P16 with p53 and P14 with p53 on the assessment of patient survival provide 
significant prognostic information. Combined abnormal expression of P16 with P14 
and P16 with p53 are strong independent predictor of poor overall and disease-free 
survival. A combination of P14 and p53 show significant association with increased 
risk of cancer recurrence. 
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Senescence-inducing chemotherapeutic agents are found to have the advantage of 
less toxicity due to lower dosage, hence they may be useful as an alternative to treat 
tumours that are specifically resistant to apoptosis-induced drugs.
[63]
 The senescence 
markers studied in this thesis may have implications in the effectiveness of such 
senescence-inducing chemotherapeutic drugs. In this thesis, it is found that a 
combination of P14 and P16 expression had an adjusted 3-fold increased risk of 
having disease recurrence (HR=3.283, 95% CI: 1.569, 6.869) and 2-fold increased 
risk of all-cause related death (HR=1.935, 95% CI: 1.108, 3.377). P14 and P16 are 
encoded by the gene CDKN2A. Future studies on the mechanisms involved in 
interactions of the components of the senescence pathway, such as P14 and P16, and 
senescence-inducing chemotherapeutic agents in breast cancer may be warranted. It 
is important to identify factors that may modify the effectiveness of therapy because 
these may provide new targets for modification of drug resistance. 
 
Future study may be directed toward the fact that cellular senescence is a 
heterogeneous state that can be characterized based on phenotypic or molecular 
marker profiles. Several markers has been listed and validated to be associated with 
senescence activity. However, single marker may not necessarily specific for 
senescence or it may absence in certain form of senescence. It remains largely 
unknown the downstream cellular signaling event that would specifically lead to 
senescence output. The effector mechanisms that contribute to cell signaling in 
senescence pathway should be exploited to elucidate the details of how senescence is 
activated over the apoptosis upon induction as they share the same initiation 
pathway. Potential markers that are specific to senescence pathway may help in 
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differentiating it with other tumour suppressive mechanisms. With the current 
advance of high throughput sequencing molecular technique, we may be able to get 
full sequence of senescent-induced cells in different type of cells population and 
explore the gene products that occupy the pathway to cellular senescence. Identifying 
the cellular signaling of senescence pathway in the oncogene-induced senescence 
type is an important step in understanding the mechanism involved during the cancer 
progression. This could prime towards designing a more effective drug for cancer 
treatment management specifically in those apoptosis-resistant cancer.    
 
In conclusion, defining the expression profiles of senescence biomarkers in the 
morphological progression of proliferative breast lesions to invasive cancer in a large 
group may enhance the understanding of the fundamental aspects of breast 
tumourigenesis. We have shown that the expression of these markers plateau or 
slightly decrease from premalignant to malignant lesions, consistent with tumour 
evasion of the senescence pathway.  Therefore, induction of senescence may assist in 
therapies aimed at inhibiting tumour growth.  Our results suggest P16, P14 and p53 
are potentially useful prognostic biomarkers in breast cancer. Subsequent 
stratification of breast cancer patients according to the expression of these 
senescence biomarkers in the tumour tissue may further optimize the management of 
their condition. 
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APPENDIX A 
TNM staging of breast cancer according to American Joint Committee on Cancer 
(AJCC)  
T/N/M Category Criteria 
T – Primary Tumour  
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
Tis (DCIS) Ductal carcinoma in situ 
Tis (LCIS) Lobular carcinoma in situ 
Tis (Paget) Paget’s disease of the nipple with no tumour 
T1 Tumour 2cm or less in greatest dimension 
T1mi Microinvasion 0.1cm or less in greatest dimension 
T1a More than 0.1cm but not more than 0.5cm in greatest 
dimension 
T1b More than 0.5cm but not more than 1 cm in greatest 
dimension 
T1c More than 1 cm but not more 2 cm in greatest dimension 
T2 Tumour more than 2 cm but not more than 5 cm in greatest 
dimension 
T3 Tumour more than 5 cm in greatest dimension 
T4 Tumour of any size with direct extension to chest wall or 
skin only as described in T4a to T4d 
T4a Extension to chest wall 
T4b Oedema (including peau d’orange), or ulceration of the 
skin of the breast, or satellite skin nodule confined to the 
same breast  
T4c Both 4a and 4c, above 
T4d Inflammatory carcinoma 
  
N – Regional Lymph Nodes 
NX Regional lymph nodes cannot be assessed (eg previously 
removed) 
N0 No regional lymph node metastasis 
N1 Metastasis in movable ipsilateral axillary lymph node(s) 
N2 Metastasis in fixed ipsilateral axillary lymph node(s) or in 
clinically apparent ipsilateral internal mammary lymph 
node in the absence of clinically evident axillary lymph 
node metastasis  
N2a Metastasis in axillary lymph node(s) fixed to one another 
or to other structures 
N2b Metastasis only in clinically apparent internal mammary 
lymph node(s) and in the absence of clinically evident 
axillary lymph node metastasis 
N3 Metastasis in ipsilateral infraclavicular lymph node(s) with 
or without axillary lymph node involvement; or in 
clinically apparent ipsilateral internal mammary lymph 
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node(s) in the presence of clinically evident axillary lymph 
node metastasis; or metastasis in ipsilateral supraclavicular 
lymph node(s) witg or without axillary or internal 
mammary lymph node involvement 
N3a Metastasis in infraclavicular lymph node(s) 
N3b Metastasis in internal mammary and axillary lymph nodes 
N3c Metastasis in supraclavicular lymph node(s) 
  
Pathologic (pN)*  
pNX Regional lymph nodes cannot be assessed (for example, 
previously removed, or not removed for pathologic study) 
pN0 No regional lymph node metastasis identified 
histologically. 
Note: Isolated tumor cell clusters (ITCs) are defined as 
small clusters of cells ≤ 0.2 mm, or single tumor cells, or a 
cluster of < 200 cells in a single histologic cross-section; 
ITCs may be detected by routine histology or by 
immunohistochemical (IHC) methods; nodes containing 
only ITCs are excluded from the total positive node count 
for purposes of N classification but should be included in 
the total number of nodes evaluated 
pN0 (i-) No regional lymph node metastases histologically, negative 
IHC 
pN0 (i+) Malignant cells in regional lymph node(s) ≤ 0.2 mm 
(detected by hematoxylin-eosin [H&E] stain or IHC, 
including ITC) 
pN0 (mol-) No regional lymph node metastases histologically, negative 
molecular findings (reverse transcriptase polymerase chain 
reaction [RT-PCR]) 
pN0 (mol+) Positive molecular findings (RT-PCR) but no regional 
lymph node metastases detected by histology or IHC 
pN1 Micrometastases; or metastases in 1-3 axillary lymph nodes 
and/or in internal mammary nodes, with metastases 
detected by sentinel lymph node biopsy but not clinically 
detected† 
pN1mi Micrometastases (> 0.2 mm and/or > 200 cells, but none > 
2.0 mm) 
pN1a Metastases in 1-3 axillary lymph nodes (at least 1 
metastasis > 2.0 mm) 
pN1b Metastases in internal mammary nodes, with 
micrometastases or macrometastases detected by sentinel 
lymph node biopsy but not clinically detected† 
pN1c Metastases in 1-3 axillary lymph nodes and in internal 
mammary lymph nodes, with micrometastases or 
macrometastases detected by sentinel lymph node biopsy 
but not clinically detected† 
pN2 Metastases in 4-9 axillary lymph nodes or in clinically 
detected‡ internal mammary lymph nodes in the absence of 
axillary lymph node metastases 
pN2a Metastases in 4-9 axillary lymph nodes (at least 1 tumor 
deposit > 2.0 mm) 
pN2b Metastases in clinically detected‡ internal mammary lymph 
nodes in the absence of axillary lymph node metastases 
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pN3 Metastases in ≥ 10 axillary lymph nodes; or in 
infraclavicular (level III axillary) lymph nodes; or in 
clinically detected‡ ipsilateral internal mammary lymph 
nodes in the presence of ≥ 1 positive level I, II axillary 
lymph nodes; or in > 3 axillary lymph nodes and in internal 
mammary lymph nodes, with micrometastases or 
macrometastases detected by sentinel lymph node biopsy 
but not clinically detected†; or in ipsilateral supraclavicular 
lymph nodes 
pN3a Metastases in ≥ 10 axillary lymph nodes (at least 1 tumor 
deposit > 2.0 mm); or metastases to the infraclavicular 
(level III axillary lymph) nodes 
pN3b Metastases in clinically detected‡ ipsilateral internal 
mammary lymph nodes in the presence of ≥ 1 positive 
axillary lymph nodes; or in > 3 axillary lymph nodes and in 
internal mammary lymph nodes, with micrometastases or 
macrometastases detected by sentinel lymph node biopsy 
but not clinically detected† 
pN3c Metastases in ipsilateral supraclavicular lymph nodes 
*Classification is based on axillary lymph node dissection, with or without sentinel 
lymph node biopsy. Classification based solely on sentinel lymph node biopsy 
without subsequent axillary lymph node dissection is designated (sn) for “sentinel 
node” – for example pN0 (sn).  
† "Not clinically detected" is defined as not detected by imaging studies (excluding 
lymphoscintigraphy) or not detected by clinical examination. 
‡ "Clinically detected" is defined as detected by imaging studies (excluding 
lymphoscintigraphy) or by clinical examination and having characteristics highly 
suspicious for malignancy or a presumed pathologic macrometastasis on the basis of 
FNA biopsy with cytologic examination. 
  
M – Distant metastasis  
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis  
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STAGE CRITERIA 
Stage 0  Tis N0 M0 
Stage IA T1 N0 M0 
Stage IB T0 N1mi M0 
 T1 N1mi M0 
Stage IIA T0 N1 M0 
 T1 N1 M0 
 T2 N0 M0 
Stage IIB T2 N1 M0 
 T3 N0 M0 
Stage IIIA T0 N2 M0 
 T1 N2 M0 
 T2 N2 M0 
 T3 N1, N2 M0 
Stage IIIB T4 N0, N1, N2 M0 
Stage IIIC Any T N3 M0 
Stage IV Any T Any N M1 
